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Abstract
RNA-based therapy is an exciting new realm of experimental medicine due to the
diverse roles of RNA in the human body. RNA function depends on sequence, structure,
and cellular location. Whereas cytosolic short-interfering RNA (siRNA) can be used to
turn off genes through RNA interference (RNAi), it was observed that the same siRNA
can also activate an innate immune response. Recognition of RNA by specialized
immune cells occurs through pattern recognition receptors, which have evolved to
respond to RNA viruses, such as the Toll-like receptors (TLR) 7 and 8 located in the
endosome of dendritic cells.
Tailoring the multiple functions of RNA for a desired clinical application will
require novel systems for intracellular delivery. A library of structurally-related cationic
lipid-like materials, termed "lipidoids", was developed to facilitate uptake of small
RNAs, and the role of drug delivery in controlling RNA function was investigated. In an
experimental animal model of RNA interference of influenza virus, treatment with a
lipidoid-siRNA nanoparticle efficiently activated a type I interferon response in a
sequence-dependent manner suppressing lung viral titer over 97%. Specific chemical
modifications to the siRNA prevented TLR7/8 engagement and also prevented antiviral
responses, confirming an RNAi-independent mechanism of antiviral activity.
Recognizing the therapeutic potential of immunostimulatory RNA (isRNA), a
novel in vitro high-throughput assay was developed to screen the lipidoid library for
delivery of isRNA. Over 800 combinations of lipidoid and isRNA were screened for the
ability to form nanoparticles and deliver isRNA in vitro. Drawing upon structure-
function relationships observed in the lipidoid library, 2 nd generation lipidoids were
synthesized. These lipidoids could efficiently deliver isRNA to TLR7/8 in vivo and
activated systemic innate immune responses following subcutaneous administration.
Further, the 2 nd generation lipidoid-isRNA nanoparticles increased antibody responses to
protein vaccination by many orders of magnitude and stimulated cell-mediated immunity.
Taken together, the results of these studies demonstrates the role of drug delivery in
controlling the function of small RNAs, and that activation of innate immune responses
to immunostimulatory small RNAs has therapeutic potential.
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Introduction
A convergence of medical knowledge of the molecular basis of disease and
biological tools for genetic engineering has led to an expansion in research of nucleic
acid-based medicine in recent years. Recent interest has focused on the therapeutic use
of RNA as a drug. RNA interference, mediated by small interfering RNA molecules, has
the potential to suppress any endogenous or exogenous gene, and could be used to treat
potentially any disease for which genetic targets can be identified. However, RNA also
has an immunostimulatory function that has only recently been appreciated to play an
important role in modulating immune responses to viruses as well as in the pathogenesis
of autoimmune diseases. The immune system has an enormous capacity to recognize
foreign substances through the adaptive immune response, but an initial pre-encoded
response must occur in order to activate long lasting and protective immunity. This
innate immune response has a variety of triggers, including bacterial and viral nucleic
acids. A wide variety of receptors exists for recognition of RNA in particular.
Activation of the various innate immune receptors by RNA can be harnessed to stimulate
the immune system against invading viruses, tumors, or synthetic vaccines. Modulation
of autoimmune diseases such as lupus may also be accomplished through RNA therapies.
Activation of the innate immune system also has consequences for the development of
RNA interference therapeutics.
The technology for enabling RNA therapeutics is only in its infancy. Drug
delivery of nucleic acids remains a significant challenge in bringing nucleic acid-based
therapy from bench-top research to bedside practice. Though nature has evolved viruses
specifically for DNA and RNA delivery, the use of engineered viruses in clinical practice
suffers from significant safety concerns: adverse immune reactions to viral vectors,
oncogenic potential of viral integration, and possibility for reversion to pathogenic states.
These concerns are not unwarranted as highlighted by a recent series of catastrophic
failures in human gene therapy clinical trials. Non-viral methods for nucleic acid
delivery are significantly safer but suffer from low efficiency and non-permanent effects.
Significant intracellular and extracellular barriers exist to in vivo application of non-viral
delivery systems. My thesis work has focused on the boundary of enabling RNA
therapeutics through drug delivery.
Initial investigations into delivery of small interfering RNA (siRNA) uncovered a
potentially enormous role for drug delivery in the activation of innate immune responses
to small RNAs. While investigating the delivery of siRNAs to inhibit influenza
replication in vivo, we discovered a novel method for stimulating innate antiviral
responses to siRNAs. It became clear that the same RNA molecule can have multiple
effects, including RNA interference and immune activation. I hypothesized that drug
delivery can control the end function of RNA by controlling the cellular targeting and
intracellular destination of a small RNA molecule.
In Chapter 1, I describe the foundations of nucleic acid drug delivery. Decades of
work has been dedicated to gene therapy using viral and non-viral methods of DNA
delivery. While most of the barriers to efficient delivery are similar for DNA and RNA,
there are some differences that have only superficially been described. As such, small
RNA delivery is still very much an unmet challenge. Delivery of siRNAs in particular is
an exploding field with many therapeutically relevant applications, but the challenges
such as intracellular location and avoiding immune responses are significant.
In Chapter 2, I describe the progress we have made in defining the role of immune
activation in activating antiviral responses to siRNAs. We have shown that robust
protection against influenza challenge in mice can be achieved through efficient delivery
mechanisms. By chemical modifications to siRNAs we prove that the antiviral responses
observed were clearly due to immune activation and not RNA interference mechanisms
as previously anticipated. This work stimulated an interest in controlling immune
responses to small RNAs through drug delivery.
In Chapter 3, I describe the development of a novel high-throughput screening
(HTS) capable method for screening libraries of materials for efficient delivery of
immunostimulatory RNAs (isRNAs). We show that we can robustly detect and quantify
type I interferons, acute signaling molecules of innate immune responses. We achieve
better resolution and orders of magnitude greater dynamic range than commercially
available methods in a high throughput method. This work enabled us to screen a large
library of materials for isRNA delivery.
In Chapter 4, I describe the characterization of a library of cationic lipid-like
materials using high throughput methods I developed. By employing HTS methods,
almost 100 structurally related materials were assessed for isRNA delivery potential. By
comparing this screening to screening for siRNA delivery, we discovered structure-
function relationships that can aid in future design of materials for intracellular RNA
delivery. Additionally, a number of promising candidates were identified for further
development.
Building on the foundations laid in Chapter 4 and the results of the isRNA
screening, In Chapter 5, I describe the identification and development of a second
generation drug delivery system that efficiently stimulates immune responses in a
therapeutic animal model. We developed and tested a variety of chemistries and physical
formulations of nanoparticles encapsulating isRNA, and carefully characterized the
immune responses to these nanoparticles. Finally, we demonstrated for the first time that
drug delivery can enable the use of isRNA as a vaccine adjuvant.
Chapter 1 - Background
Nucleic Acids in Medicine
Science has developed exquisite understanding of the structural basis of biological
information encoded in DNA and RNA since the early 1950's [1]. The toolset to enable
genetic engineering has been expanding from the creation of the first artificial plasmid
[2] to large-scale chemical synthesis of complete genes [3]. The sequencing of the
human genome in 2001 [4, 5] ushered in a new era of understanding of the genetic basis
of disease; as we learn more about the molecular basis of disease we expand the
prospective targets of gene therapy.
Using nucleic acids themselves as therapeutics, broadly classified as gene therapy,
allows for a variety of end effects potentially as diverse and as specific as the nucleotide
sequence itself. The original aim of gene therapy was to replace or supplement defective
genes in diseases such as cystic fibrosis or muscular dystrophy. The field of gene therapy
has broadened to include nucleic acid therapeutics to modulate the immune system such
as in DNA vaccination and to modulate gene expression such as in antisense (e.g RNA
interference) therapy. Further, gene-based medicine has expanded beyond monogenic
diseases to include a wider variety of targets such as cancers, infectious disease, and
cardiovascular diseases that have spawned over 1,000 clinical trials since 1989 (Figure
1) [6].
Indications Addressed by Gene Therapy Clinical Trials
Cancer diseases 66.5% (n=896)
* Cardiovascular diseases 9% (n=121)
O Monogenic diseases 8.2% (n=110)
O Infectious diseases 6.6% (n=89)
Neurological diseases 1.3% (n= 17)
O Ocular diseases 0.9% (n=12)
Other diseases 1.9% (n=26)f G: k ) 38%
ni e e.rll 1ul gi. .s lo "i-J
O Healthy volunteers 1.9% (n=26)
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Figure 1 - Diseases targeted in gene therapy clinical trials as of March 2008 broken
down into broad categories. A total of 1347 clinical trials indications were surveyed
[7].
The promise to bring gene therapy into clinical practice has been great ever since
Dr W. French Anderson's seminal success in treating adenosine deaminase (ADA)
deficiency, which causes severe-combined immunodeficiency (SCID), in two children in
1990 [8]. In 1998, the FDA approved the first nucleic acid-based therapy, Vitraven
(fomivirsen), a naked antisense phosphorothioate oligodeoxynucleotide (PS-ODN) for
cytomegalovirus-retinitis delivered by direct ocular injection. China became the first
country in the world to approve a traditional gene therapy product in 2003: Gendicine
uses an adenoviral vector carrying the p53 gene for treatment of head and neck cancer
[9]. However, despite technological advances and numerous trials, no gene replacement
therapy products are FDA approved for sale in the US.
Significant setbacks have hindered progress and cast shadows of doubt on the
safety of gene therapy. A gene therapy trial using a retroviral delivery system to cure an
X-linked form of SCID in children lacking the common gamma c chain began in Paris
and Milan in the late 1990's [10] and was wildly successful in curing 9 out of 11 patients.
Unfortunately, in 2002 [11] and 2003 [12], it became apparent that 2 of the 9 cured
patients were suffering from leukemia as a result of retroviral integration causing
oncogene activation (both patients have been successfully treated with conventional
chemotherapy). Worse, in 1999 a gene therapy trial using an adenoviral vector in the
phase I safety/efficacy stage to correct ornithine transcarbamylase (OTC) deficiency took
place at the University of Pennsylvania. An 18 year-old patient, Jesse Gelsinger, died
days after receiving an intra-hepatic infusion of the highest dose of the virus. His death
was attributed to a severe immunologic inflammatory response to the viral vector [13].
More recently, nucleic acid-based therapies have expanded to include a variety of
small RNA and DNAs for the purpose of RNA interference and innate immune
stimulation, respectively. The results have been both promising and cautionary. A
recently completed phase 2 clinical trial in early 2008 showed that siRNA therapy,
delivered by nebulizer to the lung as an inhalable naked siRNA, showed anti-viral
effectiveness against respiratory syncytial virus (RSV) reducing experimental infection
rates by 38% [14]. The use of small DNA fragments known as CpG-
oligdeoxynucleotides (CpG-ODN) has also been taken into stage 3 clinical trials. CpG-
ODN mimic the non-methylated bacterial and viral DNA and are recognized by a
specialized receptor of the innate immune system, called a toll-like receptor, to act as a
vaccine adjuvant [15]. In clinical trials of using CpG-ODN to boost vaccine responses to
hepatits B virus (HBV) vaccine, seroconversion was improved from just 60% with three
doses with the approved recombinant HBV vaccine to 100% in just two doses with aq
combination of the HBV vaccine and an immunostimulatory CpG-ODN adjuvant [16].
However, a subsequent phase III clinical trial was recently halted due to the report of
development of an autoimmune disease, Wegener's granulomatosis, in a patient after
receiving the CpG-ODN [ 17].
Nucleic Acid Drug Delivery
The question remains: what is the major roadblock to clinically viable nucleic
acid-based therapeutics? Three major concerns when evaluating a gene therapy
technology are overall efficiency, safety, and scalability [9, 18-20]. As these properties
can be defined relatively independent of the nucleotide sequence itself, they are often
intrinsically functions of the drug delivery system. A wide variety of technologies exists
for delivering DNA and RNA both in vitro and in vivo, each of which has associated
degrees of efficacy, toxicity (immunogenic or oncogenic), and production capacity.
Broadly, these delivery systems fall into one of two categories: transduction via viral-
mediated drug delivery or transfection via non-viral drug delivery.
Vectors Used in Gene Therapy Clinical Trials \f
Adenovirus 24.8% (n=342)
* Retrovirus 22.3% (n=307)
* Naked/Plasmid DNA 178% (n=246)
* Lipofection 7.4% (n=102)
Vaccinia virus 6.4% (n=93)
* Poxvirus 6.4% (n=88)
Adeno-associated virus 3.9% (n=54)
* Herpes simplex virus 3.1% (n=43)
* RNA transfer 1.4% (n= 19)
* Other categories 3.2% (n=44)
9 Unknown 3% (n=41)
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Figure 2 - Vectors used in gene therapy clinical trials as of March 2008 broken
down into broad categories. A total of 1347 clinical trials indications were surveyed
[21].
Viral Nucleic Acid Delivery
Viruses have naturally evolved to serve one primary function - DNA and RNA
delivery. Historically, virus-mediated nucleic acid delivery has been the first method of
choice for gene therapy due to the efficient gene transfer of viral delivery systems and the
potential for long-term transgene expression following viral-mediated integration into the
host genome [22]. Over 2 /3rd of all clinical trials employ viral delivery vectors, with only
1/4th represented by naked plasmid DNA or lipid-mediated non-viral drug delivery
(Figure 2) [21 ]. The major classes of viruses engineered to be used as gene delivery
systems are: retro-viruses, which stably insert genes into the host chromosomes but
require cell division to be effective, lentiviruses, which can stably insert genes into the
chromosomes of non-dividing cells, adenoviruses, which can transduce both dividing and
non-dividing cells episomally (localized to the nucleus but not integrated into the host
genome) and are easy to produce in high titers, adeno-associated viruses, which are not
known to be pathogenic in humans and can transduce genes both chromosomally
(integrated into the host genome) and episomally, and herpes virus, which has the
capacity to carry larger genes and efficiently infects neurons as well as other tissue types
[19, 22, 23].
While engineered viruses offer efficient gene transfer and long-term expression,
viral delivery systems have major safety and scalability drawbacks, which present risks
both to researchers in the laboratory and to patients in the clinical setting [20]. A primary
concern is immunogenicity. A first time exposure to a viral vector may preclude any
future use of the same vector due to the memory immune response. As in the case of
Jesse Gelsinger, any previous exposure to the viral carrier or a cross-reactive antigen can
generate immediate and strong immune responses. Direct damage to tissues transduced
by viral vectors may also limit their clinical use. In a hemophilia B gene therapy phase
I/II dose-escalation trial recently conducted, recombinant adeno-associated virus (rAAV)
vector was used to transduce the liver in 7 patients [24]. Therapeutic levels of factor IX
gene expression were achieved with the highest dosing. However, gene expression
declined over time and was correlated with liver damage induced by CD8÷ T-cells
specific for antigens of the rAAV capsid killing transduced hepatocytes [25].
Additionally safety concerns further limit viral vector use for gene therapy. Since
genomic integration entails inherent randomness, gene integration can be oncogenic as
evidenced by the two children in the X-linked SCID case [26]. If germ line integration
were to occur then there exist additional risks of the transgene becoming inheritable; this
situation has been suspected in at least one clinical trial [27]. In order to prevent
uncontrolled viral spread, viruses must be engineered to be replication incompetent. Still
a virus vector could regain the capacity for replication through recombination with other
viruses in the host. The requirement for replication-deficient viruses also leads in turn to
problems in vector production. Specialized cell lines must be established to allow for
vector packaging in vitro, and often these culture methods are expensive with low viral
titer yields and variable particle quality [9, 19, 22].
Non-viral Nucleic Acid Delivery
To avoid many of the key problems associated with viral vectors, non-viral
vectors have been developed. Non-viral vectors address the three major drawbacks of
viral vectors. They are generally much safer due to lower immunogenic potential
(depending on the materials used for transfection). Unless specifically designed to do so
[28], DNA delivered non-virally has a very low potential of host genome integration.
DNA and RNA can also be delivered without regards to total molecule size; multiple
genes or gene functions may be expressed off a single plasmid that may be too large for
incorporation into viral-vectors. Finally, non-viral delivery systems for gene therapy are
generally less complicated and cheaper to manufacture, easily scalable from laboratory to
GMP-scale production, and offer simple long-term storage compared to their viral
counterparts.
Most progress in non-viral nucleic acid delivery systems has revolved around
delivery of plasmid DNA. Injection of naked DNA plasmids has found limited success in
humans particularly when injected intramuscularly (IM) [29]. However, the rapid
degradation / clearance (half-life of under 5 minutes if injected intravenously (IV)) of
unprotected nucleic acids[30], poor induction of the desired end effect of humoral
immune responses in DNA vaccination [31], and requirement for large doses [30, 31] has
hindered progress into clinical trials[32]. Therefore, gene therapists have turned to
physical or chemical means for achieving transfection levels sufficient for therapy.
Clinically relevant physical methods that have been employed include electroporation
[33], ballistics (gene gun) [34], and ultrasound [35]. Despite achieving greater efficacy
than naked DNA administration (IM, IV, or otherwise), physical methods for gene
delivery are often limited due to local tissue damage and insufficient gene expression
[36]. Few physical methods for nucleic acid delivery have passed pre-clinical trials in
large animals, and the necessity of sophisticated equipment may preclude widespread
adaptation of these technologies particularly in resource-poor areas of the world.
Chemical methods for non-viral nucleic acid delivery have been extensively
researched for transfection agents in the laboratory and as alternatives to viral gene
delivery systems. The classes of materials employed as non-viral vectors include lipids,
polymers (including dendrimers and polypeptides), and cationic sugars / inorganic salts
[20, 30]. These materials bind and condense DNA or RNA by electrostatic interaction,
protect the nucleic acid payload from mechanical, chemical, or biological degradation,
and mediate cellular uptake. The earliest reports of transfection were with
diethylaminoether (DEAE)-dextran and calcium phosphate, however these crude methods
were inefficient, toxic, and not readily applicable to in vivo therapy [37]. Initial reports
of using polymers as transfection agents surfaced in the late 1970's [38] and early 1980's
[39] often utilizing common off-the-shelf polymers or polypeptides due to their cationic
or biocompatible properties. Cationic lipids have been used as transfection agents since
the mid-1980's [40] and have shown promise in vivo and in clinical trials [41]. The early
generations of these materials were not optimized for gene delivery, and results were
mixed in vitro and poor in vivo resulting often in an unfavorable and delicate balance
between transfection efficiency and cellular toxicity [42, 43]. Synthetic vectors have
since evolved from off-the-shelf items to rationally designed sophisticated systems to
address the issues of transfection efficiency, cytotoxicity, serum stability, cell- and tissue-
specific targeting, and in vivo biocompatibility [44].
Barriers to Efficient Nucleic Acid Delivery
The pathway for nucleic acid delivery is long and fraught with roadblocks from
the point of entry into the body to desired effects of gene expression. There exist
multiple barriers to successful drug delivery, which can be modeled at the cellular level
in vitro or at the organism level in vivo. In addition to the biological challenges
following injection of the vector, practical usage challenges such as ease of production,
cost, scalability, stability, and ease of formulation must all be addressed before any
vector, viral or synthetic, can be used in the clinical setting. These practical issues are
generally specific to each delivery system, but the physiological challenges apply to all
delivery systems. Since viral vectors have evolved specifically for efficient delivery of
nucleic acids, it is best to consider these physiologic barriers as they pertain to challenges
for the development of efficient synthetic vectors.
Intracellular Barriers to Nucleic Acid-Based Therapy
An amazing amount of research has been devoted to understanding the intracellular
barriers to gene delivery in an effort to engineer specific material functions that will
increase the effectiveness of synthetic vectors [44]. Transfection of a cell is said to occur
when a nucleic acid is delivered to its site of action, e.g. the nucleus for a DNA plasmid,
the cytoplasm for a small interfering RNA (siRNA), or the endosome for CpG-ODN and
immunstimulatory RNA (isRNA), and the nucleic acid exerts its function, e.g. gene
expression from a DNA plasmid, gene silencing by RNA interference, or innate immune
stimulation by CpG-ODN or isRNA. The major intracellular barriers to nucleic acid
delivery can be characterized as follows (not necessarily in chronological order):
1. Complex and condense DNA or RNA into vector-nucleic acid particles (V-NA)
2. Association with the cell surface
3. Internalization of the V-NA complex via endocytosis, phagocytosis, or bypassing
the cellular membrane
4. Escape of the V-NA from the internal vesicle (endosome or phagosome) if
necessary
5. Protection from or avoidance of intracellular degradation of nucleic acids, which
can occur in the lysosome or cytosol
6. V-NA trafficking to the site of action such as the nucleus or cytosol
7. Efficient dissociation of the V-NA acid before or upon reaching the target site
8. If necessary, entry into the nucleus, i.e. nuclear import
9. Association with cellular machinery to achieve desired effects (i.e. gene
expression or suppression)
10. Stable integration or sufficient half-life for therapeutic effects
Polyethylenimine
Every carrier system has unique properties particularly suited for facilitating one
of more of the steps outlined above. The available materials initially used for
transfection could serendipitously navigate through the cellular barriers. The prototypical
polymer widely used for nucleic acid delivery is polyethylenimine (PEI), and much is
known about the biological basis of nucleic acid delivery with PEI.
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Figure 3 - Schematics of branched PEI and linear PEI. Branched PEI (left) has the
highest density of tertiary amines. Primary amines shown in green, secondary amines in
red, and tertiary amines in blue.
PEI has a high potential charge density with repeated nitrogens every 3 atoms of
the backbone. It has a repeat structure of -[CH 2-CH 2-NH]-, exists in either a linear or
branched form, and is available in a wide range of molecular weights. Positive charges
can be stabilized on the amine groups depending on pH and polymer structure resulting in
a polycationic molecule, which interacts with the polyanionic phosphate backbone of
DNA or RNA resulting in condensed complexes termed polyplexes [45]. This process
occurs rapidly and spontaneously in aqueous solution at room temperature and generally
results in a polydisperse population of nanoparticles each containing multiple molecules
of PEI and DNA/RNA, which will aggregate over time. At sufficient molecular ratios
(i.e. ratios of nitrogen to phosphate, or N/P) and charge ratios, these particles maintain a
positive surface charge that facilitates cellular uptake [46]. Cationic polyplexes are
thought the bind the negatively charged cell surface through electrostatic interactions
with the poly-anionic syndecan molecules ubiquitously expressed on cell surfaces, which
then signals for internalization and transport towards the nucleus via actin tension fibers
[47]. Once internalized, late endosomes eventually acidify through an ATP-mediated,
pH-dependant hydrogen-ion pump; passive channels allow internalization of chloride
ions to maintain electro-neutrality. The primary, secondary, and tertiary amines (in the
branched form) of PEI have pKa's spanning the physiologic pH. The amines absorb
incoming protons like a "proton-sponge" while the continued influx of chloride ions leads
to an osmotic pressure increase that eventually destabilizes the endosome membrane
(Figure 4) [48].
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Figure 4 - Schematic of the "proton sponge" effect leading to endosomal escape [42].
PEI-nucleic acid complexes then escape the late endosome into the cytoplasm before the
vesicles encounter the lysosome thereby avoiding degradation of the nucleic acid payload
by lysosomal nucleases [49]. Once in the cytosol, RNA molecules can associate with
cellular machinery for gene expression or suppression, but cytosolic free plasmid DNA is
immobile due to its large size and rapidly degraded by nucleases. However, when
complexed with PEI, plasmids are protected from degradation and, through still unknown
mechanisms, these plasmids eventually enter the nucleus where gene expression occurs
[50]. Transfection efficiencies of PEI and other poly-cationic vectors (polyplexes and
lipoplexes) are highly dependant upon cell-cycle, and therefore DNA uptake is likely
dependant upon nuclear membrane integrity and association of plasmids with mitosis
machinery [51]. PEI serves as an example of a material with multiple inherent
functionalities that facilitate transfection in vitro.
Cationic Lipids
Cationic lipids have been the non-viral gene delivery vectors of choice for clinical
application since Felgner first introduced their use in 1987 [40]. Generally speaking,
these lipid formulations are a mixture of multiple compounds [52]. The cationic lipid
molecule consists of a hydrophilic positively charged head group, a linker that may
impart some functionality such as pH sensitivity, and a hydrophobic long chain tail. A
prototypical cationic lipid is 1,2-Dioleoyl-3-Trimethylammonium-Propane (DOTAP); it
is the most widely used lipid for gene delivery. For in vivo delivery, nucleic acids are
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usually encapsulated into liposomes: vesicles with lipid bilayer membranes that exist as
large unilamellar vesicles (LUVs) or multilamellar vesicles (MLVs) [53]. Liposomes
generally consist of a single cationic lipid or a mixture of cationic lipids that facilitate
nucleic acid binding and transfection, cholesterol or diolelphophatidylethanolamine
(DOPE) to impart some rigidity or stability to the complex, and PEG to shield particles
from aggregation, serum components, or other non-specific interactions (see below) [54].
Lipids have been used extensively in gene therapy and are the only non-viral delivery
vectors used in clinical trials [55]. They have found use in other applications of drug
delivery for chemotherapeutics [56] and antibiotics [57] and some are FDA approved.
The specific functionality of lipid molecular structure is poorly understood
although mechanisins for liposome uptake, in general, have been described [58].
Attachment to cellular membranes and cellular uptake mediated by charge interactions
with surface proteoglycans is similar in mechanism to polyplexes. Cationic lipids
generally form a multilayered lamellar structure when complexed with plasmid DNA.
For lamellar vesicles, fusion with the endosome occurs only with sufficiently high
liposome-membrane charge density; this membrane charge density and not the charge of
individual lipid components is the key parameter in determining transfection efficiency
[59]. Occasionally, cationic lipids when complexed with DNA plasmids will form
inverted hexagonal structures in which membrane fusion is independent of charge
density. In these structures that bear an energetically un-favored outer membrane with
positive curvature surrounding lipid-coated DNA with a negative curvature, membrane
fusion and subsequent release of the nucleic acid payload is driven by the energetically
favored process of merging the outer membrane with the cell membranes (Figure 5) [59].
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Figure 5 - Cationic lipid-mediated delivery of nucleic acids. Lamellar vesicles (left)
and inverted hexagonal structured lipids (right) fuse with cellular membranes to release
the nucleic acid payload (green). [59]
Extracellular Barriers to Nucleic Acid-Based Therapy
Whereas in vitro models of transfection efficiency can be used to identify
promising materials for gene delivery, there exist multiple extracellular barriers to
effective nucleic acid-based therapy. Ideal candidates in vitro may be completely
ineffective in vivo. Any material inside the body has the potential for cellular, tissue,
organ, and system-wide interactions leading to disruption of homeostasis and undesired
effects. Following injection into the body, the vector must shuttle its nucleic acid
payload to the target cell or tissue. The blood and immune system, the
reticuloendothelial system (RES), and secretion / excretion systems play particular
important roles in determining in vivo properties of a given vector. The major
extracellular (i.e. organism-wide) barriers to nucleic acid delivery can be characterized as
follows (not necessarily in chronological order):
1.) Stability of the V-NA particles in the presence of serum proteins
2.) Extended plasma circulation / rapid clearance
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3.) Protection from DNases and RNases
4.) Extravasation of circulating V-NA particles at the targeted tissue
5.) Non-specific cellular uptake and adherence to extra cellular matrix
6.) Interaction with innate / adaptive immune system
7.) Acute or chronic toxicity due to accumulation of synthetic vector or gene
product
The most effective cationic polymers and lipids form nucleic acid complexes that
have a net positive charge or positive surface charge [46, 47] to facilitate transfection.
However, many serum proteins such as albumin, the most abundant plasma protein, and
the extra-cellular matrix carry a net negative charge. Electrostatic interactions can
rapidly lead to aggregation of vector-nucleic acid particles with serum proteins; as
particle-protein aggregate size increases they are eliminated from circulation by the
reticulo-endothelial system (RES) or phagocytic cells, deposit non-specifically in
microvascular beds, or crash out of solution, which may cause acute toxicity [60, 61]. In
addition to containing high concentrations of negatively-charged proteins, plasma also
has a high ionic strength. Interactions between serum proteins, blood solutes, and poly-
cationic carrier materials can lead to competitive binding, de-stabilization of the vector-
nucleic acid particle, and subsequent premature release of the nucleic acid payload [30].
Interaction with complement proteins, C3 and C4 in particular, can activate the innate
immune responses resulting in acute inflammation and lead to severe acute toxicity or
death [62]. Serum also contains DNases and RNases, enzymes that specifically degrade
nucleic acids. Condensed vector-nucleic acid particles prevent the degradation of the
nucleic acid payload by steric inhibition of these D/RNases. The addition of
poly(ethylene glycol) (PEG) and other hydrophilic polymers can be used to prevent
aggregation with serum proteins and subsequent rapid clearance [62]. This simple
functionality can sharply increase the serum half-life of a particle and prevent acute toxic
events due to non-specific interactions, but also results in lower transfection efficiency
and reduced cellular targeting [30, 42].
Due to the inherently lower transfection efficiencies associated with non-viral
delivery systems (as opposed to viral delivery systems), targeting delivery to specific
tissues and cells is a must to avoid excessively large dosing schemes [63]. Avoiding non-
specific clearance and deposition and increasing circulation time of vector-nucleic acid
particles are first steps towards efficient targeting. Cell specific targeting, while not
necessary or desired for all applications of nucleic acid therapy, can significantly enhance
transfection efficiency and the desired therapeutic outcome [30, 42, 61]. The direct
conjugation of targeting moieties such as receptor ligands (small molecules [64], peptides
[65], sugars [66]), aptamers [67], and antibodies [68]) can increase cell and tissue
specificity and transfection efficiency. Additionally, targeting can be based upon internal
cell-specific signals to avoid off-target affects [69].
Following intravenous (IV) injection, particles travel to the heart; the lung is the
first microvasculature bed encountered. Particles must be sufficiently small (< 4 p~m) to
prevent deposition in the lung. Further, the spacing between the endothelial cells lining
blood vessels is organ dependant. In the RES system, fenestrations can allow passage of
particles over 100 nm in size; in most other vessels the largest intercellular gaps are 5 -
10 nm [61]. Since most non-viral nucleic acid delivery vehicles form particles larger
than 50 nm, IV injection may limit tissue targeting to the lungs and RES organs (liver and
spleen). Direct injection can surpass this limitation to allow targeting to other tissues
sites [70] such as muscle (intramuscular, IM), tumor (intratumoral, IT), and skin
(subcutaneous, SC, or intradermal, ID).
A highly efficient but more invasive alternative to injectable in vivo therapy is ex
vivo gene therapy. Cells of interest are removed from the patient, expanded and possibly
selected for specific phenotypes in tissue culture, treated with a nucleic acid vector, and
returned to the patient [71]. This methodology circumvents many of the problems of
tissue localization, cell targeting, transfection efficiency, and toxicity. However, it is
significantly more expensive, technically difficult, and limited in therapeutic application.
The SCID-X1 trial, widely regarded as the first human gene therapy success - and failure
- employed ex vivo treatment [10]. Recently many more reports of using ex vivo
treatments, particularly to target readily accessible circulating stem cells and peripheral
blood lymphocytes (PBLs), have surfaced. Ex vivo transduction with a modified
lentiviral system has shown much promise in gene therapy for hemophilia in an animal
model, particularly because this method induced immune tolerance to the transgene and
potentially the viral vector itself [72]. Recently, in what has been touted as a new
modality in cancer therapy, PBLs were transduced with a retrovirus vector encoding a T-
cell receptor to target metastatic melanoma; two out of 15 patients experienced complete
remission [73].
While cytotoxicity can be readily addressed in simple in vitro assays, toxicity due
to more complicated interactions with the immune system, liver, kidneys, or other
complex organ systems has traditionally only been assessed in vivo. PEI has been shown
to be an excellent transfection agent with multiple mechanisms for bypassing intracellular
barriers, but PEI has also reported to be highly toxic in animal models [63, 74].
Polycations such as PEI and cationic lipids such as DOTAP tend to activate complement
and the RES, aggregate with serum proteins, and can aggregate with red blood cells as
well. Toxicity issues both in vitro and in vivo can be addressed by chemical modification
of PEI [75].
However, a further concern is non-specific immune activation, such as immune
responses directed at the vector itself in the case of viral delivery. PEI and other cationic
delivery systems have been shown to activate both the innate immune system
(complement-mediated) and adaptive arms of the immune system non-specifically, which
may potentially contribute to auto-immunity [76]. Additionally, siRNAs have recently
been shown to interact with multiple receptors that stimulate non-specific innate immune
responses that may depend on drug delivery [77].
Combinatorial Design ofMaterials for Gene Delivery
Significant efforts have been made to determine the most important intracellular
and extracellular barriers to gene delivery. Quantitative modeling has shown that the
most important barriers to intracellular gene expression following PEI-mediated plasmid
delivery are endosomal escape and gene expression from nuclear-localized plasmids [78,
79]. Plasmid optimization for enhanced nuclear import through the incorporation of
nuclear localization signals (NLS) [50] may be important for increasing PEI-based
transfection efficiency. As a better understanding of vector-cell interactions has
emerged, researchers have modified materials such as PEI, other cationic polymers, and
lipids to facilitate transfection by incorporating specific functions into synthetic vectors
[42, 80].
Beyond modifications to existing materials, more recent research has sought to
rationally design synthetic vectors [42, 43, 61]. Since many of the mechanisms
underlying barriers to efficient gene delivery remain unknown, and furthermore due the
difficulties in predicting structure-function relationships a priori due to this lack of
understanding, recent work has turned to high-throughput screening methods for
identification and development of novel materials suitable for nucleic acid delivery [81-
83]. Instead of modifying known structures, the synthesis of hundreds or thousands of
chemically related yet distinct chemical structures in economical and manageably small
quantities can be rapidly evaluated using commonplace high-throughput assays for
biological properties such as DNA or RNA binding, cellular toxicity, and transfection
efficiency. Variations in chemical structure as well as formulation condition (e.g. mass
ratio of polymer to nucleic acid, pH, solvents, etc) can also be investigated cheaply and
quickly. In particular, transfection efficiency can be measured via reporter gene assays
such as luciferase or GFP gene expression or suppression. Without regards to specific
steps on the pathway to gene expression, measuring transfection activity alone captures
the overall robustness of each individual material with regards to in vitro gene delivery.
Variations to chemical structure and formulation can then be incorporated to develop
second and third generation systems with more functionality and better efficacy. Thus,
novel nucleic acid vectors may be engineered with only limited knowledge of the
intracellular barriers to gene delivery.
Poly(fl-amino ester)s
Poly(f3-amino ester)s (PBAEs) are one family of polymers amenable to high-
throughput synthesis and screening. By selecting the amino ester moiety as a basic
building block that has valuable properties for gene delivery, structural variations
including molecular weight, side chains, and end groups can be explored with respect to
functionality [84]. PBAEs are easily synthesized by the conjugate addition of primary or
bis(secondary amines) to diacrylates (Figure 6) , can bind and condense nucleic acids,
exhibit low cytotoxicity, and are hydrolytically degradable [85]. Even the first generation
of PBAE's, when optimized for molecular weight, end groups, and polymer/DNA ratio,
perform significantly better in vitro than the gold standards of PEI and Lipofectamine
2000 (a commercially available cationic lipid) [86]. Structure-function properties
elucidated from second generation PBAE's may apply to other cationic polymers.
PBAE's generated from amino alcohols that condense DNA into small particles (less than
150 nm in effective diameter) with positive surface charges exhibited the best
transfection efficiencies; further, similarities of the top performing compounds of the
library indicates some convergence in structure-function relationships as determined by
common barriers to intracellular delivery [87].
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Figure 6 - Synthesis of PBAEs by conjugate addition of primary or bis(secondary
amines) to diacrylates
Generally, non-viral vectors are considered to be safer than viral vectors, but
adverse events may inhibit the progression of synthetic nucleic acid delivery vectors into
clinical trials. Chronic accumulation of synthetic vectors, components of the vector, or
impurities following in vivo injection can cause toxic side effects as well [88]. To
address this problem, biodegradable gene delivery systems have been developed [42, 43]
including degradable cross-linked PEI [89], poly(ortho esters) [90], and poly(P-amino
esters) [85]. Much of the existing knowledge of nucleic acid delivery systems revolves
around DNA plasmid delivery. However, new materials and new strategies for delivery
small RNA molecules such as siRNA are emerging [91].
RNA Interference and siRNA Delivery
RNA interference (RNAi) was first discovered in C. elegans less than a decade
ago [92], and has since been recognized as an endogenous pathway for post-
transcriptional gene regulation in a variety of organisms including plants, fungi, and
animals including most importantly humans [93]. The introduction of long double-
stranded RNA (dsRNA) leads to efficient sequence specific knockdown of target genes,
but also leads to non-specific suppression of gene expression [94]. This non-specific
effect was found to be due to induction of intracellular interferon responses when dsRNA
activated toll-like receptors (TLR) [95]. The discovery that RNA interference is
mediated by 21 to 23 nucleotide double-stranded RNAs termed short interfering RNAs
(siRNA) [96] opened a new therapeutic potential - gene silencing mediated by siRNAs -
since these smaller RNAs seemed to avoid interferon activation [97].
RNA interference occurs in the cytoplasm when dsRNA (e.g. viral dsRNA
transcripts, microRNAs, or short hairpin RNAs) are cleaved by the Dicer enzyme, a
member of the RNase III family, into 19 to 27 nucleotide, double stranded siRNAs with
5' phosphate ends and 3' dinucleotide overhangs [96]. Alternatively, exogenously-
generated siRNA molecules synthesized chemically or in vitro using purified enzymes,
can enter the RNAi pathway at this step [94]. Resultant siRNAs are bound by the RNA
interference silencing complex (RISC) and unwound in an ATP-dependant fashion such
that one of the two strands of each siRNA is incorporated. The single RNA strand then
directs cleavage of complimentary mRNA in a highly sequence-specific manner (Figure
7).
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Figure 7 - Pathway of RNA interference. DICER cleaves dsRNA into small interfering
RNA (siRNA) that load into the RISC complex to search the mRNA pool for sequence-
specific target mRNA degradation and subsequent gene knockdown.
Challenges in siRNA Delivery
In practically every literature report since their discovery, the potential for using
siRNAs as therapeutics was immediately recognized as well as the major bottleneck to
pre-clinical development: drug delivery. Delivery of siRNA is similar to DNA delivery
in many regards. The same barriers to efficient extracellular delivery exist, and many of
the intracellular barriers to DNA delivery also apply to siRNA delivery. As such, the
same materials and vectors used for DNA delivery were originally applied to siRNA
delivery with limited success. However, a few major differences between the two nucleic
acid molecules highlight the need for tailored siRNA delivery systems [98].
Plasmid DNA is a massive molecule (in the megadaltons range) with a flexible
backbone allowing multiple conformations (circular and supercoiled); siRNAs are three
orders of magnitude smaller (in the kilodaltons range) with a more rigid backbone and
little room for non-denaturing conformational change. As a result, the persistence length
of persistence length of dsRNA is -50 nm. However the persistence length of an siRNA
molecule is -70 nm [98], but an individual siRNA does have the multiple persistence
lengths for multisite binding compared to plasmid DNA. Non-viral vectors for DNA
delivery such as PEI typically rely upon ionic interactions to condense plasmid DNA into
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small particles that are an entanglement of multiple DNA plasmids and polymer
molecules [45]. With the example of 25 kD branched PEI, one of the most commonly
used versions of PEI for gene delivery in vitro, the optimal ratios for transfection
(nitrogen to phosphorous ratio, N/P, of 6:1 to 8:1, or weight to weight, w/w, ratio of
approximately 1:1) results in approximately 75 to 100 molecules of PEI per plasmid.
Similar w/w ratios of PEI and siRNA would result in two siRNA molecules per molecule
of PEI. Though little is understood of the mechanisms of vector-nucleic acid
unpackaging within cellular compartments, the strong interactions between siRNAs and
large cationic polymers or lipids optimized for DNA delivery may inhibit efficient
unpackaging [98]. Further, whether by design or serendipity, the most efficient non-viral
delivery mechanisms for plasmid DNA delivery have some function to deliver DNA to
the nucleus [79]. In contrast, siRNA molecules bind to the RISC complex and together
degrade mRNA targets in the cytosol. Functionalities must be included specifically for
siRNA delivery in non-viral vectors to facilitate endosomal escape to and vector
unpackaging in the cytosol as opposed to nuclear entry. Finally, the nature of plasmid
DNA delivery and gene expression is a process of amplification. Single copies of
nuclear-localized plasmid DNA can exert therapeutic affects. Although the RISC-siRNA
complex is multi-turnover in catalysis of mRNA degradation [99], eventually the siRNA
is degraded. Hence, to achieve sustained or even transient gene silencing over a
therapeutically sufficient length of time, multiple copies of siRNA must be delivered to
each cell.
Viral delivery of siRNA or shRNA has been used extensively to engineer RNA
interference both in vitro [100] and in vivo, however, the majority of effort has focused
on non-viral gene delivery due to safety concerns and the inherently different nature of
siRNA therapy compared to traditional gene therapy. Early attempts at in vivo delivery
administered naked siRNAs via high-pressure tail vein injections [101, 102]. Clearly
this was not a therapeutically relevant method for siRNA delivery but rather a proof of
concept that systemic siRNA delivery could effectively inhibit gene expression. Because
siRNAs are significantly smaller than plasmids, they are amenable to direct chemical
modification to increase serum stability, resistance to degradation, and cell targeting
[103]. This approach has been successfully used to directly modify the sense strand with
a cholesterol molecule to achieve therapeutically significant in vivo delivery, albeit at
high doses [104]. Off-the-shelf and modified PEIs have also been used in vivo [105-107].
In the first reported successful use of siRNA in non-rodent species, unmodified siRNAs
were delivered by stable nucleic acid lipid particles (SNALP) in cynomolgus monkeys at
relatively low effective doses to stably knock down the endogenous liver-produced gene
ApoB [108]. More recently, siRNA encapsulated in cationic lipids have shown great
efficiency of gene knockdown in the liver [109, 110].
Inhibition ofInfluenza as a Model for siRNA Delivery
RNA interference is well suited for combating viral infections. In fact, it is
believed that RNA interference pathways evolved as a defense mechanism against gene
invasion from viruses, transposons, and other transgenes [111]. Indeed, its seems that
some viruses have co-evolved methods for suppressing RNAi in infected cells [112];
these mechanisms may reduce the clinical potential of viral systems for siRNA delivery.
When a virus infects a cell, it hijacks the cellular machinery to produce copies of the viral
genome as well as produce proteins to manufacture new viral particles. As such, every
virus must at some point use cytosolic RNA. RNA viruses in particular have single or
double stranded RNA genomes that may also be targets of RNAi. Due to the good match
of RNAi for treating viral infection, early clinically relevant work in RNAi targeted viral
gene expression of viruses like polio and HIV [113]. Influenza virus has been singled out
as one virus amenable to treatment with siRNA therapy. Influenza is a RNA virus with
no DNA intermediates in the viral life cycle, its genome consists of 8 segments of RNA
that may be targets for viral inhibition through RNAi, and the natural tissue distribution
of influenza infection limits the scope of siRNA delivery that would be necessary for
effective influenza knockdown [114].
Treatment of viral infections can be difficult particularly if no specific medicines
currently available (HCV, RSV, SARS, etc). In managing newly identified pathogens,
developing small molecule inhibitors of viral infection may take years; escape mutations
could render such efforts useless. If a platform for RNA interference to combat viral
infections was developed, it would be readily applicable to any number of viruses for
which genetic targets could be rapidly identified. Also, viral inhibition would not have to
be complete. Rather, viral replication and life cycle inhibition would only have to be
sufficient enough to allow the immune system to natural clear the virus. Therefore,
RNAi for antivirals would also be particularly beneficial in immune compromised
patients such as infants, the elderly, HIV carriers, and transplant recipients. The scope of
such a platform would be defined not by a specific pathogen, but rather by the
effectiveness of drug delivery to the site of infection.
RNA Activates the Innate Immune Response
Just as viruses have evolved to efficiently deliver nucleic acids, the immune
system has evolved methods to detect viruses by detecting the characteristic patterns
associated with pathogenic nucleic acids. Nucleic acids can interact with a variety of
intracellular sensors that have evolved to protect cells against invasion from foreign
genetic elements (viruses, transposons, etc). Recognition of pathogen-associated
molecular patterns (PAMPs) activates the immune system through a variety of
evolutionarily conserved receptors including the toll-like receptors [115-117] and other
intracellular and surface receptors. This recognition and innate immune activation is
restricted to certain cell types depending on their immunologic function and TLR
receptor expression profile [117-119]. There are at least 10 functional human TLRs
(Figure 8) (1-10). Most of the TLRs signal through an intermediate called myeloid
differentiation primary response protein 88 (MyD88). MyD88 and other adapter proteins
mediate eventual downstream activation of Nf-icB and induction of innate immune
activated genes [15]. TLRs 3, 7, 8, and 9 have specifically evolved to sense pathogenic
nucleic acids from viruses and bacteria [116, 119-122]. However, cellular mechanisms
must exist to prevent activation of TLRs to endogenously expressed DNA and RNA
[123] to prevent uncontrolled innate immune activation and the auto-immune
consequences [121, 124, 125]. These mechanisms include compartmentalization to the
endosome and cell-specific expression of TLRs [15, 123].
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Figure 8 - The Toll-like receptors (TLRs) 1 through 10 schematized with respect to
intracellular location, signaling intermediates, and purported physiologic ligand.
TLR10 is predicted by genetic and structural similarities, though the physiologic function
is not known [15].
Figure 9 - Long dsRNA can activate the innate interferon response. Almost all cell
types have the intracellular receptors PKR and RGI-I, which recognize dsRNA and
trigger an interferon response. Interaction with TLR3 in many epithelial and immune
cells can also induce the interferon response to dsRNA. siRNAs are though to avoid
these pathways.
The use of siRNA molecules for eliciting RNA interference was originally
pioneered to avoid interferon responses generated by longer double-stranded RNA
(dsRNA) molecules [126]. Long dsRNA interacts with Toll-like receptor 3 (TLR3) as
well as the PKR and RIG-I PRR molecules to induce interferon responses in a wide
variety of cell types (Figure 9) [77]. However, siRNAs have also been shown to interact
with toll like receptors 7 (TLR7) [127] and 8 (TLR8) [128] to induce interferon
responses. In both humans and in mice this interaction occurs mainly in the endosome of
a specialized cell called the plasmacytoid dendritic cell (pDC), which circulates in the
blood [123]. When activated by TLR7, pDCs are the most efficient producer of
interferon-alpha. Human B-cells express low levels of TLR7 [117], and TLR7 may also
be expressed in mouse myeloid dendritic cells (mDCs). Small RNA molecules that
interact with TLR7 to generate immune responses through interferon-alpha and other
cytokines have been termed immunostimulatory RNA (isRNA) [127]. A systemic
interferon response may confound or mask the effects of true RNA interference.
RNAi mediated by siRNAs in vitro will often avoid the generation of interferon
responses, particularly if the cells transfected with siRNAs are defective in interferon
response genes, do not express TLR7 or TLR8, or are not in contact with cell types such
as pDCs that are fully functional for generating interferon responses to siRNAs.
However, when administered in vivo, siRNA-loaded particles can readily interact with
pDCs. Additionally, RNAi machinery resides in the cytosol. There is evidence that
preferential compartmentalization of siRNAs in the endosome, which is the proposed site
of TLR7/8 - siRNA interaction, will lead to the isRNA response [123]. When siRNAs
are administered in vivo they must therefore avoid sustained internalization into the
endosome of pDCs and other TLR7-responsive cells, or siRNAs must be modified to
prevent TLR7 activation (Figure 10) [129].
Figure 10 - The same siRNA can function in two ways. siRNA retained in the
endosome of a pDC or B-cell may interact with TLR7; TLR8 resides in the endosome of
mDCs and other immune cells of the monocyte / macrophage lineage. Activation of
TLR7/8 leads to characteristic induction of the type I interferon response and release of
cytokines such as TNF-alpha and IL-6. However, siRNA released into the cytosol can
lead to RNAi-mediated gene silencing.
Cationic "Lipidoids "for RNA Delivery
Our lab has taken a cationic lipid-based approach to the development of novel materials
for systemic siRNA delivery similar to the approach we previously took for PBAE-
mediated DNA plasmid delivery - high throughput screening. Due to the uncertainty in
predicting structure-function relationships between lipid molecules and overall
transfection efficiency, particularly considering the multi-component nature of cationic
lipid-nucleic acid formulations, we have approached development from a high throughput
screening standpoint similar to the approaches used to generate PBAEs. A large library
of lipid-like materials, called "lipidoids", was generated using combinatorial chemical
synthesis [109]. To this end lipids were synthesized through the conjugate addition of
alkyl-acrylates or alkyl-acrylamides to primary or secondary amines (Figure 11). Since
these compounds were synthesized without solvent (Figure 12), raw product was simply
mixed with siRNA and screened for siRNA transfection in vitro. This library was
subsequently screened for in vitro siRNA delivery and resulted in multiple compounds
that are semi-optimized for siRNA complexation, in vitro transfection, serum stability,
and cytotoxicity without complex understanding of lipid structure or intracellular events.
Many lead compounds were identified, including 40 candidate lipids that can transfect
HeLa cells in vitro better than Lipofectamine 2000, a commercially available cationic
lipid. Most of the candidate lipids contain non-degradable amide bonds in the linker
group and had multiple tails with 8 to 12 carbon length chains. These materials were
further studied for in vivo delivery of siRNA molecules, and have been shown to very
efficiently inhibit liver-specific genes without inducing off-target toxicity of the micro-
RNA pathway in a variety of species, including non-human primates [109, 130].
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Chapter 2
Title
Suppression of Influenza Replication In Vivo by Efficient Delivery of Immuno-
Stimulatory siRNA Molecules
Abstract
RNA interference of influenza virus is an attractive strategy to suppress viral infection.
We investigated the use of a new class of materials for prophylactic delivery of siRNA to
suppress influenza A virus in vivo in the mouse lung. Lipidoid 98N12-5(1) formulated
with siRNA targeting the influenza NP gene (siNP) and injected IV efficiently inhibited
influenza with over 99% reduction in lung viral titer, a 30-fold improvement over
delivery with PEI. Delivery of an unrelated siRNA targeting GFP (siGFP) had little
effects on viral titer indicating a sequence-specific siRNA effect. However, other
unrelated siRNA sequences (siBgal) were also able to suppress influenza replication, and
this suppression was correlated to efficient activation of IFN-alpha and TNF-alpha
indicating an innate immune response to lipidoid-delivered siRNA molecules. Chemical
modification to siNP that block TLR7/8 activation completely abrogated antiviral
activity, indicating a siRNA-dependent but RNAi-independent effect. Through
optimization of lipidoid formulation, we have developed a delivery system that efficiently
targets siRNA to innate immune receptors in vivo. This innate immune activation can
have therapeutically-relevant effects, such as suppression of influenza replication.
Introduction
RNA interference, mediated by short double-stranded RNA molecules termed
short interfering RNAs (siRNAs) [1], holds significant promise as an antiviral therapeutic
and has been applied to inhibit a variety of difficult-to-control viruses such HIV [2] and
hepatitis C [3]. RNA viruses have single or double stranded RNA genomes that may be
good targets of RNAi [4]. Respiratory syncytial virus (RSV) [5], parainfluenza virus
(PIV) [5], and SARS coronavirus (SCV) [6] have all been suppressed in vivo following
intranasal (IN) instillation of naked siRNAs. Lipid carriers have also been used to deliver
siRNAs effective against ebola [7] and the DNA virus hepatitis B [8].
In 2003, Ge et al [9] reported selection of siRNA sequences that efficiently
inhibited influenza viral reproduction in cell culture and chicken eggs. The most
promising siRNAs targeting the NP (siNP-1496) and PA genes of Influenza A/PR/8/34
(PR8) were subsequently used by Ge et al [4] to inhibit influenza in vivo in mouse
models of infection. They reported inhibition of viral titers in the lungs of mice
following intravenous delivery by linear poly(ethylenimine) (PEI). Tompkins et al [10]
used the same siRNA sequences delivered by hydrodynamic IV injection followed by IN
instillation of oligofectmaine/siRNA complexes to demonstrate protection against a lethal
challenge of multiple different influenza subtypes including H5N 1. Thomas et al [ 11] in
2005 demonstrated efficient inhibition of influenza in mouse lungs also using PEIs as
delivery materials for siNP-1496. In all reports, the same GFP sequence (siGFP-949)
was used as a control for any non-specific effects.
We have recently established a combinatorial library of cationic lipid-like
materials for delivery of nucleic acids termed "lipidoids" [12]. Using high-throughput
screening methods, promising novel materials were identified that exhibited highly-
efficient in vitro and in vivo delivery of siRNA molecules to elicit RNAi-mediated down-
regulation of liver-specific targets. Here we describe the highly efficient prophylactic
inhibition of influenza A in mouse lungs following delivery of unmodified siRNA
molecules encoding the same NP-gene previously described (siNP-1496) [9] using a
novel lipidoid nanoparticle formulation. In an outbred Black Swiss mouse strain, the
PEI-mediated delivery of siNP-1496 and a control siRNA targeting GFP (siGFP-949) had
a modest effect on lung influenza viral titers. Delivery of siNP-1496 with an optimized
lyophilized formulation of 98N12-5(1) was approximately 30-fold more efficient at
inhibiting lung viral titers than PEI. Viral titer reduction following lipidoid nanoparticle
injection was orders-of-magnitude more pronounced using si-NP-1496 than using siGFP-
949.
Viral inhibition with this lyophilized formulation of 98N12-5(1), however, was
found to be associated with a robust interferon (IFN) response that depended upon siRNA
sequence. Lipidoid nanoparticles containing siNP-1496 elicited high levels of IFN-alpha
and TNF-alpha, while particles with siGFP-949 did not cause marked elevation of these
cytokines. Additionally, viral inhibition in response to the irrelevant siBgal-728
sequence known to induce interferon [13] was similar to responses from siNP-1496
particles. Certain chemical modifications that abrogated the immune response were also
found to eliminate an inhibitory effect of siNP-1496. Here we have shown that these
interferon and related cytokine responses to siRNAs can be controlled through drug
delivery. By optimizing delivery to induce immune responses, we have developed a
method for immunostimulatory siRNA delivery that can significantly decrease viral
burden in a mouse model of influenza infection.
Methods
siRNAs
Unmodified siRNA molecules with 3'UU overhangs were purchased from Dharmacon
(Lafayette, CO) with the "in vivo" processing option or the "A4" processing option. The
siNP-1496 [9], siGFP-949 [9], and si-Bgal728 [13] sequences were as previously
reported. Chemically modified siRNAs with the siNP-1496 sequence and GL3 firefly
luciferase sequence (si1955/Luc) were synthesized by Alnylam Pharmaceuticals
(Cambridge, MA). See Table 1 for sequences and chemical modification.
Lipidoid and PEI nanoparticle preparation
Lipidoid 98N12-5(1) [12] was dissolved to 120 mg/mL in ethanol, cholesterol
(Ch) (Sigma Aldrich, St Louis, MO) was dissolved to 25 mg/mL in ethanol, and N-
palmitoyl-sphingosine- 1-[succinyl(methoxypolyethylene glycol)2000] (C 16 mPEG 2000
ceramide) ("PEG") (Avanti Polar Lipids, Alabaster, AL) was dissolved to 100 mg/mL in
ethanol. Lipidoid, Ch, and PEG were combined at a 15:0.8:7 mass ratio (L:C:P),
vortexed briefly, and diluted in a mixture of ethanol and sodium acetate (25 mM with
16.67 mg/mL sucrose) for a final lipidoid concentration of 7.5 mg/mL in 40% ethanol,
60% NaAc. siRNAs were diluted in NaAc, 25 mM, to 500 gtg/mL. Diluted
Lipidoid/Ch/PEG were added to diluted siRNA at a 15:1 mass ratio (L:R) and vortexed
for 20 minutes to allow complexes to form. Complexed lipidoid-RNA nanoparticles
were then extruded 10 passes through a double 200 nm membrane (Whatman, Florham
Park, NJ) on a Northern Lipids (British Columbia, Canada) extrusion system at 400 C. To
remove ethanol prior to injection, nanoparticles were dialyzed in a Slide-A-Lyzer 3500
MWCO dialysis cassette (Pierce Biotech) against PBS. For lyophilization, 10 mg of
sucrose was added per mL of extruded complexes prior to freezing at -800 C for >2 hours
followed by >1day lyophilization. Nanoparticles were resuspended or diluted in PBS to
250 ýtg siRNA/mL immediately prior to injection.
In Vivo Jet-PEI was purchased from Polyplus, Inc (New York, NY). PEI-siRNA
complexes were made according to the manufacturer's protocols immediately prior to
injection and diluted in PBS with 5% glucose.
Lipidoid nanoparticle characterization
For quantification and encapsulation efficiency of siRNA, a 50 tL sample of
nanoparticles was diluted 200-fold in Tris-EDTA buffer (TE), mixed with either 50 ýiL of
TE buffer or 50 pL of 0.4% Triton-X-100 (T-X) in TE, and incubated with 100 pL
Quant-It Ribogreen reagent (Invitrogen) according to the manufacturers protocols for 20
minutes at 370C in a 96-well black plate. Fluorescence intensity was determined at 485
nm (ex) / 535 nm (em). Total fluorescence in the presence of T-X was compared to a
standard curve of siRNA diluted in TE to determine total siRNA concentration; siRNA
encapsulation efficiency was determined by the ratio of fluorescence signal without T-X
and with T-X. Nanoparticle size was assayed by light scattering using a Zeta-PALS
instrument (Brookhaven Instruments).
Nanoparticle injections
Male Black Swiss mice were purchased from Taconic Farms and cared for
according to the standards of the Massachusetts Institute of Technology under the
guidance of the Division of Comparative Medicine. Mice were anesthetized with a
mixture of ketamine (10 mg/mL) and xylazine (1.5 mg/mL) in PBS by IP injection. PBS
at volumes equivalent to nanoparticle injections was used as a control. Injections were
made intravenously into the retroorbital plexus.
Influenza infection and viral titer assays
Mice were dosed with nanoparticles twice at 0 hours and 20 hours with influenza
infection at 24 hours. Influenza virus A/PR/8/34 (PR8) was diluted to 240,000 PFU/mL
in PBS with 0.3 wt% BSA and 100 U/mL penicillin / streptomycin. After anesthetizing
mice with ketamine/xylazine mixture, 50 ýtL (12,000 PFU) of diluted PR8 virus was
instilled intranasally (IN) dropwise. At 48 hours, 24 hours after infection, mice were
sacrificed and the lungs removed. Whole lungs were flash frozen in liquid nitrogen in
2mL of PBS with 0.3 wt% BSA and subjected to two freeze-thaw cycles. Lungs were
then homogenized by sonication to release virus, centrifuged at 800 RCF, 40C for 4
minutes, and supernatant samples were frozen at -800 C until analysis.
To determine viral titer by plaque forming units (PFU) assay, MDCK cells were
seeded at 0.5 x 106 cells/well in 6 well plates in DMEM (with 10 mM HEPES, 10% FBS,
100 U/mL pen/strep, 2 mM glucose) and allowed to grow to single-layer confluence
overnight. Media was aspirated from wells, and 200 gL of virus-containing samples
serially diluted 10-fold in PBS were added onto cells in triplicate. Following a one hour
incubation period with periodic shaking to distribute viral particles evenly, cells were
covered with 2 mL of semi-solid 1% agar / media solution to limit viral particle spread to
cell-to-cell contacts. Plaques were counted after 3 days.
To determine viral titer by viral RNA levels, lungs were harvested and flash
frozen with liquid nitrogen. Frozen lungs were then pulverized, and samples were
reconstituted in PBS and assayed for RNA level using a branched DNA assay
(Genospectra, Fremont, CA). RNA levels ofH1N1 genome (probes specific to HA gene)
were measured and compared to GAPDH mRNA levels as a housekeeping gene for
normalization to total RNA.
In vivo cytokine assays
Mice were dosed with nanoparticles following a similar schedule as described
above without influenza infection. Mice were dosed with nanoparticles twice at 0 hours
and 20 hours. At 28 hours, 8 hours after the second injection, mice were sacrificed and
blood was collected by cardiac puncture. Serum was collected following clotting and
centrifugation in serum collection tubes (Sarstedt, Newton, NC). Sandwich ELISA was
used to quantify serum interferon-alpha levels (PBL Laboratories, Piscataway, NJ) and
serum TNF-alpha levels (eBioscience, San Diego, CA).
In vitro cytokine assays
Human peripheral blood mononuclear cells were purified from anonymous donor
buffy coats by density centrifugation in Ficoll and plated in 96-well plates at 10^6
cells/mL. Gene Porter 2 and DOTAP were complexed with siRNAs and incubated at 130
nM concentration with PBMCs. After 24 hours, supernatants were collected and assayed
by sandwich ELISA for levels of IFN-alpha (PBL Laboratories) and TNF-alpha
(eBiosceinces).
In vitro RNAi assays
MDCK cells were seeded at 10,000 cells/mL in X-well plates. Cells were then
infected with PR8 influenza A virus. Following infection, cells were transfected with
siRNA after complexing 20 minutes with Lipofectamine 2000 (Invitrogen) according to
manufacturer's protocol. Viral titer was assayed by ELISA.
Results
98N12-(5)1-siRNA nanoparticles have antiviral activity
Short-interfering RNA's were encapsulated in nanoparticles based upon 98N12-
(5)1 lipidoid, a novel lipid-like material that has been used for efficient in vivo siRNA-
delivery to the liver (Figure 1). We have developed a method for generating stable
nanoparticles by formulation and extrusion of lipidoid with cholesterol and PEG-
ceramide in sodium acetate and ethanol. These particles consistently exhibit a
characteristic size of 70 - 100 nm as measured by dynamic light scattering with greater
than 90% encapsulation of RNA (Table 2). We investigated the use of lipidoid
nanoparticles for inhibition of the PR8 strain influenza A virus in a mouse model of
infection. Initial studies indicated a dose-dependent response following prophylactic
treatment with freshly formulated 98N12-(5)1 (Figure 2) particles. At 3 mg/kg siRNA
dosing, up to 13-fold (-93%) reduction in lung viral titer compared to PBS injections was
observed 24 hours after infection with a super-lethal challenge of 12,000 PFU. However,
siGFP-949 containing freshly extruded lipidoid particles also exhibited a 4.7-fold (-77%)
reduction in viral titer. Commercially available poly(ethyleneimine) (PEI), for
comparison, demonstrated a 5.8-fold (83%) viral titer reduction at 3 mg/kg dosing of
siNP-1496.
Optimization offormulation to increase antiviral activity
To further optimize particle formulation we varied our method of particle
preparation. Extrusion of particles through a 400 nm filter resulted in similar sizes as
extrusion through a 200 nm filter (data not shown). Extrusion of particles through a 400
nm filter without lyophilization did not result in knockdown as efficient as extrusion
through a 200 nm filter followed by lyophilization (Figure 4). Upon lyophilization and
reconstitution in PBS, lipidoid nanoparticles increased in size to between 400 and 700 nm
(Table 1). These larger particles were more efficient than non-lyophilized freshly
prepared particles at inhibiting influenza reproduction. At a lower dose (2 mg/kg) than
previously used with freshly extruded particles, viral titer reduction with lyophilized
particles was on average 36-fold (-97%) compared to PBS (Figure 3a). Compared to
freshly prepared nanoparticles, lyophilized lipidoid-siGFP-949 particles did not
significantly change viral titers. Freshly prepared PEI-siRNA nanoparticles also
demonstrated some inhibitory effect at 2 mg/kg dosing (3.6-fold inhibition of viral titer);
this effect was similar for both siGFP-949 and siNP-1496 (Figure 3a). Lyophilized
nanoparticles at 3mg/kg siRNA dosing reduced viral titer 13.4-fold (92.5%) for siGFP-
949 and over 300-fold (99.7%) for siNP-1496 (Figure 3b). However, at these high doses
lyophilized nanoparticles caused weight loss of 8% after the first injection and 16% after
the second injection.
Antiviral activity is not due to sequence homology with influenza genome
To address issues of sequence independent inhibition of influenza observed with
siGFP-949 particles, we added a scrambled control sequence of siNP-1496 to our
experimental set of siRNAs. Lyophilized lipidoid nanoparticles were formulated with
siGFP-949, siNP-1496, or scrambled si-1496-sc. We also investigated serum interferon
responses following dosing with nanoparticles. We observed a strong correlation
between viral inhibition (Figure 5a) and interferon induction (Figure 5b) with efficient
suppression of viral titers and activation of an immune response using the scrambled
siNP-1496 sequence. We then selected a siRNA sequence known to produce immune
responses, siBgal-728 [13], and compared anti-viral activity side-by-side with siNP-1496.
These siRNA's were synthesized by Dharmacon with the A4 processing option as
opposed to the in vivo processing option. Surprisingly, siNP and siBgal lipidoid particles
inhibited influenza reproduction equivalently, achieving over 90-fold reduction in viral
titer compared to PBS controls (Figure 6a). Both siNP and siBgal elicited large serum
IFN-alpha responses, while neither siGFP-nanoparticles nor PBS injections generated
detectable levels of serum IFN-a (Figure 6b).
Antiviral activity is due to immune responses
Chemical modifications to the siRNA backbone were investigated to block
immune responses to siRNAs. The siNP-1496 sequence was modified with various
backbone and nucleic acid substitutions (Table 1). Immune responses to modified
siRNAs were investigated in vitro by transfecting cultured human peripheral blood
mononuclear cells (PBMCs) with Gene Porter 2 or DOTAP. IFN-alpha and TNF-alpha
levels of culture supernatants were measured by ELISA 24 hours after transfection
(Figures 7a and 7b). Incorporation of neither deoxythymidine overhangs nor
substitution with a phosphorothioate linkage, which inhibits exonuclease activity, was
able to prevent immune responses. Endonuclease activity was inhibited by substituting
the hydroxyl group on the 2' carbon of ribose with a 2'-O-methyl group. This
endonuclease modification prevented immune responses when present on either sense or
antisense strands in vitro. Chemically modified siRNAs retained the ability to inhibit
influenza through RNAi mechanisms in vitro (Figure 8) with the IC50o of most duplexes
in the sub-nM range (< 0.4 nM). Notably, duplexes with the si3590 modified strand
exhibited a slightly reduced potency with IC50 approaching 1 nM.
A subset of combinations representing unmodified, endonuclease, and
exonuclease modifications retaining full in vitro RNAi activity was selected for in vivo
investigations of immune responses and antiviral activity. These modified siNP-1496
sequences were incorporated into optimized lyophilized 98N12-(5)1 nanoparticles. We
investigated both immune responses and inhibition of influenza in vivo in mice.
Chemical modifications that inhibited immune responses in human PBMCs in vitro also
prevented activation of IFN-a and TNF-a in vivo in Black Swiss mice (Figure 9a). We
have established a correlation between functional viral particles, as measured through
plaque forming assay, and levels of viral mRNA. Measurement of mRNA levels can then
be normalized to a house-keeping gene, GAPDH, to investigate specific inhibition of a
target gene. General reduction of RNA production would be expected in the event of
lipidoid-mediated toxicity. Elimination of the immune response abrogated antiviral
responses as measured by branched DNA assay for viral HA gene RNA levels (Figure
8c). Additionally, the GL3 si1995/Luc sequence targeting an irrelevant gene, firefly
luciferase, formulated in lyophilized 98N12-(5)1 particles did not induce significant
immune responses or antiviral responses (Figures 9a and 9b). Delivery of stimulatory
RNA's was associated with 10-fold reduction in viral mRNA levels normalized to
GAPDH mRNA levels, providing evidence that replication of the influenza genome was
specifically inhibited by the interferon responses and not due to carrier-mediated toxicity.
siRNA Strand Sequence Resistance
siNP-1496 S GGAUCUUAUUUCUUCGGAGUU
siNP-1496 AS CUCCGAAGAAAUAAGAUCCUU
siGFP-949 S GGCUACGUCCAGGAGCGCAUU
siGFP-949 AS UGCGCUCCUGGACGUAGCCUU
siBgal-728 S CUACACAAAUCAGCGAUUUUU
siBgal-728 AS AAAUCGCUGAUUUGUGUAGUU
si4746 S GGAUCUUAUUUCUUCGGAGdTdT
si4747 AS CUCCGAAGAAAUAAGAUCCdTdT
si3583 S GGAUCUUAUUUCUUCGGAGdTsdT exo
si3584 AS CUCCGAAGAAAUAAGAUCCdTsdT exo
si3589 S GGAucuuAuuucuucGGAGdTsdT exo and endo
si3590 AS CUCCGAAGAAAuAAGAUCCdTsdT exo and light endo
siLuc/1955 S cuuAcGcuGAGuAcuucGAdTdT exo and endo
siLuc/1 955 AS UCGAAGuACUcAGCGuAAGdTdT exo and endo
Table 1 - Sequences of siRNA molecules used throughout this study. S = sense strand,
AS = antisense strand. Chemically modified residues are underlined: dT =
deoxythymidine; s = phosphorothioate; lower case lettering = 2'O-methyl modification.
Resistance to exonuclease (exo) or endonuclease (endo) activity is also indicated. The
same base sequence is used for siNP-1496, si4746, si4747, si3583, si3584, and si3589;
these sequences all target the nucleoprotein (NP) gene of influenza A.
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Figure 1 - Chemical structure of 98N12-5(1) consisting of the 98 core (in blue) and 5
alkyl chains with 12 carbons each (in red). The 1st amine is left unsaturated.
Size (nm) Encapsulation (%)
Pre-lyophilization After resuspension
siGFP-949 94.3 +/- 0.8 624.4 +/- 78.2 96%
siNP-1496 91.8 +/- 1.4 442.2 +/- 23.8 90%
Table 2 - Physical characteristics of lipidoid-siRNA particles from representative
batches
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Figure 2 - Dose-dependent inhibition of influenza viral replication in mouse lung.
Mice were injected IV twice with freshly prepared un-lyophilized 98N12-5(1), PEI
nanoparticles, or PBS at 1 or 3 mg/kg siRNA prior to challenge with 12,000 PFU. Lung
viral titer was determined by quantitative plaque forming assay. A 13.8-fold viral titer
reduction was observed after 24 hours with 98N12-5(1) + siNP-1496 nanoparticles. * p <
0.05 by 6 group 1-way ANOVA followed by Bonferroni's multiple comparison test.
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Figure 3 - Lyophilization of 98N12-5(1) nanoparticles increases anti-influenza
effects of siRNA in the lung. Mice were injected IV twice with un-lyophilized or
lyophilized 98N12-5(1) siRNA nanoparticles at (a) 2 mg/kg or (b) 3 mg/kg siRNA prior
to challenge with 12,000 PFU. PEI and PBS treated mice are shown for comparison.
Lung viral titer was determined by quantitative plaque forming assay. Compared to PBS,
lyophilized 98N12-5(1) siNP-1496 particles reduced viral titer after 24 hours 36-fold
(97%) at 2 mg/kg and over 300-fold (99.7%) at 3 mg/kg. * p < 0.05 by 7 group 1-way
ANOVA followed by Bonferroni's multiple comparison test. ** p < 0.002 by two-tailed
t-test.
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Figure 4 - Fold reduction of viral titer due to different lipidoid particle
formulations. Particles were extruded through a 400 nm filter followed by dialysis, a
200 nm filter followed by direct lyophilization, or a 200 nm filter followed by first
dialysis then lyophilization. Mice were injected IV twice with nanoparticles at 2mg/kg
siRNA prior to challenge with 12,000 PFU. Mean viral titers were normalized to PBS-
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treated group mean viral titers to facilitate comparison between two separate batches of
infections.
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Figure 5 - Inhibitory effects of scrambled siRNA control sequence correlated with
induction of systemic Type I interferon response. Mice were injected IV twice with
lyophilized 98N12-5(1) siRNA nanoparticles at 2 mg/kg siRNA prior to (a) infection
with 12,000 PFU, or (b) blood collection by cardiac puncture. (a) Lung viral titer was
determined by quantitative plaque forming assay. (b) Serum IFN-alpha concentration
was determined by ELISA. Nanoparticles with siNP-1496 or scrambled control sequence
both elicited high levels of IFN-alpha that corresponded with significant reductions in
viral titer over nanoparticles formulated with siGFP-949. * p < 0.05 by 4 group 1-way
ANOVA followed by Bonferroni's multiple comparison test.
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Figure 6 - Inhibitory effects of siRNA sequences correlated with induction of
systemic Type I interferon response. Mice were injected IV twice with lyophilized
98N12-5(1) siRNA nanoparticles at 2 mg/kg siRNA prior to (a) infection with 12,000
PFU, or (b) blood collection by cardiac puncture. (a) Lung viral titer was determined by
quantitative plaque forming assay. (b) Serum IFN-alpha concentration was determined
by ELISA. Nanoparticles with siNP-1496 or unmatched siBgal-728 sequence elicited
high levels of IFN-alpha that corresponded with significant reductions in viral titer over
nanoparticles formulated with siGFP-949. * p < 0.05 by 4 group 1-way ANOVA
followed by Bonferroni's multiple comparison test.
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with 130 nM unmodified and modified (see Table 1) versions of siNP-1496 complexed
with (a) GenePorter 2 (GP2) or (b) DOTAP. Controls are untreated cells, cells with
empty transfection agent, or direct incubation with CpG oligo ODN2216 at 500 nM to
elicit IFN-alpha responses through TLR9 interactions. For (a) Donor A IFN-alpha is
plotted on the left axis (red) and Donor B IFN-alpha is plotted on the right axis (blue) -
note scale change to highlight correlation between two independent donors.
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Figure 8 - In vitro RNA interference of influenza virus using native and modified
siRNAs. Cultured cells MDCK were infected with influenza virus and transfected with
siRNAs. Culture viral titer is expressed as a percentage relative to non-treated control
viral titers. The dose-response RNA interference effects of siRNA were not significantly
altered by chemical modifications.
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Figure 9 - Chemical modifications to the siRNA backbone decrease in vivo
induction of serum inflammatory cytokines and antiviral responses. Mice were
injected IV twice with lyophilized 98N12-5(1) siRNA nanoparticles at 2 mg/kg siRNA
prior to (a) blood collection by cardiac puncture, or (b) infection with 12,000 PFU PR8
64
A
virus. (a) Serum IFN-alpha concentration was determined by ELISA. (b) Lung viral
RNA level was determined by bDNA assay and normalized to GAPDH mRNA levels. *
p < 0.05 by 3 group 1-way ANOVA followed by Bonferroni's multiple comparison test.
Discussion
The discovery that RNA interference is mediated by 21 to 23 nucleotide double-
stranded RNAs termed short interfering RNAs (siRNA) [1] opened a new therapeutic
potential - gene silencing mediated by siRNAs - since these smaller RNAs seemed to
avoid interferon activation [14] that was observed with longer double-stranded RNA
molecules [15]. Induction of intracellular interferon responses resulting in reductions in
protein expression occurs when longer dsRNA activates toll-like receptors (TLR) [16]
and cytosolic receptors of RNA such as PKR, Rig-1, and OAS [17]. However, siRNAs
have recently been shown to interact predominantly with toll like receptors 7 (TLR7) [18]
and 8 (TLR8) [19] to induce interferon responses. In both humans and in mice the
interferon-producing TLR7/8-siRNA interaction occurs mainly in the endosome of a
specialized cell called the plasmacytoid dendritic cell (pDC), which circulates in the
blood [20] and also resides in large numbers in the liver [21]. Other cell types, including
myeloid dendritic cells (mDCs), monocytes, and monocyte-derived DCs (mo-DCs)
express functional TLR8 in humans [22, 23]. While TLR8 appears to be only active in
mice under specific combinations of ODNs with small molecule TLR8 agonists [24],
TLR7 has been shown to have a functional role in both murine [25] and human [23, 26]
B-cells. Small RNA molecules that interact with TLR7 to generate immune responses
through type I interferons and other cytokines have been termed immuno-stimulatory
RNA (isRNA) [18].
Clinically relevant use of siRNAs requires a method of drug delivery. We have
developed a library of materials that can efficiently deliver small RNA's across cellular
barriers. We investigated one promising candidate material, 98N12-(5)1 for its ability to
deliver siRNA to the lung using a murine model of influenza infection. By optimizing
formulation of 98N12-(5)1 particles based on the criteria of enhanced suppression of
influenza viral replication, we have effectively developed a novel delivery system that
efficiently delivers siRNAs for immune stimulation.
The components of our nanoparticle system are the lipidoid 98N12-(5)1,
polyethylene glycol (PEG) ceramide, cholesterol (Ch), and RNA. PEG is well known to
increase circulation times by preventing aggregation and opsonization of particles to
avoid clearance by the reticuloendothelial system [27]; Ch serves the function of
imparting rigidity to the nanoparticle. It is unknown how the novel material 98N12-(5)1,
which was derived from a large screen of combinatorial materials, facilitates cellular
uptake. It is highly efficient for cytosolic delivery of siRNA molecules for functional
RNAi in vitro and in vivo to the liver and spleen [12]. We have observed similar isRNA
activity using 98N12-(5)1 delivery to human PBMCs in vitro (data not shown). Given
that efficient TLR7/8 engagement with siRNA molecules requires endosomal localization
[19], our results indicate endosomal uptake as one method of 98N12-(5)1 internalization
in vivo. It has also been shown that autophagocytosis is important for TLR7-mediated
recognition of ssRNA viruses in pDCs [28]. Considering that 98N12-(5)1 also shows
properties of endosomal escape via functional RNAi delivery, induction of autophagy
may also be facilitated by this material. Lyophilization clearly increases particle sizes,
though lyophilization alone is not sufficient as dialysis to remove ethanol prior to
lyophilization produced particles with decreased antiviral activity (Figure 4). Since
freshly prepared 98N12-(5)1-based siRNA nanoparticles efficiently target the liver and
spleen [12], we hypothesize that lyophilizing these particles and increasing the particle
size preferentially increases uptake in liver and splenic pDCs. Alternatively, these
particles may activate circulating pDCs or alveolar macrophages, which have been shown
to be potent producers of IFN-alpha following IN challenge with the RNA virus
Newcastle disease virus [29].
Previously it was reported that a 13-fold reduction in viral titer in a super-lethal
infection model similar to the one described here can lead to a survival benefit; a 63-fold
reduction in viral titer approached 100% survival rate [10]. Here we report inhibition of
viral titers that approaches 90-fold reduction at 2 mg/kg RNA dosing (Figure 6a) and
300-fold reduction at 3 mg/kg dosing (Figure 3) using unmodified siRNAs. Antiviral
activity of lyophilized 98N12-(5)1 nanoparticles was superior to PEI nanoparticles
encapsulating the same siRNAs. This antiviral activity was correlated with efficient
induction of a Type 1 interferon response through induction of IFN-alpha and a pro-
inflammatory cytokine response through the induction of TNF-alpha (Figures 6b and
9a). This innate immune response was correlated to siRNA sequence as the siGFP-949
sequence was not immunostimulatory but the siNP-1496 sequence did induce systemic
IFN-alpha. PEI-mediated delivery of these same sequences was not previously found to
induce an interferon response to either siRNA sequence [4, 11], although antiviral
activity was also lower than that reported here. Delivery with lyophilized 98N12-(5)1
particles preferentially to interferon-producing cells is likely to amplify the differences in
immunostimulatory potential between these two sequences.
The function of isRNAs can also be modulated by structural motifs such as a 5'
triphosphate [30] and intracellular localization to the late endosome [19]. Chemical
modifications that stabilize the siRNA molecule such as 2'-fluoro pyrimidines and 2'-0-
methyl purines have been shown to abrogate the interferon response [8]. 2'O-methyl
substitutions to the ribose backbone in particular have been shown to suppress TLR7 and
TLR8 interactions with isRNAs [31]. It has been hypothesized that these modifications
modulate binding of the Toll-like receptor through structural conformational changes and
affecting hydrogen bonding in the minor groove of dsRNA [32]. Additional evidence
points to stronger activity of TLR7/8 due to single stranded RNA ligands [33] and may
contribute to differences in inhibitory effects observed between synthetic "A4" option
and "in vivo" option siRNAs used in this study.
The immunostimulatory properties of unmodified siRNA are sequence-specific
and seem attributable to overall GU content [18, 19] but there is no complete consensus
on design criteria to avoid interferon responses. The sense strand of the siNP-1496
sequence has been suggested to activate human PBMCs in vitro [31]. Our findings are
consistent with this report. Replacement of the 3' overhangs with deoxythymidine had
no effect on immune activity in vitro in human PBMCs (Figure 7) or as formulated in
vivo in Black Swiss mice (Figure 9a). Further modification of the 3' overhangs with a
phosphorothioate linkage, which blocks exonuclease activity, also had little effect on
siRNA-mediated immune activation. Only with 2'O-methyl modifications, which
prevent endonuclease activity, were we able to block interferon responses in vitro and in
vivo. Accordingly, only endonuclease modifications blocked antiviral responses (Figure
9b). Previous reports have indicated that a minimum of 2 residues must be modified to
prevent immune responses [31 ]. We observed blockade of TLR activity with 2'O-methyl
modification of just one central uridine residue (si3590) in the antisense strand of the NP-
1496 sequence that efficiently prevented interferon responses (Figure 7). This central
base modification also slightly decreased the potency of RNAi activity, although it was
not eliminated, (Figure 6) and was not further investigated in vivo. Interestingly, heavier
modification with multiple 2'O-methyl bases on the sense strand (si3589) molecule did
not change RNAi potency. All of the other modifications completely preserved in vitro
RNAi activity.
RNAs modified on one strand with 2'O-methyl can even act as antagonists of the
isRNA-TLR7 interaction in a trans fashion, preventing isRNA responses from the
unmodified strand [32, 34] though there is some discrepancy in these reports between the
types on modifications that can exhibit this function. We observed a trans-inhibition of
interferon activity with the 2'O-methyl modified si3589 and si3590 strands both in vitro
and in vivo. While this property may be useful for preventing immune responses to
siRNAs, it may also present challenges for the design of a siRNA molecule that both
inhibits viral activity through RNA interference and promotes antiviral innate immune
responses through isRNA activity at the Toll-like receptor. Since TLR7 engagement is
important for innate antiviral responses [32, 35], avoiding TLR7 antagonists will be
clinically relevant for using RNAi in the infectious disease setting. A single RNA with
dual functionality may therefore only be readily achieved by controlled delivery to a
cytosolic location for RNAi activity and an endosomal location in pDCs for innate
immune activation.
Commonly used and commercially available cationic lipid transfection agents
such as DOTAP and Lipofectamine have been used to investigate isRNA activity in vitro
[8, 13, 18, 32]. Both lipid-based and PEI-based nanoparticles have also been reported to
generate isRNA activity in vivo [18, 31, 34]. However, most of these materials are
designed for general intracellular delivery and endosomal escape [27]. The antiviral
effects of 98N12-(5)1 nanoparticles encapsulating the isRNAs siNP-1496 or siBgal-726
were robust. This is the first report to our knowledge of the efficient delivery in vivo of
isRNA molecules to activate immune responses and is an important step towards
controlling delivery of RNA molecules.
The influenza virus is highly sensitive to Type 1 interferons, and pDC-mediated
production of Type 1 interferons is a critical component of innate defense against
influenza and other viruses [35]. A member of the RNAi pathway, Dicer, which
generates siRNA molecules from larger dsRNA molecules, has also been implicated in
the defense against influenza infection in vitro [36]. Small molecule TLR7/8 agonists
[37] and the stabilized TLR3-agonist poly(I:C-L:C) [38] have shown potent antiviral
activity in vivo. Additionally, isRNA molecules have been used to induce anti-tumor
immunity [39]. The application of isRNA for immune activation may also be readily
applied to adjuvant vaccine responses [40]. Beyond the potentially therapeutic benefits
of isRNA, here we describe evidence that specific delivery of small RNA molecules may
also significantly alter RNA function. As we have observed, a systemic interferon
response may confound or mask the gene-specific effects of true RNA interference. We
were unable to distinguish any antiviral effect due to RNAi from the large antiviral effect
brought on by the systemic interferon responses. Since TLR7 activity is both cell-
specific and compartmentalized to the late endosome, controlled delivery can influence
the level of immunostimulatory siRNA activity. Excessive activity of TLR7/8 leading to
increased Type 1 interferon secretion from the pDC has been associated with
autoimmunity [41]. When siRNAs are administered in vivo they must therefore avoid
sustained internalization into the endosome of pDCs and other TLR7/8-responsive cells,
or siRNAs must be modified to prevent TLR7/8 activation. An attractive therapeutic
potential use of controlled siRNA delivery would be simultaneous RNA interference
activity and immunostimulatory RNA activity from the same short interfering RNA
molecule. Our work offers a proof of concept of optimizing in vivo drug delivery for one
set of RNA functions. Further work is needed to define the properties of drug delivery
systems that will allow more exquisite control of RNA function through targeting to the
desired tissue site, cell type, and intracellular compartment.
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Chapter 3
Title
A Novel High-Throughput Cell-Based Method for Integrated Quantification of Type I
Interferons and In Vitro Screening of Immunostimulatory RNA Drug Delivery
Abstract
We have developed a cell-based assay to detect Type I IFNs that reliably senses
both IFN-alpha and IFN-beta simultaneously. The 293T cell line was stably transfected
with a fusion gene of monomeric red fluorescent protein (RFP) under the promotional
control of an interferon-sensing response element (ISRE). Through optimization of
fluorescence detection methods using high throughput fluorescence assisted cell sorting
(FACS) analysis, we have achieved lower detection limits approaching that of ELISA
with a greater dynamic range. We apply a simple two-step process for transfection of
PBMCs and detection of secreted Type I IFN with the 293T-ISRE-RFP system to
discovery of materials for isRNA delivery potential. Utilizing high throughput
microplate methods, we report screening of a variety of cationic non-viral nucleic-acid
delivery materials as a proof of concept. The screening and detection methods described
herein are not limited to isRNA delivery and could be applied to other applications for
which high throughput detection of type 1 interferons is desired such as small molecule
investigations of the biology of siRNA-TLR receptor interactions or chemical
modifications for preventing immune responses to siRNAs. The method described herein
could be a useful tool in elucidating structure-function relationships governing delivery
of RNA molecules to the innate immune system.
Introduction
The application of large chemical libraries generated for gene delivery or other
clinically relevant applications can benefit from high-throughput-capable biological
assays [1]. The screening of combinatorial materials is a powerful tool for the
development of material structure-function relationships in systems too complex to be
currently understood by first principles [2, 3] such as the immune system. The traditional
workflow of combinatorial materials discovery is material generation, screening for
simple biological readouts in vitro, and selection of a few candidate materials for in vivo
study. A driving factor in this process is the ease of use and relatively low expense of
simple in vitro diagnostics. By comparison, animal experimentation often produces
unexpected and complex results due to materials and drug interactions at the tissue and
systems level that are not captured at the in vitro level. Additionally, in vivo
experimentation is time consuming and expensive.
The immunologic responses to materials are often only considered once the level
of in vivo work has been reached. The development of in vitro screening protocols to
investigate immunologic responses to materials can provide additional data at an early
stage in the process of material development. Candidate materials eliciting undesired or
harmful immune responses could be eliminated in an early development stage. If the
desired function is activation of the immune system, early stage in vitro diagnostics can
provide valuable insight into library design and can generate focused information on a
much greater variety of materials than can be afforded at the in vivo testing stage.
We are interested in the controlled delivery of RNA for RNA-based therapeutics.
RNA molecules hold great promise due to the diverse functions of RNA such as gene
expression, regulation [4], and immune stimulation [5]. RNAi, mediated by small 21-23
nucleotide double-stranded short interfering RNAs (siRNA), holds the therapeutic power
of turning off genes in a transient and controlled fashion to modulate diseases such as
viral infection, cancer, or a genetic pathology [6]. Small RNA molecules, including
siRNAs, can also stimulate the innate immune system [7], which can lead to antiviral
properties [8], anti-tumor activity [9], and adjuvant vaccine responses [10]. However,
siRNA interactions with the immune system may cause undesired off target effects and
uncontrolled immune activation [7, 11, 12].
The immunostimulatory property of RNA arises through interactions with pattern
recognition receptors (PRR) such as the Toll-like receptors (TLR) [13]. In particular,
TLR 7 and TLR8, which are highly expressed in the plasmacytoid dendritic cell (pDC),
seem to be the most physiologically important receptors for siRNA molecules in mouse
and humans [14, 15]. The pDC is a circulating cell of hematopoetic origin which also
resides in large numbers in the liver [16]. It is specialized for the detection of ssRNA
viruses and responds by producing Type 1 interferons and other cytokines that activate
anti-viral responses. A hallmark of the pDC is its ability to produce over 1000 times
more interferon (IFN) alpha/beta per cell than any other cell type [15]. TLR7 has also
been found in B-cells where it may serve some roles in regulation of antibody generation,
and functional TLR8 in humans is also observed in myeloid dendritic cells, monocytes,
and monocyte-derived dendritic cells [17]. TLR7 and TLR8 are segregated to the
endosome where they can function only after acidification [18]. RNA molecules that
activate the immune response through TLR engagement have been termed isRNA [13,
15]. However, this definition is more functional than it is absolute as RNA sequence,
structure, and intracellular location can influence immunostimulatory properties.
The power to harness the potentially therapeutic properties of RNAi or isRNA lies
in the ability to deliver RNA in a clinically relevant manner. Unfortunately, the broad
field of nucleic acid medicines in general has been hindered by a lack of suitable agents
for drug delivery [19]. Decades of experience optimizing delivery of DNA has yielded
many technology platforms for gene delivery such as engineered viruses, ballistic gene
gun systems, cationic polymers, and liposomes [20]. While some viral and non-viral
methods have emerged as promising, the direct application of DNA delivery technologies
to RNA delivery has been significantly more difficult than originally anticipated [21].
One approach has been to deliver plasmid DNA encoding for short hairpin RNA
(shRNA) that can enter the RNAi pathway [22]. Yet this method is limited by the same
cellular and intracellular barriers facing DNA delivery. Differences in relative size and
stability of RNA and DNA, different intracellular sites of action, and differential
functional goals have led researchers to seek novel methods for delivery of RNA
therapeutics.
One method for materials discovery is high throughput screening of material
libraries [2]. By probing a library of chemically related materials one can also define
structure-function relationships governing gene delivery, as has been demonstrated for
poly(beta-amino esters) and plasmid DNA delivery [23]. We have recently synthesized a
large library of cationic lipid-like materials termed "lipidoids" [24]. These lipidoids
were screened for functional delivery of siRNA in vitro. Briefly, a stable cell line
expressing two reporter genes, Renilla and firefly luciferase, was generated to allow rapid
quantitative and high throughput screening of gene specific inhibition following
transfection with lipidoids and siRNA targeting the Renilla gene (firefly serves as a
control). Using this method, over 20 materials were discovered with the ability to
transfect siRNA into cells in vitro with target-specific knockdown greater than that of
Lipofectamine 2000, a commercially available transfection agent.
We have developed a new method for screening for a specific type of innate
immune response to RNA drug delivery that results in pDC-mediated generation of Type
I interferons. Here we report the development of a simple in vitro method for screening
for isRNA delivery to human immune cells. A limiting factor in screening for Type I
interferon responses is the traditional reliance on low-throughput and costly ELISA
assays to quantify interferon levels. Our high-throughput method is enabled by the
generation of a novel cell-based assay for detection of human interferons that has a high
dynamic range, robust sensitivity, and 96-well plate compatible workflow. As a further
proof of concept, we demonstrate the utility of this method in screening a subset of PBAE
and lipidoid materials for immunostimulatory RNA drug delivery.
Materials and Methods
Recombinant protein standards, ELISA assays, and RNAs
Carrier free recombinant human interferon-alpha A (hIFN-a), specific activity
0.233 U/pg), and interferon-beta la (hIFN-b), specific activity 0.3 U/pg) were purchased
from PBL Laboratories (Piscataway, NJ), diluted to 1.0 x 106 U/mL in PBS with 0.1%
BSA, and stored in 250 ýtL aliquots at -800C until use. To verify screening results,
samples were diluted 1/6 in dilution buffer and interferon concentration was quantified by
sandwich ELISA with a hIFN-alpha multiple-subtype ELISA kit or hIFN-beta ELISA kit
(PBL Laboratories) according to manufacturer's protocols. Unmodified siRNA
molecules with 3'UU overhangs were purchased from Dharmacon (Lafayette, CO) with
the "A4" processing option. The siGFP [25], and siBgal [26] sequences were as
previously reported. R1362 single-strand isRNA was a gift from Coley Pharmaceuticals.
Stable transfection of a 293T cell line with reporter gene construct
The 293T-ISRE-RFP-CAT cell line was obtained from collaborators at Mount
Sinai School of Medicine (Adolfo Garcia-Sastre). This cell line was treated with 10,000
U/mL of recombinant hIFN-a for 24 hours and then sorted by FACS with gating for mid-
level RFP expression. This subset and subsequent generations (referred to as 293T-
ISRE-RFP) were used in all experiments reported herein.
Flow cytometry analysis and quantification of Type I IFN activity
For quantification of Type I IFN activity in samples or standard curves, 293T-
ISRE-RFP cells were seeded overnight at 10,000 cells per well in 150 ýtL of growth
media (D-MEM, 10% FCS, 100 U/mL penicillin/streptomycin) in 96-well tissue culture
plates. To generate standard curves, hIFN-a or hIFN-b was serially diluted in
supplemented RPMI media (RPMI 1640 medium with 10% FCS, 1mM MEM sodium
pyruvate, 10 mM HEPES, and 100 U/mL penicillin/streptomycin). In triplicate, 50 gL of
standard or sample was added to wells followed by overnight incubation.
To prepare cells for flow cytometry, media was completely aspirated from each
well and replaced with 25 tL of 0.25% Trypsin-EDTA (Invitrogen) for 10 minutes. An
additional 50 gL of FACS buffer (PBS with 1% BSA and 2 mM EDTA) was added to
each well and cells were resuspended by repeated pipetting. All 75+ PiL was transferred
to a round bottom 96-well analysis plate for high throughput flow cytometry. Fluorescent
flow cytometry was performed on a Becton Dickson LSR II system equipped with a HTS
option. Fluid handling settings were 50 ýpL sample per well at 2.5 giL/sec flow rate.
Cells were excited using the 488 nm laser and mRFP signal with mRFP detection using
the PE-Texas Red filter set (610 nm with 20 nm bandpass) and auto-fluorescence
detection using the PE filter set (575 nm with 26 nm bandpass). Treestar FlowJo
software (Ashland, OR) was used for cytometry gating and data analysis.
Screening of lipidoids and PBAE polymers
Donor-blind buffy coat packs were obtained from the Massachusetts General
Hospital Blood Bank and diluted in PBS with 2mM EDTA. Peripheral blood
mononuclear cells (PBMC) were obtained by Ficoll-Paque Plus (Amersham Biosciences)
density centrifugation at 400 RCF and washed twice in PBS/EDTA. Cells were
resuspended in supplemented RPMI and plated at 5x1 05 cells/well in 180 ýtL in 96-well
tissue culture plates.
Lipidoids [24] and poly(betaaminoester) polymers [27, 28] were synthesized as
previously described. These cationic transfection materials were dissolved in 25 mM
sodium acetate (NaAc), pH 5.0, to 0.5 mg/mL; RNA was diluted to 50 ýtg/mL in NaAc
and arrayed into a 96-well round bottom assay plate to facilitate high throughput.
Transfection materials were added to RNA at the indicated weight:weight ratios (15, 10,
5, and 2.5 : 1 for lipidoids; 30 and 10 : 1 for PBAEs) and thoroughly mixed by pipetting.
After 20 minutes of incubation at room temperature to allow formation of stable
complexes, complexes were diluted in supplemented RPMI and 25 ýpL of diluted
complexes were added to PBMCs for a dose of 100 ng RNA (-45 nM) per well. As a
positive control, siRNAs were mixed with Lipofectamine 2000 (L2K) (Invitrogen) in
Opti-MEM media (Invitrogen) for 20 minutes according to manufacturer's protocols
prior to adding 100 ng RNA per well to PBMCs. Mock transfection with uncomplexed
RNA diluted in NaAc and supplemented RPMI media was used as a negative control at
100 ng/well.
Following transfection and 24 hours of incubation at 37C, PBMC plates were
centrifuged at 450 G to clear suspended cells. A 100 jiL per well aliquot of supernatant
was stored at -800 C for later quantification of Type I IFN activity using the 293T-ISRE-
RFP system or for specific interferon levels by ELISA as described above.
Results
Generation and characterization of reporter cell line
A stably-transfected cell line based on the HEK 293T cell line was created by
retroviral insertion of a fusion gene construct of monomeric red fluorescent protein
(mRFP) [29] and chloramphenicol acetyltransferase (CAT) under control of an
interferon-sensing response element (ISRE) (Figure 1). Upon engagement of the IFN-
alpha receptor, 293T-ISRE-RFP cells increase mRFP expression, which is readily
detected by fluorescent cell cytometry with excitation from a 488 nm laser (Figures 2b
and 2c). Gating by cell size (Figure 2a) and non-specific fluorescence as measured by
PE-channel intensity (Figure 2b, left) allows for detection of RFP+ cells (Figure 2c,
left) that would not be discernible from the background autofluorescence of non-RFP
positive cells using single dimension gating (Figures 2b and 2c, left). Though mRFP
has low excitation at 488 nm (peak excitation at 584 nm, peak emission at 607 nm [29]),
this careful two-dimensional gating allows distinction of red fluorescence signal even
without a yellow laser.
Detection of Type I interferons
Expression of mRFP was interferon dose dependent. In the low range of hIFN-a
sample concentration, detection of RFP positive cells via two-dimensional gating for
mRFP signal allows for quantification of as low as 2.44 U/mL of hIFN-a (-10.5 pg/mL)
(Figure 3a). Concentration of hlFN-a followed a log-log relationship with percentage of
RFP-positive cells, independent of single-cell fluorescence intensity, that is highly linear
(R2 > 0.99) up to at least 625 U/mL. At greater concentrations of hIFN-a, the log of
mean fluorescence intensity of two-dimensional gated cells correlates to the log of hIFN-
a concentration with a linear range (R2 > 0.99) (Figure 3b) extending from 781 U/mL up
to at least 1x10 5 U/mL. The 293T-ISRE-RFP cell line is dose-responsive to both hIFN-a
and hIFN-b with a 4-fold lower detection limit for hIFN-a (Figure 4).
Screening of 10 lipidoid and 5 PBAE polymers for isRNA delivery
The robust and simple nature of the 293T-ISRE-RFP assay enables high-
throughput screening of materials for induction of type I IFN immune responses. We
used a 3 step workflow, outlined in Figure 6, comprised of complex formation,
transfection of PBMCS, and type I IFN detection. Due to incubation times, the process
takes 3 days from start to finish, but relatively minimal time per step. As the amount of
materials to be screened increase, the time per compound tested decreases significantly.
The bulk of time is usually spent in preparation of the PBMCs, which takes
approximately 3 hours, but other steps require minimal work. We have found that a
single buffy coat (-70 - 100 mL) can provide enough cells for 7 to 10 96-well
transfection plates. Additionally, the process can be accomplished in a piece-meal
fashion by freezing PBMC supernatants or preparing PBMCs a day in advance. We did
not observe loss in activity with PBMCs isolated and stored overnight at 40C in PBS with
2 mM EDTA (data not shown), providing further flexibility in workflow timing.
We applied this screening method to two combinatorial material libraries
synthesized in our lab for gene delivery that are cationic in nature and form nanoparticle
sized complexes with nucleic acids. Candidate compounds were pre-selected for
screening based upon prior activity for delivery of siRNA molecules for RNA
interference (10 lipidoids) [24] or DNA plasmids for gene delivery (5 PBAEs) [28].
Each compound was dissolved in sodium acetate at pH 5 to facilitate cationic - anionic
charge interactions and complex formation. In a 96-well plate format, samples were
arrayed and complexed with RNA at four different w:w ratios (for lipidoids) or two w:w
ratios (for PBAEs). The resulting particles were added to freshly isolated human PBMCs
and incubated for 24 hours. Supernatants were collected and frozen for subsequent
analysis by the 293T-ISRE-RFP cell-based assay for Type I IFN activity or ELISA assay
for specific IFN subtypes.
Of the 10 lipidoids tested, 4 compounds displayed significant induction of mRFP
above baseline levels. Lipidoids based on the 98-core chemistry, 3-tailed NA116, and 3-
tailed NC 100 all showed significant levels of activity with siBgal siRNA, a sequence
with known immunostimulatory potential [26] (Figure 7a). Only NC 100-3 exhibit
immunostimulatory effects with siGFP, a relatively non-stimulatory RNA. As a negative
control, naked RNA did not show isRNA properties, while siRNA delivered by
Lipofectamine 2000 (L2K) as a positive control did show isRNA properties for both
siBgal and siGFP (Figures 7a and 7b). Higher ratios of lipidoid produced greater
amounts of activity; RNA concentration was held constant across all transfection
conditions. The PBAE polymers were complexed with a single-strand RNA molecule,
R1362, which is a specific and strong agonist of TLR7/8. None of the 5 polymers
exhibited immunostimulatory delivery of RNA (Figure 7c).
One set of supernatants from PBMCs transfected with lipidoids complexed with
siBgal or siGFP was assayed by ELISA for hIFN-a and hFIN-b levels to verify cell-based
detection methods. Qualitatively, ELISA for (multitype) hIFN-a and cell-based analysis
detected interferon in the same wells (Figure 5), but the absolute quantity detected by
each method differed. Note that the 293T-ISRE-RFP assay is standardized to
recombinant hIFN-a and reported in terms of interferon activity (activity units, or U/mL)
whereas ELISA results are standardized by quantity (mass, or pg/mL). Specific activity
of the recombinant hIFN-a used as a standard for the 293T-ISRE-RFP assay was
approximately 4.3 U/mL, but the activity of hIFN-a standards supplied with the ELISA
kits used was unspecified. Levels of hIFN-b as assayed by ELISA were undetectable in
all wells (data not shown). We did not perform analysis for other types of Type I IFNs or
other cytokines.
Figure 1 - Development of a stably integrated cell-based Type I interferon detector.
A 293T cell line was stably transfected with the reporter construct depicted above. A
fusion gene of monomeric red fluorescent protein (mRFP) and chloramphenicol
aminotransferase (CAT) was placed under promotional control of an interferon sensing
response element (ISRE). This construct was transfected into a 293T cell line via
retrovirus and stable insertions were selected for by FACS.
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Figure 2 - FACS analysis and gating of RFP positive cells - 293T-ISRE-RFP cells
were plated at 10,000 cells/well in a 96-well plate overnight prior to incubation for an
additional 18-24 hours (b) with or (c) without 5000 Units/mL hIFN-alpha standard. Cells
were analyzed on a BD LSRII FACS analysis machine equipped with HTS plate
handling. (a) Forward scatter (FSC) and side scatter (SSC) pulse area (A), height (H),
and width (W) data were collected and used for gating based on cell size and complexity
to avoid cell debris and cell doublets. Cells were excited by a blue laser (488 nm) and
emission was collected in the PE channel (575/26 nm) and PE-Texas-Red channel
(610/20 nm). Two dimensional gating (PE vs PE Texas-Red, left) was found to be
superior to uni-dimensional (histogram, right) gating due to the ability to discern
autofluorescence. mRFP has an emission peak at 607 nm.
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Figure 3 - Low range and high range standard curves for interferon quantification
- Type 1 interferons cause dose-dependent expression of mRNA. Standards were
prepared by serial dilution of recombinant hIFN-alpha. For each point, 50 uL of diluted
standard were added to 150 uL of 293T-ISRE-RFP cells for a final dilution of 1:4. Pre-
dilution concentrations are plotted on the abscissa. Low range and high range signals
require different data processing. (a) Low range linear standard curve between 2.44
U/mL and 625 U/mL hIFN-alpha reveals a log-log correlation (filled squares, left
ordinate) of percentage RFP-positive cells by 2D-gating and pre-diluted sample
concentration. The same data are plotted in log-linear transformation (open circles, right
ordinate) for comparison. As low as 2.44 U/mL (- 10.5 pg/mL) hIFN-alpha can be
detected. (b) High range linear standard curve between 781 U/mL and 100,000 U/mL
(-4.29x105 pg/mL) reveals a log-log correlation (filled squares, left ordinate) of mean
fluorescence of 2D-gated cells and pre-diluted sample concentration. The same data are
plotted in log-linear transformation (open circles, let ordinate) for comparison.
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Figure 4 - Detection of either IFN-alpha or IFN-beta - Standard curves of
recombinant hIFN-alpha (type A and 2a) (blue squares) and recombinant hIFN-beta (type
)935 7
1 a) (green circles) were generated by serial dilution. For each point, 50 uL of diluted
standard were added to 150 uL of 293T-ISRE-RFP cells. Pre-dilution concentrations are
plotted on the abscissa.
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Figure 5 - Comparison of PBL hIFN-alpha multitype ELISA kit and 293T-ISRE-
RFP detection for a typical 96-well screening experiment. Human PBMCs were
transfected with various lipidoid compounds and isRNA (wells 1-12 & 49-60 siBgal, 25-
36 & 73-84 R1362) or non-is, siRNA (13-24 & 61-72 siGFP, 37-48 & 85-96 R1263) as
part of the lipidoid screen. Supernatant Type I IFN was assayed using 293T-ISRE-RFP
cells with recombinant hIFN-alpha type A as a standard. To verify Type I activity,
ELISA was performed using a PBL Laboratories hIFN-alpha multiple-subtype ELISA
kit.
Consideration ELISA 293T-ISRE-RFP
Fixed Costs $ Plate reader
Antibodies, plates,
Disposable Costs $$$$ reagents
Workflow + 4-6 man-hours per plate
Specificity ++++ mAb mediated
Sensitivity ++++ <20 pg/mL
Dynamic Range ++ 12.5 - 5000 pg/mL
HTS compatible Cost and time prohibted
$$$$ HTS FACS Machine*'**
$ culture media and plates
++++ <1 man-hour per plate
Ubiquitous Type 1 IFN
receptor
++++ <2.5 U/mL
++++ 2.5 - 100,000 U/mL
Yes
*FACS costs can be distributed over institution
**RFP may be adaptable to plate reader, reducing time and costs of FACS analysis
***Multitype ELISA for human IFN-alpha available; multiplex assays also possible
1 U ~ 4.3 pg recombinant IFN-alpha
Table 1 - Comparison of ELISA assay with 293T-ISRE-RFP assay
293T-ISRE-RFPConsideration ELISA
I
I
Nanoparticles + PBMCs
,q 4 1
A 1(b)
AT
Type I IFN 293T-ISRE-RFP
(c)
FACS Analysis
Figure 6 - Workflow for HTS screening of isRNA delivery - (a) Nanoparticles
containing siRNA are formulated in a 96 well plate and incubated with PBMCs for 24
hours. (b) Supernatants containing Type I IFNs are transferred onto a 96-well plate
containing 293T-ISRE-RFP cells. (c) HTS FACS analysis for RFP expression levels are
quantified after 24 hours of incubation.
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Figure 7 - Sample screening of 10 lipidoid and 5 poly(beta-aminoester) materials for
isRNA delivery - A set of (a-b) 10 lipidoid and (c) 5 poly(beta-aminoester) polymers
designed by combinatorial chemistry for gene delivery were screened for isRNA delivery
properties by complexing at the indicated weight:weight ratios (carrier to RNA) with (a)
siBgal, a double-stranded sequence with known isRNA activity, (b,c) siGFP, a double-
stranded sequence with low isRNA activity, or (c) R1362, a single-strand sequence with
known isRNA activity. Control transfection with Lipofectamine 2000 and naked RNA
shown for comparison.
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Figure 8 - Structures of lipidoid starting componetnets pre-synthesis. (a) Lipidoids
were synthesized as described [24] by reacting (b) amine-containing cores (red) with
alkyl-acrylate side chains (blue). Side chain substitutions are possible on all primary and
secondary amine of each core. Purified products are described by the side-chain, core
molecule, number of side-chain tails, and isomer if not fully substituted. For example, (c)
ND98-(5)1 refers to the 12-carbon alkyl-acrylate side chains on the 98 core with 5 (of a
possible 6) substitutions.
Discussion
We report here a new method for high throughput screening of isRNA delivery
utilizing cell-based assays for both innate immune activation and detection of responses.
Immune stimulation is a complex process involving multiple cell types and effector
molecules that can be difficult to reconstitute completely in vitro. We have focused on a
simple model of innate immune activation in donor peripheral blood mononuclear cells
(PBMC). This subset includes pDCs, monocytes, B-cells, and other dendritic cells. The
major hallmark of ssRNA-virus infection and siRNA-mediated immunostimulation is
production of Type 1 interferons by pDCs [5, 15, 30, 31]. Other cytokines and
inflammatory markers are also upregulated in response to TLR or other PRR engagement
by siRNAs including IL-10, TNF-alpha, and IL-6 [30, 32]. We have chosen to focus on
(8b)
Type I interferons as these are the most predominant responses to siRNAs and crucial for
generation of both innate and adaptive immune responses to viral infection [31, 33].
Detection of Type I interferon has traditionally relied upon enzyme-linked
immuno-assay (ELISA) and similar methods that rely upon the highly specific interaction
of monoclonal and polyclonal antibodies to detect and amplify the signal of IFN and
other cytokines. While ELISA is highly sensitive for detection and quantification, this
methodology is time consuming, requires multiple steps, relies on antibodies (and is
hence expensive), and typically exhibits 2-3 logs of dynamic range. Additionally, each
ELISA usually detects only 1 subtype of IFN or cytokine due to the specificity and low
cross-reactivity of antibodies. Multiplexed antibody-coated bead technology has
increased the throughput and spectrum of cytokine detection, but it remains expensive
and rooted in antibody-based technology.
To address the problems and limitations associated with ELISA-based assays for
interferon responses, we developed a cell-based assay for IFN detection. We have
utilized the HEK 293T cell line for its IFN receptors by expressing RFP under the control
of an ISRE (Figure 1). IFNAR activation causes a Jak/Stat signaling cascade that
eventually drives mRFP expression in a dose-dependent manner. Through optimization
of parameters for mRFP signal detection by fluorescent flow cytometry (Figure 2) and
subsequent data analysis (Figure 3), we can readily quantify the presence of both hIFN-a
and hIFN-b through the 293T-ISRE-RFP system. Because this system is cell-based, an
overnight incubation time period is require. However, the steps required are simply
addition of samples of PBMC supernatants to the 293T-ISRE-RFP cells followed by
quick preparation and flow cytometry, which was facilitated by HTS FACS analysis
capabilities. A list of pro's and con's of this cell-based assay compared to standard
ELISA is presented in Table 1.
At low ranges of interferon concentration, the most reliable method for
quantification of IFN activity was based upon counting the number of RFP-positive cells
(Figure 3a). This dependence upon the activation of mRFP in an off/on fashion indicates
threshold activity. Since activation of receptors is a stochastic process, purely on/off
signaling is expected to be dependent upon concentration of the receptor ligand and
independent of receptor surface concentration when well below receptor saturation. As
the concentration of IFN decreases, an individual cell is exposed to lower and lower
quantities of IFN in its local vicinity. Cells experiencing low local interferon
concentrations will therefore only activate a small number of IFN-receptors and not
express mRFP in large quantities. Therefore, if the limiting factor in mRFP expression is
IFN concentration, the most sensitive method for IFN detection using a cell-based
detection assay such as the 293T-ISRE-RFP system will be methods such as FACS
analysis that can distinguish single-cell fluorescence from the fluorescence intensity of
the entire population. The sensitivity for single-cell fluorescence is greatly increased by
controlling for cellular autofluorescence. This was achieved by two-dimensional gating
with simultaneous detection of mRFP signal on the PE-TR channel and autofluorescence
on the PE channel (Figures 2a and 2b), both of which are activated by the same laser.
As total interferon concentration increases, the local concentration an individual cell
experiences may be large and mRFP expression will be dependent on total surface
receptor activation up to saturation. In this case, increased activation of surface IFN
receptors may increase mRFP expression levels dynamically such that simple on/off
measurements of mRFP signal are not indicative of total activation. As a result, the high
range of IFN concentration was best correlated with mean single-cellular fluorescence
intensity (Figure 3b).
A benefit of these mRFP activation process is that the same methods can be used
to produce either low-range or high-range detection; merely the interpretation of flow
cytometry data must be changed to reflect the ligand-receptor dynamics. We were able to
detect as low as 2.44 U/mL hIFN-a, or approximately 10.5 pg/mL. The molecular weight
of h-IFN used is 19.4 kD, and 50 ýtL of sample or standard was diluted in 150 jtL of
media, indicating a sensitivity of 540 femtomolar hIFN-a for the 293T-ISRE-RFP
cells.We have achieved linear-range detection of type I IFN activity up to 100,000 U/mL
(sample concentration), which is approximately 4.3x105 pg/mL of standard recombinant
h-IFNa. For comparison, the high end of ELISA detection is approximately 5,000
pg/mL. It is possible that increasing the number of cells per well may increase the
dynamic range by reducing the ratio of interferon ligand to receptor ratio per well. We
chose 10,000 cells/mL because this amount resulted in the most consistent standard
curves without obvious overgrowth of an individual well in the 2 days between cell-
seeding and flow cytometry. Utilization of a yellow laser, which emits light with a
wavelength much closer to the absorption peak of mRFP [29], was unable to increase
detection limits (data not shown). Additionally, attempts at using fluorescent plate
readers for quantification of mRFP were only useful at very high levels of mRFP
expression (data not shown). The low range capabilities of FACS analysis are due to the
simultaneous detection of multiple channels allowing for autofluorescence quantification
and increase of the signal-to-noise ratio (SNR). Standard fluorescent plate readers are
limited to single channel emission detection for each excitation event and therefore have
a low SNR that prevents differentiation of RFP signal from autofluorescence background
at low concentrations of RFP.
An added benefit of quantification using a cell-based assay, which relies on
ligand-receptor activation, is the ability to simultaneously detect and integrate signals
from multiple sources. We have demonstrated this by independent activation of hIFN-a
and hIFN-b (Figure 4). While it may be desirable at times to differentiate the two
signals, in the case of HTS screening encapsulation of general type I IFN response into a
single output is more efficient than the multiple parallel assays that would be required
using standard ELISA. In a sample transfection of PBMCs, comparison of output from
293T-ISRE-RFP assays to ELISA assays revealed a distinct similarity in quality of
detection; hIFN-a detected by ELISA was also detected by 293T-ISRe-RFP cells (Figure
5). However, there was a striking difference in the detected quantity of overall type I
IFN activity. A much larger value was detected by cell-based assay than by ELISA. One
possible explanation for this discrepancy is IFN receptor signal amplification through
induction of autocrine signaling. Indeed, IFN-a receptor engagement can trigger hIFN-b
production that acts locally upon IFN-b receptors. Another possible explanation is the
presence of a type I interferon not detected by multitype IFN-a ELISA. We investigated
whether our results were skewed by the presence of hIFN-b in the supernatants, but none
was detected by h-IFNb ELISA (data not shown). There are other possible cytokines
which activate a receptor-mediated Jak/Stat pathway that can increase mRFP expression
through the ISRE. For example, type III IFNs have been shown to play an important roll
in antiviral immunity and are activated by type I activity [34]. It is possible that the
293T-ISRE-RFP cell has receptors for type III IFNs or other cytokines known and
unknown. We have not characterized 293T-ISRE-RFP activation beyond hIFN-a and h-
IFNb.
The development of a cell-based assay allows for the simple and cost-effective
high throughput screening of novel materials for isRNA-mediated immune stimulation in
vitro in a 3 step process (Figure 6). The utility of this process is not limited to only
isRNA delivery, and could be applied to investigate the incompletely understood
structure-function relationships of modified siRNAs and TLR interactions [11, 12],
sequence-dependent interactions with TLRs [15, 26], or other investigations where
detection of type I IFNs is crucial such as detecting early viral infection. As a proof of
concept, we investigated the isRNA delivery properties of 15 novel materials developed
originally for non-viral delivery of nucleic acids. Approximately 100 independent
reactions and PBMC transfections were performed in quadruplicate in a 96-well plate
format in less than one day, and measurement of type I IFN response was accomplished
with minimal effort using the 293T-ISRE-RFP assay.
PBAE polymer-mediated delivery of single-stranded isRNA was low for all
polymers tested (Figure 7c). It was previously found that a crucial function of PBAE
polymers that efficiently delivered DNA is related to ability to bind and complex plasmid
DNA into small particles and facilitate endosomal escape [27]. We did not investigate
the ability of the PBAE polymers form stable complexes with or encapsulate significant
amounts of RNA. However, immune stimulation by TLR7/8 RNA agonists requires
endosomal localization [18], and the final location of RNA delivery may explain the lack
of isRNA properties observed with PBAEs in vitro. The differences between polymer-
mediated delivery of DNA plasmids and siRNA molecules for RNAi have recently been
reviewed by Gary et. al. [21]. Because the site of isRNA action is indeed the endosome
and not the cytosol or nucleus, the delivery of RNA molecules preferentially to the
endosome or cytosol can be an additional method to control immunostimulatory nature of
siRNA molecules.
Screening revealed distinct immunostimulatory activity for some lipidoid
materials that was RNA-specific for siBgal (ND98-(5)1, NC98-(5)1, and NA116-3) as
well as high activity for both siBgal and siGFP with the NC 100-3 lipidoid (Figures 7a
and 7b). The 98 core has been found to be very useful for delivery of siRNA molecules
for RNAi both in vitro and in vivo [24]. We have also observed strong
immunostimulatory responses to siRNAs delivered by ND98-(5)1 (aka 98N12-(5)1)
(Figure 8c) in vivo (see Chapter 2). Here we find that siRNA delivery using ND98-(5)1
is immunostimulatory in vitro as well, providing clear evidence of the predictive power
of our isRNA delivery screening methodology. Consequently, it appears ND98-delivered
siRNA can reach at least two intracellular sites of action, the late endosome and cytosol.
The dual nature of ND98-delivered siRNA provides insight into the uptake mechanism.
It is unlikely that ND98-siRNA nanoparticles escape the endosome efficiently or isRNA
activity would not be as pronounced as it is, but delivery to the cytosol must be robust in
order to sustain an RNAi effect. Therefore, either ND98 nanoparticles are endocytosed
very rapidly, or endocytosis and endosomal escape is not the only route of entry. Of
note, both ND98-5(1) and NC98-(5)1 particles exhibited isRNA delivery potential.
These materials both have the same 98 core with 5 alkyl-acrylamide tails 12 carbons in
length for ND98 and 11 carbons in length for NC98 (Figure 8b). Our initial results
indicate that increasing hydrophibicity of the delivery material may increase isRNA
delivery. The 116 core, which is more hydrophobic that the other cores investigated, also
exhibited isRNA delivery potential. The 100 core of NC100 is very similar to the 98
core, but with only 4 possible substitutions. Changing from the 98 to 100 core increases
the molar ratio of secondary amine to alkyl chains and this may increase the
immunostimulatory delivery potential. However, NC 100-3 also was immunostimulatory
when complexed with siGFP.
The sequence of siGFP is has been shown to be a less stimulatory sequence than
siBgal in vivo (see Chapter 2) and repeatedly in our hands in vitro (data not shown)
though in this screening examples, siGFP seemed to elicit immune responses when
delivered by Lipofectamine 2000 (Figure 7b). The activity of L2K-delivered siGFP was
unexpected and is atypical, as repeated experiments rarely have show L2K-siGFP isRNA
activity (data no shown). It is possible that siGFP becomes more immunostimulatory
under certain conditions, such as sufficiently high late-endosomal concentrations.
Alternatively, the NC 100-3 material itself may interact with TLRs (TLR4 recognizes
bacterial Lipopolysaccharide [35]) or other innate immune receptors directly. In the case
of immunostimulatory oligonucleotides, CpG-mediated innate immune activity depends
on superstructure formation into nanoparticles that resemble viruses in order to interact
with TLR9 [36].
The other lipidoid cores (110, 111, 112, and 114) are all similar iterations of
similar chemistry that might a priori be expected to result in similar levels of isRNA
activity. Without a suitable method for in vitro screening, in vivo investigations would be
the only way to determine the immunostimulatory properties of these materials. Our
results demonstrate that delivery of siRNA with these materials is in fact not
immunostimulatory (Figure 7b) and highlights the utility of in vitro screening for isRNA
activity. Most methods for controlling innate immune responses to siRNAs has focused
on siRNA design [37]. By applying in vitro screening for isRNA delivery to the
complete lipidoid library, we hope to discover novel materials and elucidate design
criteria that will allow control of immunostimulatory RNA potential via drug delivery.
Conclusions
The delivery of RNA molecules holds great therapeutic promise to regulate both
gene function and immune activation, but efficient delivery has been a bottle-neck in
bringing RNA-based drugs into clinical use. Combinatorial chemistry has been utilized
by our groups and others to explore new materials for RNA delivery for siRNA
therapeutics. The immunstimulatory potential of siRNAs as it relates to intracellular
location is an important consideration in the rational design and iteration of these
materials. However, efficient screening methods for detecting immune responses to
siRNAs have not been available. Our new method, based upon cell-mediated detection
of the RNA-induced type I interferon response, is highly quantitative, efficient, and high-
throughput compatible. This method is not limited to isRNA delivery and may be
applicable in a wide range of investigations of innate immune responses. We have
applied this method in a proof-of-concept screening of two combinatorial material classes
for isRNA delivery. We characterized differential activation of the innate immune
response depending on material chemistry. Although the results of screening of just 15
materials is not sufficient to infer all the complex structure-function relationships
surrounding isRNA delivery, we have shown that the method outline herein can be an
important tool for defining materials properties in RNA drug delivery. Further
characterization of the lipidoid library and other materials used for RNA delivery using
the 293T-ISRE-RFP system may provide valuable insights into structure-function
relationships of materials with the innate immune system.
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Chapter 4
Title
Screening of a Novel Lipidoid Library for Functional Immunostimulatory RNA Delivery
and Comparison to siRNA Delivery Reveals Structure-Function Relationships Governing
Intracellular Delivery of RNA
Abstract
The delivery of single strand RNA (ssRNA) ligands of TLR7 and TLR8 could
potentially open a door to a variety of therapeutic applications in antivirals, anti-cancer,
vaccines, and autoimmune diseases. However, isRNA delivery to immune cells presents
a unique challenge for drug delivery. A library of cationic, lipid-like materials, termed
"lipidoids" was investigated for delivery of immunostimulatory RNA (isRNA) to human
PBMCs in vitro using a novel high throughput screening approach. Multiple compounds
that delivered isRNA to TLR7 in the pDC were identified, and many of these materials
exhibited similar structural features. Screening results for isRNA delivery were
compared to screening results for siRNA delivery. We found that lipidoid core chemistry
was more important than tail chemistry for defining overall activity potential, but tail
chemistry can modify or eliminate activity. Efficiency of siRNA delivery was more
affected by lipidoid tail composition than isRNA delivery, indicating that lipidoids have
multiple mechanisms of nanoparticle uptake and delivery. Lipidoid nanoparticles highly
efficient for both isRNA and siRNA activity were in the 150nm to 250 nm size. These
efforts offer important insights into structure-function relationships related to intracellular
RNA delivery and have highlighted novel materials for future investigation of RNA
delivery mechanisms, focused criteria for subsequent second generation lipidoid design,
and identified lipidoid cores useful for particular therapeutic applications.
Introduction
The controlled delivery of RNA to TLR7 and TLR8 to activate the innate immune
response has potentially therapeutic implications in a wide variety of clinical applications
[1] including antiviral activity (Chapter 2) [2, 3], anti-cancer applications [4, 5], and
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control of the adaptive immune response including vaccine adjuvants (Chapter 5) [6].
Additionally, TLR7/8 activation has been implicated in a wide range of autoimmune
diseases including lupus and allergy [1, 7-11]. Controlled delivery to immune cells
expressing TLRs could be harnessed for a novel treatment of autoimmune diseases by
delivery of chemically modified RNAs that can prevent activation of these TLRs
(Chapter 2)[12, 13]. Finally, the promises of RNA interference as a therapeutic are yet
untapped and will require sophisticated delivery of siRNA molecules [14-17]. While
much work has been pursued towards the goal of clinically viable siRNA therapy,
delivery mechanisms intended for RNA interference may not be suited for delivery
intended for TLR activation and will certainly need to avoid immune activation.
We hypothesized that drug delivery resulting in cellular and intracellular targeting
of RNAs can control the activity of an RNA molecule, as we and others have observed
with siRNA molecules (Chapter 2)[13, 18-22]. RNA recognition by TLRs is restricted
to the cell types expressing these receptors such as various dendritic cells and B-cells [11,
23-26]. In particular to the plasmacytoid dendritic cell, which expresses TLR7 and TLR9
in high amounts, is specialized to secrete large amounts of IFN-alpha in response to
TLR7 or TLR9 activation [6, 21, 24]. Monocyte dendritic cells also express TLR7 in
mice, and in humans have functional TLR8 as well [6, 24, 25, 27]. TLR3/7/8/9 activity is
restricted to the endosomal compartment [1, 19, 27, 28] and all activate through MyD88-
dependent signaling [28, 29]. In addition, certain structures and sequences appear to
differentially activate TLR7 and TLR8 in a manner that has yet to be completely defined
[13, 18-21, 27, 30-34]. Lipid-mediated delivery of CpG ODN, a high affinity ligand for
TLR9, using DOTAP has even been shown to control the activity and cell-specificity of
different types CpG ODNs by changing intracellular endosomal-lysosomal trafficking
[28]. Controlled delivery of RNA can therefore differentiate immunostimulatory RNA
(isRNA) from non-isRNA depending on dendritic cell uptake, endosomal localization
and duration, and potentially unknown factors such as achieving sufficiently high local
concentrations of RNA to unmask low-affinity receptors (Chapter 5).
The specific of macromolecule drug delivery to dendritic cells are largely
unknown. In general, uptake of drug delivery carriers by immune cells such as the
macrophages of the reticulendothelial system (RES) and other immune cells has been
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largely considered undesirable [35-40]. Additionally, the field of gene delivery has
concentrated on plasmid DNA, which must be delivered to the nucleus, or more recently
siRNAs for RNA interference, which occurs in the cytoplasm. As such, with focus on
cationic polymers and cationic lipids, many mechanisms have been designed into the
repertoire of materials for non-viral gene delivery to cross cellular barriers such as the
endosome and lysosome [35, 36]. These include endosomal buffering and the so-called
"proton sponge effect" of poly(ehtyleneimine) and related polymers [41, 42], direct
membrane fusion occurring by insertion following phase-transitions of lipid carriers [40,
43], or as in the case of cholesterol-conjugated siRNA, receptor-mediated cellular uptake
via physiological cycling of blood serum components such as lipoproteins [44].
As such, the specific delivery to the endosome of pDCs or mDCs, where TLR 7
and TLR8 are functional, presents a new challenge in the field of gene therapy as much
of the current rationale has been developed to accomplish the exact opposite. However,
there are some common design criteria that must be met for efficient non-viral delivery of
isRNA. These include: low toxicity, binding, stabilization, and protection of the nucleic
acid payload from ubiquitous intracellular and extracellular RNases, nanoparticle size
and stability to facilitate interstitial trafficking and cellular uptake, and eventually
endosomal release of the RNA payload in the endosome for interaction with TLRs.
Novel biomaterials encapsulating all of the known and unknown design criteria
might prove difficult to design de novo, so we have taken a high throughput screening
(HTS) and optimization approach to engineering drug delivery systems for this complex
problem. HTS methods for novel biomaterial design serve a dual purpose of discovering
new materials as well as providing design criteria for subsequent second generation
design [45, 46]. We have had great success in the development of novel polymers for
gene therapy by HTS methods [47] with subsequent second and higher generation
optimization based upon similar principles [48].
Recently, we have designed a novel library of lipid-like materials for the purpose
of RNA delivery [14]. These materials, termed "lipidoids", consist of amine-containing
core molecules that can be reacted with a variety of acrylate- and acrylamide-linked alkyl
chains to produce a large library of structurally-related yet distinct compounds. To
facilitate screening of this lipidoid library, a novel cell-based assay for quantification of
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type I interferons was developed (Chapter 3). For investigation of isRNA delivery, we
chose to deliver small, single-stranded RNA as these are the physiologic ligands for
TLR7 and TLR8 [23, 32], and ssRNA appear to be more immunostimulatory than double
stranded RNA and siRNAs [30] with respect to TLR7/8 activation.
We screened 96 different lipidoid compounds at 4 conditions with 2 RNAs, in
quadruplicate, using simple 96-well plate HTS methods over the course of 1 month. Our
results have highlighted a number of candidate compounds that efficiently delivered an
immunostimlatory RNA to human peripheral blood mononuclear cells (PBMCs), which
includes pDCs and mDCs. We hypothesized that drug delivery to specific cellular
compartments can determine RNA function in as much as the same RNA in the
endosome can activate TLRs and subsequent type I IFN production as well as it can
initiate RNAi in the cytosol (Chapter 2). Therefore, activity of either RNAi or immune
stimulation can serve as a surrogate for intracellular location. Although isRNA function
was not investigated with siRNA molecules directly, it is likely that for many lipidoids
the delivery properties are inherent to the material itself and not the RNa payload. We
compared the results of this library screen to a similar screen for siRNA delivery for
RNA interference purposes, and have identified many compounds for further pursued for
detailed analysis of structure-function relationships. As a first pass, nanoparticle physical
properties such as surface potential and particle size were investigated for a subset of
interesting lipidoids representing functional classes of the entire library.
Materials and Methods
Lipidoid synthesis and screening
Lipidoids were synthesized as described [14], in solvent free conditions and
purified of excess reactants (Figure 1). Crude mixtures were used to form nanoparticle
complexes in vitro with RNA in 96-well plate format to facilitate high throughput
screening. Similar methods for nanoparticle formation were used for both
immunostimulatory RNA delivery screening and for RNA interference siRNA delivery
screening. Briefly, lipidoids were complexed with RNA at four different weight ratios of
lipid to RNA (L/R ratio): 15, 10, 5, and 2.5 to 1, holding the concentration of RNA
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constant and varying lipidoid concentration during complex formation. Complexes were
incubated for 20 minutes prior to dilution in transfection media.
For RNA interference drug delivery screening [14], lipidoids were complexed
with siRNA targeting firefly luciferase and transfected into a HeLa cell line stably
expressing both firefly luciferase and Renilla luciferase for control. After 24 hours,
luciferase expression was assessed by light production following cell lysis and addition of
Dual-Glo luciferase substrate (Promega) according to manufacturers protocols. Gene
knockdown was quantified as a percentage of firefly luciferase activity inhibited
following transfection compared to untransfected cells, averaged over 4 independent
transfections per group. Non-specific inhibition of Renilla luciferase activity was
assessed as toxicity.
For immunostimulatory RNA drug delivery screening (Chapter 3), lipidoids were
complexed with ssRNAs R1362 (a strong activator of human TLR7/8 [33]) or R1263 (a
weak activator of TLR7/8 [33]) and transfected into human PBMCs. Human PBMCs
were obtained from donor buff coats or leukopaks obtained from the MGH blood donor
center by density centrifugation in Ficol-Paque (Amersham) according to manufacturer's
protocols. Occasionally, isolated PBMCs were stored overnight in PBS with 2 mM
EDTA at 40C prior to transfection. In 96-well tissue culture plates, 5 x 105 PBMCs/well
were transfected with 200 ng RNA (1 ýpg/mL, -140 nM) in supplemented RPMI (RPMI
1640 medium with 10% FCS, ImM MEM sodium pyruvate, 10 mM HEPES, and 100
U/mL penicillin/streptomycin). After overnight incubation, PBMC supernatant was
analyzed for content of type I interferons released in response to lipidoid nanoparticle
transfection. Type I IFN was quantified by cell-based 293T-ISRE-RFP assay (Chapter
3) and normalized to control activation by Lipofectamine 2000 for each batch of PBMCs.
Immunostimulatory activity was quantified as average type I IFN activity of 4
independent transfections per group relative to L2K activity.
Nanoparticle Zeta Potential and Sizing by Dynamic Light Scattering
Lipidoid nanoparticle complexes were freshly prepared in the same manner as
described for isRNA screening with R1362 ssRNA. After 20 minutes incubation to allow
of complex formation, nanoparticles were further diluted 1/5 in either sodium acetate (25
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mM, pH 5.0) or PBMC transfection media (RPMI 1640 supplemented with 2% FBS and
10 mM HEPES). Nanoaprticle sizes were immediate assayed by dynamic light scattering
followed by immediate investigation of zeta potential on a Brookhaven Instruments Zeta-
PALS instrument. Diluted nanoparticles were incubated for 2 hours at 370 C for at least 2
hours prior to a second analysis of particle size and zeta potential. If intial dilution
resulted in particle counts greater than 500,000 CPS, nanoparticles were further diluted '/4
in sodium acetate or RPMI 1640 media without FBS. Particle sizes were measured for 3
repeats of 30 seconds. Zeta potential was read for 20 cycles.
Results
High throughput screening of the lipidoid library was undertaken to identify
lipidoid compounds efficient at activating human PBMCs to produce the type I interferon
response of interferon alpha that follows TLR7/8 recognition of RNA molecules by pDCs
[21, 23, 31, 32, 49] and potentially other cell types [31, 50]. Over 800 independent
transfection reactions were performed in quadruplicate using 96 different crude lipidoids
(Table 1) and 2 RNAs. RNA R1362 (aka R-004[33]) has been shown to be a strong
ligand for both TLR7 and TLR8 in vitro in human PBMCs transfected with DOTAP [33],
and in vivo in mice (Chapter 5) and was used for isRNA delivery. RNA R1263 has not
been shown to interact with either human or mouse TLR7 or TLR8 when complexed with
DOTAP [33] and was used as a control for non-specific activation of type I IFN.
Type I IFN production by activated PBMCs was measured by FACS analysis
using reporter gene induction in 293T-ISRE-RFP cells (Chapter 3). Quantitative
analysis and comparison of lipidoid function was enabled by high throughput FACS
analysis of activated 293T-ISRE-RFP cells. We routinely were able to distinguish over 3
logs of interferon intensity with sensitivity, on average, below 50 U/mL of recombinant
IFN-alpha control. A total of 8 different batches of donor PBMCs were used to screen
the entire lipidoid library. To control for donor-to-donor variability in type I IFN
activation potential, isRNA transfection with Lipofectamine 2000 (L2K) was used as a
normalization control, and all isRNA activity data presented is normalized to L2K for
each donor. Additionally, for each donor, a purified version of ND98, ND98(5)-1
(Chapters 2 and 3) that is active for isRNA delivery was also used to delivery both
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R1362 and R1263 and had similar levels of strong R1362 and weak R1263 in all donors.
Finally, within each set of donor PBMCs, between 6 and 30 lipidoids were screened, and
both highly active and poorly active materials were observed with every batch. Together,
we have high confidence in our screening methodology and results.
Type I IFN activity for each weight ratio (L/R) was measured and all 96 lipidoids
were ranked according to the highest activity of any ratio (Figure 2a). Many lipidoid
compounds exhibited some level of activity, and this activity seemed to be more related
to the core amine component rather than the alkyl tail length. Of the 16 lipidoids that had
activity equal to or greater than that of L2K at any L/R ratio (Figure 2a), 4 had the 100
core (Figure la) including the top 3 lipidoid compounds, even though the 100-core
represented only 7 of the 96 lipidoid compounds tested. Further, each L/R ratio for each
lipidoid was ranked by isRNA delivery activity (Figure 2b). Of the almost 900
conditions tested, 106 combinations of lipid, RNA, and L/R ratio exhibited activity
greater than half that of L2K (Figure 2b). As highlighted in red in Figure 2b, the 100-
core is highly enriched in the subset of active lipidoid/RNA combinations making up 10
of the top 34 L/R combinations including the top 6 with the most active, NF 100 at an L/R
of 2.5, inducing on average 3.4 times more type I IFN production from PBMCs than
L2K. A total of 5 out of 7 100-core lipidoids exhibited some level of isRNA delivery
activity, while 1/7 (NH-100) was completely insoluble in sodium acetate and therefore
could not form lipidoid-RNA complexes. Activation of PBMCs with 100-core mediated
delivery was highly RNA-specific as none of the 7 tested compounds at any L/R ratio
induced above background detectable amounts of activity when complexed with R1263
(Figure 4a).
While 100-core lipidoids were the best performing lipidoids in the isRNA
screening pool, other lipidoid cores exhibited a consistent pattern of activity. The 86 core
and 87 core, which are structurally related dialcohols differing by only 1 carbon (Figure
1), were also highly active and are colored in blue in Figures 2a and 2b. Interestingly,
the most active of these materials exhibited greater activation of PBMCs with R1263 than
with R1362 (Figures 2b, 5a, and 5b). In the cases of NF86, NG86, and NG87, both
non-specific (R1263) and specific (R1362) delivery activity seemed to follow a classic
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dose-response relationship with respect to L/R ratio, implying that the lipid itself may
have some intrinsic activity not observed with 100-cores or other lipidoid compounds.
However, not all 100-core or 86/87-core lipidoids exhibited off target effects of
isRNA delivery, indicating modification of the intrinsic function associated with the
lipidoid core by the alkyl side chains. The lipidoid mixtures tested were all crude
compounds that were purified of excess unconverted reactants prior to screening. While
we do not know the exact composition of each lipidoid tests, lipidoid chemistry was
designed to drive all reactions towards full substitution of all available amines in the core
(Figure lb). The 100-core has two primary amines that can be substituted with up to two
alkyl tails each for a total of 4 possible substitutions. At low carbon-length tails, such as
LB 100 and LB 109 made with a 10-carbon alkyl-acrylate tail, maximum activity was
significantly less than the LD or ND lipidoids with the same core (Figure 2a). Further,
increasing from ND (12 carbons) to NF (14 carbons) to NG (15 carbons) increased
isRNA activity for the 100 core (Figures 2a and 4a). This trend, however, was not
reflected in other cores. Increasing tail length too much creates insoluble lipidoid
products. Lipidoid NH100 was insoluble in sodium acetate even after heating and
sonication.
Acrylate-linked tails, with the "L" designation, are degradable while acrylamide
linked tails, with the "N" designation", are stable bonds. While NF100 had the highest
activity of all lipidoids, the degradable version, LF 100, was not as active (Figure 2a) but
did exhibit isRNA activity across a broader range of L/R ratios (Figure 4a).
Quaternization was performed (Figure 1c) to introduce a permanent positive charge on
some acrylate-linked lipidoids. Quaternization (Figure 1c) of the degradable version of
NG100 severely reduced delivery potential (Figure 4a) while retaining the L/R ratio
activity smoothing effect observed for acrylate linkages. Further, quatemization of the
degradable versions of NG86, NF87, and NG87 also smoothed the L/R ratio activity
relationship (Figures 5a and 5b) as well as eliminating the non-specific R1263 activity
observed with these materials (for NG86 and NG87).
To gain more insight into potential and structure-function relationships governing
lipidoid RNA delivery, we compared the isRNA delivery potential of lipidoids with their
siRNA delivery potential. The completed screening of first-generation lipidoid-mediated
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siRNA delivery for RNA interference is currently in review [14]. The data set from this
siRNA delivery screening was compared to isRNA delivery screening data for
overlapping lipidoid compounds (Table 2). Activity in terms of siRNA delivery,
normalized to L2K isRNA delivery activity, was assigned to each compound and plotted
against RNAi-mediated gene knockdown efficiency. The results of this comparison are
presented in Figure 3.
Materials based upon the 100 core seem to have robust activity for both isRNA
delivery and siRNA delivery (Figures 3 and 4). ND100, NF100, and NG100 in
particular were highly efficient for both activities. The L/R ratio activity trends of
ND 100 were similar for both isRNA and siRNA activity, but this correlation was not
observed for the NF100 or NG100 lipidoids (Figure 4b). Similarly to what was observed
for isRNA delivery, the 86 and 87 cores also had mid-level activity for siRNA delivery as
well (Figure 3a). Interestingly, not all cores followed similar activity trends. Strikingly,
the 31 core, which had baseline activity in the isRNA screen (Figure 2a), was highly
efficient for delivery of siRNAs (Figure 3a) for three different compounds. A
structurally similar lipidoid, ND32 (Figure la), also had high activity for siRNA
delivery. The 95, 96, and 98 cores also seem to have high intrinsic intracellular activity.
Tail length seemed to have a greater effect on siRNA activity than isRNA
activity. For the 31-core, 100-core, and 103-core increasing tail length decreased siRNA
activity more than it decreased isRNA activity, but for the 109-core increasing tail length
reduced both isRNA and siRNA activity (Figure 3b). Not all data was available for
quaternized lipidoids, but the smoothing of the L/R activity relationship observed with
isRNA delivery for quaternized lipidoids was not observed with NF86 / QF86 (Figure
5a) or NF87 / QF87 (Figure 5b). Our experience with siRNA delivery indicated that
fully substituted materials were hydrophobic and insoluble in sodium acetate, depending
on tail length and number of possible tails. As such, in vitro screening is highly biased
against fully substituted materials. Further, the larger the tails become the less likely that
full substitution occurs during synthesis due to steric inhibition of the final substitution.
It is likely that all events observed during in vitro screening are dominated by n-1
substituted lipidoids.
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The physical properties of nanoparticles formed from lipidoids of interest were
further investigated for nanoparticle size and zeta potential in both sodium acetate and
serum-containing transfection media at 20 minutes and after long-term incubation
(greater than 2 hours). Lipidoids were complexed with R1362 at an L/R of ratio
obtaining the maximal isRNA delivery activity, and for the 100-core the range of L/R
ratios was investigated for ND100, NF100, and NG100. Focusing on the 100-core,
comparison of isRNA/siRNA activity (Figure 4b) reveals a correlation between
differences in nanoparticle size in media (Figure 4e) across L/R ratios. For NG100 and
ND 100, the L/R activity relationship in isRNA activity was followed by a similar trend in
particle size, though the absolute particle size was not necessary predictive of isRNA
delivery activity. Highly active compounds were between 200 and 300 nm after 2 hours
in media (Figure 4e). Smaller particle sizes between 150 nm and 250 nm did seem to be
more predictive of siRNA function. In sodium acetate, particle sizes for low L/R ratio
were larger than at high L/R ratio (Figure 4c), which correlated with higher zeta potential
(Figure 4d) and decreased isRNA and siRNA activity (Figure 4b).
We grouped the lipidoids into three groups based upon characteristics of isRNA
and siRNA delivery potential (Figures 3 and 6a). Group G1 lipidoids have low isRNA
activity but high siRNA activity, which includes the 31-core lipidoids. Group G2
lipidoids have high activity for both isRNA and siRNA delivery, including ND 100 and
NF100 as well as LF100 and ND98. Group 3 has high activity for isRNA delivery but
low siRNA delivery efficiency. As expected, lipidoid-RNA complexes in sodium acetate
generally exhibited a highly positive zeta potential that tended to increase over time
(Figure 6). Particle size trends in sodium acetate were more variable. Lipidoid-RNA
complexes in media had a negative zeta potential, likely due to interaction with serum
proteins. The most striking trend observed was the tight clustering of G2 (high isRNA,
high siRNA) lipidoid complexes between in a size range of 100 nm to 250 nm in serum-
containing media after 2 hours (Figure 6d). These materials also formed tighter
nanoparticles in terms of size at just 20 min in both sodium acetate and media than other
lipidoids. The zeta potential in media for this group was also fairly tightly distributed
between -10 and -25 mV (Figure 6e). Interestingly, the 31-core materials, which
dominate G1 grouping, had a peculiar characteristic. Over time in sodium acetate, they
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almost doubled in size, but this trend was not found in media (Figures 6h, left). More
strikingly, the zeta potential in sodium acetate over time inverted from highly positive to
negative, bucking the trend of highly positive zeta potential observed on essentially all
other lipidoids regardless of grouping and time (Figure 6h, right). By comparison, we
did not observe similar time-dependent behavior for ND32, a similar lipidoid based on
the 32 core but with non-degradable acrylamide linkages between the core and tails.
Other lipidoids based on the degradable acrylate linkage, such as LB 100 which had
similar siRNA/siRNA activity to GI lipidoids (Figure 6h), also did not exhibit a similar
trend.
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Figure 1 - Parent compounds of lipidoid library for isRNA delivery - (a) A subset of
components from the larger lipidoid library [14] used in this study. When combined with
amine-containing cores (red) to form lipid-like structures, alkyl-acrylate (L) tails form a
hydrolysable ester bond, and alkyl-acrylamides (N) form non-degradable amine linkages.
Tail groups (blue) are coded according to linkage and number of carbons in the alkyl
chain. (b) Schematic of solvent-free batch synthesis process resulting in crude mixtures
of lipidoid components. All reactions were performed in excess of tail groups to drive
towards full substitution of all core amine groups. Primary amines may accept up to two
tail substitutions and secondary amines can accept up to one. Crude products typically
contain a mixture of fully n-substituted and n-1 substituted lipidoids with rare n-2
substitutions. (c) A subset of degradable lipidoids was further reacted with methyl-iodide
to form quaternized amine structures with a permanent positive charge. These materials
were coded with the "Q" designation.
112
ND(12) NF(14,) NG(s5) NP(s), NH(18) L Q
ND20 NF20 NG20 NP62 NH20 LB100 QD94
ND24 NF25 NG28 NP63 NH28 LB109 QD99
ND25 NF28 NG32 NP86 NH32 LD31 QD109
ND28 NF32 NG61 NP87 NH61 LD87 QF80
ND32 NF60 NG64 NP95 NH95 LF31 QF86
ND36 NF61 NG77 NP96 NH96 LF93 QF87
ND61 NF63 NG86 NP98 NH98 LF94 QF91
ND66 NF64 NG87 NP99 NH99 LF95 QG87
ND94 NF70 NG95 NP103 NH100 LF96 QG100
ND95 NF86 NG96 NP109 NH103 LF99
ND96 NF87 NG98 NH109 LF100
ND98 NF91 NG99 LF103
ND99 NF95 NG100 LF109
ND100 NF96 NG103 LG31
ND109 NF98 NG109 LG76
NF99 LG93
NF100 LG96
NF103
NF109
Table 1 - List of the 96 crude lipidoid products screened for isRNA delivery.
Lipidoids arranged by tail chemistry and length. Lipidoids that were common to both
isRNA and siRNA screening are underlined. Nomenclature reflects alkyl tail linkage
(acrylate = L, acrylamide = N), alkyl tail carbon-chain length (A=9, B = 10, D = 12, F =
14, G = 15, P = 16, H = 18 carbons), and amine-containing core. Quaternized core-
amines were all generated on alkyl-acrylates and are further referred to with a Q
designation instead of L. Purified lipidoids includes number of tails in parenthesis ()
following tail name.
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20-28 36-64 86 91-94 96 99 103
ND20 ND36 QF86 QF91 NP96 QD99 NP103
ND24 NF60 NF86 LG93 NH96 NH99 NH103
ND25 NH61 LF93 NG96 NG99 NG103
ND28 NF61 LF94 NF96 NF99 NF103
NF64 ND96 ND99 LF103
LG96 LF99
LF96
31-32 76-80 87 95 98 100 109
LG31 LG76 QF87 NH95 NP98 NH100 QD109
LF31 QF80 NF87 NG95 NH98 NG100 NG109
LD31 LD87 NF95 NG98 NF100 NF109
ND32 ND95 NF98 ND100 ND109
LF95 ND98 LF100 LF109
LB100 LB109
Table 2 - List of the crude lipidoid products common to both the isRNA and siRNA
screen. Lipidoids arranged core chemistry.
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Figure 2 - Results of in vitro screen of 96 lipidoids - All 96 lipidoid compounds were
screened for isRNA delivery in vitro at 4 different mass ratios of lipidoid to RNA (15, 10,
5, 2.5 to 1), with an immunostimulatory RNA (R1362) and control RNA (R1263).
Complexes were added to 5x10 5 human PBMCs in 96 well plates at 200 ng RNA per well
(1 .tg/mL - 140 nM) for 16 - 20 hours. Type I interferon activity was determined by
cell-based 293T-ISRE-RFP assay and activity was normalized for each batch of PBMCs
to activity of Lipofectamine 2000 complexed with R1362. (a) Highest activity per
lipidoid of all 96 lipidoids. (b) Activity of any formulation (lipidoid, L:R ratio, or RNA)
with relative activity above 0.5. Specific core chemistries are highlighted: 100 cores are
colored in purple, 86 or 87 cores are colored in blue, 98 cores are colored in yellow, and
31 or 32 cores are colored in light green. Quaternized lipidoids indicated by color and by
green hash marks. Dashed line indicates relative activity of Lipofectamine 2000. Each
bar is the average of 4 repeats with standard deviation.
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Figure 3 - Comparison of immunostimulatory activity and RNA interference
activity of delivered RNA for selected lipidoids. Screening data sets were compared
for overlapping materials and coordinate activates of common lipidoids are shown. For
both screening methods, nanoparticles were prepared form the same crude lipidoid batch
by dissolving and complexing with RNA in 25 mM sodium acetate for 20 minutes prior
to dilution in media. (a) Activity for isRNA delivery of single stranded R1362 isRNA to
human PBMCs was normalized to activity of Lipofectamine 2000 and plotted on the x-
axis. Activity for RNA interference after delivery of double-stranded siRNA,
siLuciferace, to a luciferase-expressing HeLa cell-line was expressed as a percentage
inhibition of luciferase gene expression and plotted on the y-axis. Specific core
chemistries are highlighted: quaternized lipidoids in green, 100 cores in pink, 86 or 87
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cores in blue, 98 cores in yellow, and 31 or 32 cores in orange. Dashed lines indicates
relative activity of Lipofectamine 2000. Three groups of interest are circled in purple:
G1 - high siRNA, low isRNA; G2 - high siRNA, high isRNA; G3 - low siRNA, high
isRNA. Axis were broken and compressed into three segments to accentuate grouping.
Several lipidoid crudes were insoluble in sodium acetate and are represented as having no
activity on either axis. (b) Arrows connecting increasing tail length for a variety of cores.
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Figure 4 - Details of RNA delivery activity, nanoparticle size, and zeta potential for
100 core lipidoids. In total, 7 versions of 100-core lipidoids were investigated for (a)
immunostimulatory activity following delivery of R1362 or R1263 ssRNA (left axis) or
RNAi activity following delivery of luciferase siRNA (right axis). (b) The isRNA (left)
and RNAi activity (right) of the three 100-core lipidoids ND 100, NF100, and NG100 are
displayed side by side to facilitate comparison of activity with physical characteristics.
Lipidoid nanoparticles were made with R1362 RNA and assessed at 20 minutes and 2
hours following complex formation and dilution in (c,d) 25 mM, pH 5.0 sodium acetate
or (e,f) PBMC transfection media for (c,e) particle size and (d,f) zeta potential. Four
different weight ratios of lipidoid to RNA were investigated: 15 (red), 10 (yellow), 5
(green), and 2.5 (blue) to 1. For isRNA delivery, type I interferon activity was
normalized to Lipofectamine 2000 delivery of R1362.
124
NF86 NG86
R1362 R1263 siRNA
[Not Available]
R1362 R1263 siRNA
NP86 QF86
[Not Available]
R1362 R1263 siRNA
(5a)
it
R1362 R1263 siRNA
125
n"' ii
n
LD87
inIz
Ad
.>
azu.
Z
zu.
(5c)
t;
z
LL
2
Idz
100m 15:1
5:1
M 2.5:1 -60
= L2K
-40
-20
R1362 R1263 siRNA
LG31
4-
3
2
-iii
NF87
R1362 R1263 siRNA
NG87
Ij I I IL [Not Available]
R1362 R1263
NP87
R1362 R1263 siRNA
QF87
36
2-
R1362 R1263 siRNA
QG87
4 Ic
-8c3
-6C
2
-4(
1 2C
[Not Available]
R1362 R1263 siRNA
LD31
R1362 R1263
LF31
R1362 R1263
100
-80
-60
-40
H1 20U, ----
R1362 R1263 siRNA
(5b)
siRNA
[Not Available]
siRNA
siRNA
126
A-in iýr - I~~r" 0
u , . O...
.] -· ~---- ----- Y
n Ike~ I.--- .
i,/i
(5d)
ND32 NF32
M 15:1
= 10:1
5:1
2.5:1
L 2K
-Ri
-80
3-
-60 Z 220
-40 z
-20 1
0 
n0 [Not Available]
100
-80
-60 Z
-40
-20
C
4- 100
@ _ 3- -80
3 
z80z
a 2-
1- 20
[Not Available]
0 1 a :R1362 R1263 isRNA R1362 Ri263 silNA
Figure 5 - Activity for isRNA or RNAi activity for highlighted lipidoid cores.
Screening results for immunostimulatory activity following delivery of R1362 or R1263
ssRNA (left axis) or RNAi activity following delivery of luciferase siRNA (right axis)
are shown for (a) 86-core lipidoids, (b) 87-core lidpidoids, (c) 31-core lipidoids, and (d)
32-core lipidoids. Four different weight ratios of lipidoid to RNA were investigated: 15
(red), 10 (yellow), 5 (green), and 2.5 (blue) to 1. For isRNA delivery, type I interferon
activity was normalized to Lipofectamine 2000 delivery of R1362.
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Figure 6 - Representative lipidoids for each delivery activity group were selected to
investigate nanoparticle physical characteristics. Selected lipidoid nanoparticles were
made with R1362 RNA and assessed at 20 minutes and 2 hours following complex
formation and dilution in sodium acetate or PBMC transfection media. (a)
Immunostimulatory and RNAi activity for the selected lipidoids studied are plotted for
reference with activity groups circled in red. Nanoparticle size (b,d,f) and zeta potential
(c,e,g) are graphed with respect to isRNA for each group (b,c) G1, (d,e) G2, (f,g) G3. (h)
Nanoparticle characteristics of the 31 and 32 cores are highlighted with comparison to
LB 100 nanoparticles.
Discussion
Screening of the lipidoid library for isRNA delivery was a rapid and robust
process that uncovered a variety of materials for further characterization and potential for
therapeutic use. Screening for type I IFN responses was enabled by the development of a
cell-bsaed assay to accurately and sensitively quantify type I IFN production by human
PBMCs (Chapter 3). However, high throughput screening would not have been possible
without the use of HT-compatible FACS machines. Screening for transfection and
activation of human PBMCs is more relevant to the eventual goal of human clinical use
of these lipidoid materials, and large amounts of human PBMCs for screening are readily
available from blood donation centers. However, TLR activity and cell-expression,
particularly with respect to TLR7/8, differ from species to species [6, 32, 33]. Therefore,
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extension of these findings to animal models will be important (Chapter 5). Therefore,
we performed screening with a ssRNA molecule that activates both mouse and human
TLR7 as well as TLR8 in anticipation of conversion of results from in vitro screening to
animal studies [33].
TLR7 in human PBMCs is restricted to pDCs and B-cells to a lesser extent, while
TLR8 is found in mDCs [6, 25]. Both of these TLRs are restricted to the endosome [19,
27, 28]. However, only pDCs can respond with high amounts of interferon alpha
production [6, 21, 27, 28]. The 293T-ISRE-RFP system does not distinguish between the
many characterized and uncharacterized interferons making up the type I IFN class
(Chapter 3) such as IFN-alpha and IFN-beta. Type I IFN activity was determined by
ELISA to be entirely due to IFN-alpha production, as no IFN-beta was detectable (data
not shown), consistent with delivery of ssRNA to pDCs. We have not tested for TNF-
alpha or IL-6 levels, which would be indicative of mDC activation through TLR8, but
TNF-alpha and IL-6 should not activate 293T-ISRE-RFP cells. Additionally, depletion
of the PBMC subset of pDCs completely abolished 203T-ISRE-RFP activation to
supernatants of lipidoid-transfected PBMCs (data not shown). Therefore, by high
throughput screening of the lipidoid library we have discovered materials that are very
efficient for controlled delivery of ssRNA to pDCs.
In particular, the 100-core lipidoids were very highly enriched in the isRNA
delivery-active population of lipidoids indicating a conserved function imparted
specifically by the 100 core and not by the alkyl side chains. None of the 100-core
compounds exhibited activity above baseline when complexed with R1263 (data not
shown) indicating that Type I interferon activity in human PBMCs was due to efficient
activation of TLR7 and not due to activation of TLR9, which also exists in pDCs and
activates IFN-alpha. Additionally, low R1263 indicates a lack of 100-core lipidoid-
mediated cytotoxicity or other direct interaction with a different trigger of IFN-alpha
production in pDCs.
The R1362-specific isRNA activity result with 100-core lipidoids is in direct
contrast to non-RNA specific activation of IFN-alpha in PBMCs following transfection
with some, but not all, 86-core and 87-core lipidoids. The 86 and 87 core lipidoids are
closely related structures with two pendent alcohols off a tertiary amine core (Figure la).
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This non-specific activity was not observed with quaternized lipidoids or lipidoids
containing degradable ester bond, indicating a possible acrylate-specific mechanism of
non-RNA specific activation. Unfortunately the acrylate linked versions of all of the
quatemized lipidoids were consumed in the quaternization procedure and were not
available for direct comparison. Additionally, there is a dose-response relationship
between amount of lipid and total activity with R1263, and often the activity with R1263
was higher than that of R1362. These results have been reproduced with similar dose-
response trends (data not shown) for the 86/87 cores. Cytotoxicity is a possible
explanation for this non-specific activity, and although we did not observe death of
PBMCs in general following 87/87 transfection we have not investigated pDC-specific
toxicity events directly. Other possibilities include direct activation of TLRs or other
pattern recognition receptors such as TLR1, 2, 5, or 6, which detect bacterial lipids and
lipoproteins [51]. Finally, it is possible that these lipids mediate activation of TLRs by
ssRNA the reduces sequence-specificity as has been observed for CpG ODNs [28] and
co-delivery of poly(dT) ODNs [34] with DOTAP (Chapter 5).
Lipidoids based on the 100-core also were highly efficient for siRNA delivery. It
is likely that 100-core materials enter cells through endosomal uptake as this is where
TLR7/8 are located. As such, it would be important for these materials to also escape the
endosome to functionally deliver siRNA molecules to enter the RNAi pathway. One
method for endosomal escape is buffering of the endosome [41] by sequential charging of
primary, secondary, and tertiary amines with free hydrogen ions in the low-pH
environment of the late endosome. This process leads to increased osmotic pressure due
to Clf counter-ions entering the endosome to maintain charge neutrality, and the
endosome is subsequently destabilized. This is known as the proton-sponge mechanism
[41, 42]. However, lipid-based systems are also known to fuse directly with cellular and
endosomal membranes [40, 43].
The contribution of proton-sponge mechanisms can be investigated by
quaternization of the amine core. This reaction is performed in great excess of methyl-
iodide to ensure the highest conversion possible to quaternized amines. Without free
amines to absorb protons, quatemized lipidoids should not be able to buffer the
endosome. TLR7 exists in the late endosome, and it is believed that acidification is
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necessary for TLR7 activation by both small molecule ligands and ssRNA as
bafilomycin, which inhibits the endosomal ATP-dependent H÷ pump, also prevents TLR7
activation [19, 21, 27, 28, 34]. Bafilomycin also inhibits TLR7 activatoin in response
DOTAP-mediated delivery. Quaternization seems to level to L/R ratio trend for siRNA
delivery activity across a variety of lipidoid cores, indicating that endosomal buffering at
certain L/R ratios may effect TLR7 activation in these cases. However, quaternization
does not prevent siRNA activity (see QD99, QF86, QD109 in Figure 3), so it is unlikely
that endosomal buffering and escape are the only mechanisms for lipidoid-mediated
delivery of RNAs.
From inspection of the core chemistry alone we cannot derive the methods of
endosomal uptake and escape active with 100-core materials. However, 100-core
lipidoid activity was relatively independent of tail length for isRNA activity, but highly
dependent on tail length for siRNA delivery indicating that 100-core materials probably
deliver RNA to its site of action utilizing multiple modalities that are both tail-dependent
and tail-independent. The greater dependence on tail-length for siRNA activity for 100-
cores and other lipidoids implies that tail-length is more important for endosomal escape
than uptake. This hypothesis fits the description of 31-core lipidoids as well. These
lipidoids exhibited almost no isRNA delivery potential yet still delivered siRNA
materials very efficiently, indicating that cellular uptake is not the limiting step. The 98-
core is similar to the 100-core with additional amines (Figure la) and ND98 has also
shown high activity for isRNA and siRNA delivery both in vitro (Figure 3a) and in vivo
(Chapter 2) [14, 52]. Further investigation of the activity of these cores including are
warranted.
Macromolecular structure is equally as important as the chemistry of lipidoid
materials in defining overall function. Nanoparticle size and surface charge have been
observed to be highly correlated to transfection efficiency for polymer-mediated [48, 53]
and lipid-mediated [40, 54] delivery of DNA. We investigated nanoparticle size and
zeta-potential for a subset of lipidoid materials based on their characteristic activities.
We observed that lipidoid materials efficient at both isRNA and siRNA delivery (Group
2, Figure 3) formed small and stable nanoparticles. It is likely that larger particles
unstable over time aggregate and are unable to mediate transfection. In general, lipidoid
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particles were relatively stable in media and readily associated with serum proteins as
evident by the overwhelming trend towards negative surface charge in serum-containing
media.
However, particle size and stability was not the only criteria as 31-core materials,
which were highly active for siRNA delivery but not isRNA delivery (G ) exhibited
dynamic changes over time that included drastic size and zeta potential shifts. The
inversion of surface charge observed in sodium acetate from positive to negative may be
indicative of a phase change or a superstructural reorganization in low pH conditions that
is specific to this core chemistry. It is possible that pH-sensitive reorganization may
facilitate highly efficient endosomal escape and delivery of RNA to the cytosol and
would explain the low isRNA activity as well as the high isRNA activity of 31-core
lipidoids. We have not directly imaged these lipidoids, so we are unable to comment on
organization of the nanoparticle. However, ND98 particles do not form micelles or
liposomes spontaneously, in combination with RNA, or after formulation with PEG and
cholesterol.
Conclusions
The screening of the lipidoid library resulted in identification of novel compounds
such as 100-core lipidoids that are highly promising for isRNA delivery, and we have
identified novel materials that efficiently deliver isRNAs to TLR7 in the endosome of
pDCs. It appears that delivery can be controlled through careful management of tail
components, as changing tail lengths seems to affect siRNA delivery more than it affects
isRNA delivery. Therefore, designing tail functionality around a central 100-core may be
a useful strategy to tailor lipidoid-mediated delivery of RNA molecules to either
endosomal compartments for innate immune stimulation through TLR7/8, or to target
siRNAs for delivery to the cytosol to enter RNAi machinery. It also appears that lipidoid
materials exploit multiple functions to delivery RNA, so modifications of tail chemistry
alone may not be sufficient to fully design lipidoid delivery systems de novo and further
investigation of the mechanism of 100-core and closely related structures in delivery of
RNA are warranted. While nanoparticle size and zeta potential are certainly important
for lipidoid function, less information was contained in the data we obtained to correlate
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structure and function at this level. However, it is clear that small particle sizes are
important for uptake as materials efficient for both isRNA and siRNA delivery had
characteristic sizes in the 150nm to 250 nm range. The utility of comparing isRNA and
siRNA function for the same lipidoid library has shown that by considering these two
functions as surrogates for final intracellular destination of RNA we can identify
materials exhibiting interesting behavior (such as 31-core lipidoids) and generate more
informed hypotheses to more closely investigate detailed mechanisms. Finally,
classification of lipidoid materials by two measures of activity will inform and focus
second generation development of materials for specific therapeutic targets.
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Chapter 5
Title
Novel Lipidoids for the Controlled Delivery of Immunostimulatory RNA
Activates MyD88-dependent and MyD88-independent Innate Immune Responses that
Adjuvant Protein Vaccination
Abstract
Activation of the closely related Toll-like receptors (TLR) 7 and 8 by viruses
engages a strong and coordinated innate and adaptive immune response. Clinical use of
synthetic small molecule agonists has proven the potential of these innate immune
receptors as therapeutic targets in cancer and infectious disease. However, activation of
TLR7/8 by ssRNA, the natural ligand for TLR7/8, has proven impractical due to the low
stability of RNA and the necessity for endosomal uptake. Here we report the
development of novel materials for efficient delivery of immunostimulatory RNA
(isRNA) to TLR7/8 receptors by high throughput in vitro screening of 96 structurally
related compounds in a combinatorial library of lipid-like structures termed "lipidoids".
Out of over 900 combinations of lipidoid, RNA, and lipidoid-RNA ratio tested, a
common structure emerged for delivery of single strand isRNAs to activate innate
immune responses measured by type I IFN activation in human PBMCs. Two second
generation lipidoids based on this structure were synthesized and formulated into sub-200
nm nanoparticles that were stable for at least one month. These materials proved highly
efficient for activating IFN-alpha, IP-10, and IL-6 in a RNA sequence-specific and dose-
dependent manner in multiple strains of mouse by SC and IV routes. We observed
evidence of target cell-type specificity to either pDCs or mDCs for the 2 lipidoid
formulations tested in terms of interferon and cytokine response profile. IFN-alpha and
IP-10 were activated in a TLR7-dependent manner. IL-6 activation, however, did not
require TLR4 or TLR9 activity, and had both TLR7-dependent and TLR7-independent
activity that was lost in mice lacking MyD88 signaling. While we cannot rule out
lipidoid-mediated direct activation of TLR1/2/6, the cytokine profile and RNA sequence-
specific activity are consistent with that expected of TLR8 activation. Functional TLR8
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activity in mice has not been previously reported with either small-molecule agonists
alone, ssRNA alone, or ssRNA in complex with DOTAP. We hypothesize that TLR8 in
mice is a low affinity receptor that requires high endosomal concentrations of ssRNA that
are achieved through efficient delivery by lipidoids but not observed with DOTAP.
Finally, we report that lipidoid-mediated delivery of ssRNA and TLR7/8 activation can
adjuvant cell-mediated and humoral activation of IM protein vaccination to levels equal
to or exceeding that of CpG ODN activation of TLR9.
Introduction
Innate immune activation is a crucial step in activating mammalian responses to
microbial infection, and activation of pattern recognition receptors (PRRs) allows for
rapid identification of common pathogen-associated molecular patterns (PAMPs) without
the need for prior education of an adaptive response [1, 2]. The activation of specific
PRRs called the Toll-like receptors (TLR) is a hallmark of innate immune activation.
The TLRs, of which 11 have been identified in humans, recognize conserved structures
among a diverse group of pathogens such as long dsRNA (TLR3), lipopolysachharide of
bacterial cell walls (TLR4), and flagella (TLR5) [2]. TLR 7-9 comprise a closely related
genetic sub-family whose expression is species-dependent, cell-type specific, is
functionally compartmentalized to the endosome [3]. TLR9 recognizes CpG in
unmethylated bacterial or viral DNA and synthetic CpG oligodeoxynucleotides (ODN).
In humans, TLR7 seems to be highly expressed and functional mainly in plasmacytoid
dendritic cells and B-cells, while TLR8 expression is localized mostly to monocytes,
myeloid DCs (mDCs), and monocyte-derived DCs (moDCs) [4].
In particular, recognition of bacterial and viral nucleic acids by TLRs 3, 7, 8, and
9 in the endosomal compartment of plasmacytoid dendritic cells (TLR3 and TLR9) and
myeloid dendritic cells (TLR3 and TLR8) results in a characteristic type I interferon
response and coordinated Thl cytokine profile [1]. This innate immune response can
have clinically relevant effects by adjuvanting immune responses to vaccines [5],
activating anti-viral defenses [2], and increasing immune surveillance of cancer [6], but is
also implicated in allergy and auto-immune diseases such and SLE [7]. Small-molecule
agonists of TLR7 and TLR8 such as imiquimod and R-848 have been used clinical as
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cancer therapies [6, 8]. However, therapeutic activation of TLR7 and TLR8 with small
single-stranded RNAs, the natural ligands for TLR7/8 [9, 10], has proven difficult due to
low stability, nuclease degradation [11-13], and requirement for endosomal uptake [9,
14]. Many groups have focused on strategies to chemically or physically alter ssRNA
and siRNA to increase serum stability and increase circulation time, but these
modifications may also inhibit TLR activation [13, 15-17] or require impractically large
dosing [11] to achieve immunostimulatory effects. Typically, DOTAP has been used to
facilitate cellular uptake and to investigate isRNA effects in vitro or in vivo [9, 10, 13,
18-20]. We hypothesized that delivery could control the cellular uptake and intracellular
location of ssRNA, as these events are crucial to induction of TLR7/8 responses [14, 21].
Controlled delivery of ssRNA to TLR7 or TLR8 could therefore efficiently activate
innate immune responses for therapeutic uses such as vaccine adjuvants mimicking the
robust adaptive immune responses triggered by viral infection [2, 5].
Many non-viral methods for gene delivery have been developed utilizing various
materials such as polymers[22] and lipids [23], but no systems for controlling delivery of
isRNAs to TLRs currently exist. We have recently reported the discovery of new
cationic lipid-like materials for siRNA delivery [24] termed "lipidoids". These materials
are based upon a combinatorial library of amine-containing hydrophilic cores and
hydrophobic tails. Combinatorial chemistry was specifically designed for gene delivery
utilizing electrostatic interactions of amine-containing cores with the negatively-charged
phosphate groups of nucleic acids. These amines may also provide a buffering effect to
facilitate endosomal escape [22]. Alkyl chains of various length with degradable
(acrylate) and non-degradable (acrylamide) linkages impart hydrophobic regions to
facilitate particle superstructure formation, stability, and uptake [23]. These compounds
can be synthesized in a solvent-free environment to reduce purification needs.
As the design criteria for isRNA delivery to TLR7/8 in the endosome are different
from that of polymer DNA delivery and siRNA delivery, we approached this problem by
high throughput screening of the lipidoid library. The principal of high throughput
screening of delivery materials is to identify unknown sequence motifs that may impart
specific function, even if those functions are previously uncharacterized [25]. Screening
of the large library of lipidoid materials under multiple conditions with active and control
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RNAs required development of high throughput compatible methods for quantifying
innate immune stimulation in vitro (Chapter 3). We screened in vitro for isRNA-
mediated innate activation in human PBMCs and quantified type I interferon production
using a cell-based reporter assay (Chapter 3).
Screening hits were then optimized for innate immune activation in vivo.
Optimized lipidoid-RNA nanoparticle formulations were highly efficient for delivery of
isRNA in a variety of mouse strains and activated type I IFN responses, cytokine
signaling characteristic of dendritic cell activation, and stimulated splenic lymphocytes.
We investigated the nature of the immune response to lipidoid-mediated isRNA delivery
and in knockout mice models of various TLR receptors and MyD88, a common signaling
intermediate shared by most TLRs [21]. We demonstrate, for the first time, that ssRNA
by itself can potentially activate TLR8 in the mouse if delivery is efficient, and we
hypothesize that TLR8 in mice is a functional but low affinity receptor for ssRNA.
Finally, activation of the innate immune system is a critical step in generation of the
second signal, or "danger signal", necessary for efficient production of specific T-cell
mediated production and high-affinity antibodies [1, 26]. We applied lipidoid-mediated
delivery of isRNAs to adjuvant responses to intramuscular protein administration
achieving highly efficient induction of both cellular and humoral immune responses.
Materials and Methods
RNA
All RNAs used were fully phosphorothioate-modified, 20-base, single-stranded
RNA synthesized by Coley Pharmaceuticals:
R1362 [5'-UUGUUGUUGUUGUUGUUGUU-3'], aka R-0006 in ref [18], and
R1263 [5'-GCCACCGAGCCGAAGGCACC-3'].
Combinatorial Lipidoid Synthesis
Lipidoids were synthesized as previously described [24] and as depicted in
Figure lb in solvent-free conditions by reacting primary and secondary amine-containing
cores (Figure la, right) with alkyl-acrylate or alkyl-acrylamide (Figure la, left) tails at
a high tail-to-core monomer ratio to drive synthesis of fully- and (n-1)-substituted
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lipidoids. Lipidoid products were purified of un-reacted core and side-chain reactants
resulted in crude mixtures of undefined relative compositions of fully and incompletely-
substituted lipidoids. Some alkyl-acrylate-tail lipidoids were further reacted with methyl-
iodide (Figure 1c) to form quaternized amines with a permanent positive charge.
Promising lipidoids for further study were purified. Nomenclature reflects alkyl tail
linkage (acrylate = L, acrylamide = N), alkyl tail carbon-chain length (A=9, B = 10, D =
12, F = 14, G = 15, P = 16, H = 18 carbons), and amine-containing core. Quaternized
core-amines are further referred to with a Q designation instead of L. Purified lipidoids
includes number of tails in parenthesis () following tail name. A complete list of crude
lipidoids screened is found in Table 1.
Second-generation lipidoids (Figure 4a) were synthesized in a four-step process
(Figure 4b). The primary amine was protected on one side by reacting 10x molar excess
pure 100-core with di-tert-butyldicarbonate (Boc20). ND tails were reacted with the free
primary amine in excess prior to deprotection and regeneration of the opposite primary
amine resulting in ND(2)-100. ND(2)-100 was further reacted with NA or LD tails and
purified into 3-tail or 4-tail derivatives, which have been renamed lipidoids A-D for
clarification.
High-throughput Screening for Lipidoid-mediated isRNA Delivery
Donor-blind buffy-coat packs were obtained from the Massachusetts General
Hospital blood bank. Peripheral blood mononuclear cells (PBMC) were obtained by
Ficoll-Paque Plus (Amersham Biosciences) density centrifugation at 400 RCF and
washed twice in PBS with 2 mM EDTA. PBMCs were resuspended in supplemented
RPMI (RPMI 1640 medium with 10% FCS, 1mM MEM sodium pyruvate, 10 mM
HEPES, and 100 U/mL penicillin/streptomycin) and plated at 5x105 cells/well in 175 iL
in 96-well tissue culture plates. Lipofectamine 2000 (L2K) (Invitrogen) was used as a
positive control for transfection of RNA according to manufacturers protocols and to
normalize interferon responses across different donors.
Crude or purified lipidoid products and RNA were dissolved in 25 mM sodium
acetate, pH5, to 0.5 mg/mL. For lipidoids with poor solubility, up to 10% DMSO was
added to stock lipidoid solutions; sonication in a common laboratory utensil cleaner was
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also used to increase solubility. Lipidoid solution was arrayed in 96-well round-bottom
reaction plates and mixed at 15, 10, 5, and 2.5 : 1 mass ratios of lipid to RNA (at 50
pg/mL also in sodium acetate) for 80 pL total volume. After 20 minutes incubation at
room temperature to allow for nanoparticle complexes to form, 120 pL RPMI media was
added to dilute complexes and buffer sodium acetate. 25 giL of diluted complexes were
then added to PBMCs for a final RNA concentration of 200 ng RNA per well in 200 tL
media (1 gig/mL - 140 nM). Following 16 - 20 hours of incubation, supernatants were
taken from PBMC cultures after centrifuging at 400 RCF for 10 minutes and stored in 96-
well plates at -800C for later quantification. Transfections were performed in
quadruplicate for each weight ratio and both immunostimulatory R1362 and control
R1263 RNA.
To quantify Type I interferon activity, a HTS-compatible cell-based detection
assay (Chapter 3) was utilized. Briefly, 293T-ISRE-RFP cells were incubated with 50
pL PBMC supernatant overnight prior to quantification of red fluorescence signal.
Recombinant human interferon alpha (hIFN-a) (PBL Laboratories) serially diluted in
supplemented RPMI was used as a standard, and type I interferon activity of each
screening well was normalized to activity from L2K transfections.
Lipidoid-RNA Nanoparticle Formulation and Characterization
Purified lipidoid was dissolved to 120 mg/mL in ethanol, cholesterol (Ch) (Sigma
Aldrich, St Louis, MO) was dissolved to 25 mg/mL in ethanol, and N-palmitoyl-
sphingosine-1-[succinyl(methoxypolyethylene glycol)2000] (C16 mPEG 2000 ceramide)
("PEG") (Avanti Polar Lipids, Alabaster, AL) was dissolved to 100 mg/mL in ethanol.
Lipidoid, Ch, and PEG were combined at a 15:0.8:7 mass ratio (L:C:P), vortexed briefly,
and diluted in a mixture of ethanol and 200 mM sodium acetate (with 16.67 mg/mL
sucrose for lyophilization) for a final lipidoid concentration of 7.5 mg/mL in 35%
ethanol, 65% NaAc. RNAs was resuspended in H20 to 10 mg/mL and diluted to 35%
ethanol. Lipidoid/Ch/PEG were added to diluted RNA at a 15, 11.5, or 10:1 mass ratio
(L:R) and vortexed for 20 minutes to allow complexes to form. Complexed lipidoid-
RNA nanoparticles were then extruded once through a double 200 nm membrane and
then twice through a double 80 nm membrane (Whatman, Florham Park, NJ) on a
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Northern Lipids (British Columbia, Canada) extrusion system at 400C. To remove
ethanol prior to injection, nanoparticles were dialyzed in a Slide-A-Lyzer 3500 MWCO
dialysis cassette (Pierce Biotech) against PBS. For lyophilization, 10 mg of sucrose was
added per mL of extruded complexes prior to freezing at -800C for >2 hours followed by
>1 day lyophilization.
For quantification and encapsulation efficiency of RNA, a 50 pL sample of
nanoparticles was diluted 200-fold in Tris-EDTA buffer (TE), mixed with either 50 pL of
TE buffer or 50 ptL of 2% Triton-X-100 (T-X) in TE, and incubated with 100 [tL Quant-
It Ribogreen reagent (Invitrogen) according to the manufacturers protocols for 20
minutes at 370C in a 96-well black plate. Fluorescence intensity was determined at 485
nm (ex) / 535 nm (em). Total fluorescence in the presence of T-X was compared to a
standard curve of RNA diluted in TE to determine total RNA concentration; RNA
encapsulation efficiency was determined by the ratio of fluorescence signal without T-X
and with T-X. Binding affinity of formulated lipidoid complexes was investigated by
measuring Ribogreen signal following incubation of nanoparticles with a dilution series
of T-X between 0 and 4% T-X.
Nanoparticle size and zeta-potential of formulated lipidoid-RNA nanoparticles
was assayed by light scattering using a Zeta-PALS instrument (Brookhaven Instruments)
after 1/50 dilution in PBS or with a Mastersizer instrument (Malvem Instruments) after
dilution in HBSS.
In vivo Characterization of Innate Immune Responses
All studies were conducted at Coley Pharmaceuticals (Ottowa, ON, Canada)
under the approval of the institutional care committees and in accordance with the
guidelines set forth by the Canadian Council on Animal Care. Formulated lipidoid-RNA
nanoparticles were resuspended or diluted in HBSS prior to injection under isofluorane
anesthesia. Innate immune responses of multiple lipidoid formulations with R1362 RNA
were compared after subcutaneous (SC) injections in BALB/c mice. To further
investigate RNA-specific immune responses, nanoparticles were injected SC at
increasing doses or intravenously (IV) into 129sv mice. TLR-specific responses were
investigated following IV injection in C57B1/6, C57B1/6 TLR7T/ . C57B1/6 TLR9/-,
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C57B1/6 MyD88-" , C3H, or C3H TLR4 /1. As a control, DOTAP (1,2-dioleoyloxy-3-
(trimethylammonium)propane) (Roche) was complexed with RNA at a 2 : 1 weight ratio
(L : R).
Blood samples for serum isolation were taken by direct cardiac puncture on
heparin at indicated timepoints. Plasma samples were analyzed by ELISA with
commercially available antibodies (IFN-alpha, PBL Labs) (IP-10, BD Pharmingen) or
10-plex Luminex technology (BioSource International). Spleenocytes were also
harvested for surface expression of activation markers by staining with anti-CD69-FITC,
anti-CD86-APC, anti-CD3-PE/Cy7, anti-CD19-ECD, and anti-DX5-PE.
Lipidoid-RNA Nanoparticles Adjuvant Immune Responses
Lipidoid-RNA nanoparticles were formulated in liquid form with either R1362 or
R1263 at 15:1 ratio (lipidoid to RNA) and dialyzed to remove ethanol. Lipidoid-RNA
nanoparticles with 28 ptg of RNA were mixed with 20 ýtg chicken ovalbumin protein
antigen (Ova) immediately prior to IM injection into C57B1/6 mice (n=10). Control mice
were vaccinated with Ova protein antigen alone, and vaccination with the TLR9 agonist
CpG 1826 ODN mixed with Ova antigen was investigated for comparison. Mice were
dosed three times, at days 0, 14, and 21. After 28 days, blood was collected by direct
cardiac puncture on heparin (n= 10). Plasma antibody levels of anti-Ova IgG1 and IgG2c
were determined by sandwich ELISA.
Spleenocytes (SC) were harvested for flow cytometric analysis of surface
expression markers and cytokine production. SC (n=5) were directly stained for antigen-
specific T-cells with CD44-FITC, SIINFEKL-tetramer-PE, CD8-ECD, CD62L-APC,
PD-1-biotin + strepavidin-PE/Cy7. The same SC samples were independently stimulated
in vitro in RPMI-1640 + 1% L-glutamine + 1% Pen/Strep + 10% FBS + 3-
mercaptoethanol with 5 ýtg/mL SIINFEKL peptide for 1 hour, stimulated with Brefeldin
A (1 ýig/mL) for 4 hours, and then stained with SIINFEKL tetramer-PE and CD8-ECD
followed by intracellular staining with IL2-FITC, TNF-APC, and IFNy-PECy7.
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Results
Screening Reveals Lipidoids Capable ofIn vitro isRNA delivery
The therapeutic use of nucleic acids as a therapeutic requires a mechanism for
protection against physiologic nucleases and delivery across cellular and tissue barriers.
Further, due to the specific cell-type expression and intracellular location of TLR7 and
TLR8, the mechanisms for controlling RNA delivery for activation of innate immune
responses are unknown. We have chosen to approach this problem by high-throughput
screening of a combinatorial library of cationic lipid-like materials (Figure 1), termed
lipidoids, originally developed for delivery of short interfering RNAs [7]. We screened
this lipidoid library for in vitro immunostimulatory RNA (isRNA) activity in human
PBMCs using short ssRNAs. R1362 is a GU-rich isRNA sequence that, when complexed
with DOTAP, is a highly active TLR7 & TLR8 agonist producing Type I interferon and
Thl-type cytokines [18]. To control for lipid-mediated toxicity or direct activity, we also
screened with a sequence exhibiting low TLR7 and TLR8 activity, R1263, when
complexed with DOTAP [18].
Crude mixtures of 96 different lipidoid combinations with a variety of core and
tail structures (Table 1) were screened at 4 mass ratios of lipid to RNA with both active
and control RNA. Lipidoid-mediated activity was normalized to Lipofectamine 2000
(L2K)-mediated transfection with R1362 to control for donor PBMC variability in type I
interferon activation levels. Many lipidoid compounds exhibited some level of activity.
Of the 16 lipidoids that had activity equal to or greater than that of L2K at any L/R ratio
(Figure 2a), 4 had the 100 core (Figure la) including the top 3 lipidoid compounds. Of
the almost 900 conditions tested, 106 combinations of lipid, RNA, and L/R ratio
exhibited activity greater than half that of L2K (Figure 2b). As highlighted in red in
Figure 2b, the 100-core is highly enriched in this subset. Of the 7 lipidoid 100-core
products tested, 5 exhibited highly efficient delivery of R1362 (Figure 3). Lipidoid
NH 100 was insoluble in sodium acetate even after heating and sonication. While NF 100
had the highest activity of all lipidoids, the degradable version, LF 100, was not as active.
Further, quaternization (Figure ic) of the degradable version of NG100 severely reduced
delivery potential. None of the 100-core compounds exhibited activity above baseline
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when complexed with R1263 (data not shown) indicating that Type I interferon activity
in human PBMCs was due to efficient activation of TLR7/8.
Synthesis and In vitro Activity of Second Generation Lipidoids Based on the I 00-core
Focusing on the intrinsic activity of the 100-core material, we designed new
lipidoids for further screening. The 100-core has two primary amines that can be
substituted with up to two alkyl tails each for a total of 4 possible substitutions. Long
akyl-chain tails were avoided due to decreased solubility. We focused on 3 and 4 tail
versions of the 100-core as prior work with lipidoid-mediated siRNA delivery indicated
that fully and (n-1)-substituted lipidoids exhibited the most efficient siRNA delivery [24].
Purified versions of ND 100 and derivatives of ND 100 with a mixture of ND and NA (A
and B) or LD tails (C and D) (Figure 4a) were synthesized by step-wise substitution of
each primary amine (Figure 4b). Purified three-tailed lipidoids all exhibited high levels
of isRNA delivery activity that was RNA-specific and greater than ND(5)-98-1 (Figure
4c), a lipidoid material previously shown to have high capacity for siRNA delivery in
vitro and in vivo [24]. However, 4-tailed lipidoids (ND(4)-100, B, and D) were not
soluble in sodium acetate and therefore had low in vitro activity. These 100-core and 2 nd
generation derivatives were further investigated for in vivo isRNA delivery.
Optimization ofLipidoid-RNA Nanoparticle Formulation for In vivo isRNA Delivery
To increase solubility and in vivo stability, lipidoids were formulated with
poly(ethylene-glycol) (PEG) and cholesterol (Ch) and extruded at through an 80 nm pore-
size membrane to generate nanoparticles. RNA binding affinity was investigated by
competitive binding with the RNA-specific fluorescent dye Ribogreen in the presence of
Triton-X, a detergent that disrupts lipidoid-RNA binding. 2 nd generation lipidoids A and
B (ND/NA derivatives) bound R1362 more tightly than lipidoids C and D (ND/LD), with
NC(3)-100 intermediate between the 2 nd generation lipidoids. 98-core materials bound
more tightly to R1362 than did 100-core materials. At an L/R ratio of 11.5, nanoparticles
in liquid form (prior to lyophilization) ranged in size from 70 nm to 300 nm with high
encapsulation of RNA (Table 2).
Lyophilized and dialyzed versions of lipidoid-RNA nanoparticles encapsulating
R1362 at a L/R ratio of 11.5 were injected subcutaneously in BALB/c mice. The time-
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course of innate immune cytokine signaling was monitored over 24 hours (Figures 6a-c)
and immune-cell activation in the spleen was assayed at 24 hours (Figures 6d-h). While
many lipidoids were above baseline (HBSS control injections) and DOTAP-complexed
R1362, the 2 nd generation B and D lipidoids (both 4-tail versions) in particular exhibited
high potential for isRNA delivery. Compared to DOTAP-mediated delivery, lipidoid D
induced, on average, up to 10-fold greater production of IFN-alpha and 5-fold greater
production of IFN-gamma-induced protein 10 (IP-10) (Figures 6a-b), while lipidoid B
induced up to 50-fold greater IL-6 activation (Figure 6c) and 30-fold greater IL-5
activation (data not shown). T, B, and NK cells showed high activation in response to
both C and D (3-tailed and 4-tailed ND/LD-100) as dialyzed formulations, but
lyophilized B and D lipidoids (both 4-tailed lipidoids) showed high cell-activation
(Figures 6d-h). Compared to DOTAP-mediated delivery of R1362, lyophilized D
activated, on average, 2.6 times as many CD3÷ T-cells (Figure 6d), 11 times as many
CD19 + B-cells (Figure 6e), and increased NK-mediated lysis of target cells over 3-fold
(Figure 6h). Similar results were observed for lyophilized lipidoid B. Other lipidoids
based on the 98-core were not as active as the 100-core materials.
Focusing on lyophilized versions of the 2nd generation 100-core lipidoids,
nanoparticles were formulated with R1362 RNA at 10:1 and 15:1 L/R ratios.
Surprisingly, liquid formulations at a 15:1 L/R ratio had the highest activity for cytokine
induction (Figures 7a-c, and data not shown). Again, formulation D exhibited highest
activation of IFN-alpha and IP-10 (Figures 7a-b), up to 18-fold and 4.5-fold compared to
DOTAP, respectively, while formulation B induced highest activation of IL-6 (Figure
7c) with a 30-fold increase over DOTAP delivery. Formulation B also activated high
levels of IL-5 and GM-CSF (data not shown). Splenic T, B, and NK-cells were
activated by both B and D in liquid forms (Figures 7d-h). CD19 + B-cells in particular
responded highly to lipidoid D in all forms (Figures 7e-f). All lyophilized lipidoid
particles were found to have a heterogeneous size distribution (into the micron range)
after resuspension in HBSS (Table 3), but dialyzed liquid formulations were in the true
nanoparticle size range (below 200 nm), with lipidoid D particles being slightly larger
than lipidoid B nanoparticles.
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Lipidoid-RNA nanoparticles based on the B and D lipidoids were formulated with
either R1362 or R1263 at 15:1 L/R ratio and dialyzed to remove ethanol. Nanoparticles
sizes of formulations of B and D were not dependent on encapsulated RNA and were
stable in size over the course of 1 month (Table 4) with some increased in aggregation
observed with lipidoid D. Mixing Ova protein antigen with lipidoid-nanoparticles did not
alter size-distributions.
Characterization ofInnate Immune Responses to Lipidoid-RNA Nanoparticles
To investigate the RNA-specific nature of innate immune responses, we
investigated profiles of innate immune activation in 129sv mice following SC
administration of 3 to 100 ýig of R1362 RNA. There was a clear difference in potency
for activation of IFN-alpha and IP-10, with lipidoid D nanoparticles activating much
greater amounts of these two markers of pDC activation (Figure 8a top and middle).
Interestingly, B and D nanoparticles elicited equally high IL-6 responses (Figure 8a
bottom). To investigate sequence specificity in innate immune activation, we compared
the same batch of lipidoid B and D nanoparticles with R1362 to a new batch formulated
with R1263. After IV injection, a sharp contrast in stimulation of serum IFN-alpha and
IP-10 between nanoparticles containing the strong TLR7/8 agonist R1362, and the weak
agonist R1263 (Figure 8b left and middle). Activation of IFN-alpha by nanoparticles
with R1263 was higher for lipidoid D formulations than for lipidoid B (Figure 8b left).
Both R1362- and R1263-containing nanoparticles induced IL-6 production (Figure 8b
right) that was greater for lipidoid B than lipidoid D.
The potential for non-TLR7/8-mediated activation of these cytokines was
explored by IV injections of 75 pCg RNA into knockout mice that are TLR7-', MyD88 / ,
or wild-type (WT) all on the C57B1/6 background. Production of IFN-alpha, IP-10, and
IL-6 were all dependent on MyD88 signaling, but only IFN-alpha and IP-10 production
were dependent upon TLR7 (Figure 8c). IL-6 production in response to B-R1362
nanoparticles was diminished in TLR7/' mice, but IL-6 production in response to B-1263
nanoparticles was not effected by loss of TL7 function. Lipidoid D nanoparticles seemed
to have a lower potential for IL-6 production than lipidoid B nanoparticles. IL-6
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production in response to lipidoid D nanoparticles was RNA-specific and completely
dependent upon TLR7 (Figure 8c right).
Concerned with endotoxin contamination (LPS) or other unknown strong
stimulant of IL-6 production activated by TLR4 or TLR9, we formulated new batches of
B lipidoid nanoparticles with either R1362 or R1263. LAL assay for bacterial endotoxin
was below detectable limits. The older batches of lipidoid B and D nanoparticles with
either R1362 or R1263 previously studied (Figures 8a-c) were directly compared to the
new batches of lipidoid B nanoparticles. TLR7 /' and TLR9-' on the C57B1/6 background
as well TLR4- mice on the C3H background were injected IV with 30 gg of lipidoid-
RNA nanoparticles. Injections of D-R1263 were not investigated in TLR7-/' or TLR9"
mice. LPS was included as a control for comparison except for in TLR7- mice. Profiles
of IFN-alpha and IP- 10 responses were similar to those previously observed (Figures 8c
and 8d). IFN-alpha and IP- 10 production in TLR9- and TLR4-/ mice was similar to or
greater than that in WT mice (C57B1/6 or C3H, respectively), was RNA-specific, and
completely dependant on TLR7 signaling (Figure 8d). IL-6 signal was completely
dependent upon TLR7 signaling at this lower 30 gg dose for all formulations except the
older batch of lipidoid B with R1263. This phenomena was not observed with the newer
batch of lipidoid B with R1263. IL-6 production was otherwise RNA specific and did not
depend on TLR4 signals (Figure 8d).
Lipidoid-RNA Nanoparticles Adjuvant Immune Responses to Protein Antigen
Lipidoid-RNA nanoparticles were mixed with chicken ovalbumin protein antigen
(Ova) to investigate the adjuvant activity of lipidoid-mediated delivery of TLR7/8 RNA
agonists. C57B1/6 mice were vaccinated with 3 intramuscular injections at 0, 14, and 21
days with Ova protein without adjuvant, lipidoid nanoparticles mixed with Ova protein,
or CpG 1826 ODN, a TLR9 agonist, mixed with Ova protein. After 28 days, cell-
mediated and humoral responses were investigated.
Vaccination with B-R1362 nanoparticles induced greater numbers of splenic
antigen-specific CD8 + T-cells than with CpG 1826 ODN, and all lipidoid formulations
increased antigen-specific CD8+ T-cells to levels greater than that with pure Ova protein
vaccination (Figure 9a left). Only B-R1362 particles decreased PD-1 expression levels
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on splenic antigen-specific CD8+ T-cells to levels found on antigen-specific CD8 + T-cells
in mice vaccinated with CpG 1826 ODN (Figure 9a right). Spleenocytes were
stimulated in vitro with SIINFEKL peptide and intracellular staining for Thl cytokines
was performed. IFN-gamma production was greater in antigen-specific CD8+ T-cells
from mice vaccinated with lipidoid particles with some increase from R1362 RNA,
though R1263 RNA nanoparticles also elicited IFN-gamma producing T-cells (Figure 9b
left). RNA-specific increases in TNF-alpha-producing antigen-specific CD8 + T-cells
were observed with both lipidoid B and lipidoid D nanoparticles (Figure 9b right).
Total anti-Ova IgG antibody production was greatly increased by adding lipidoid-
based or CpG 1826 ODN adjuvants (Figure 9c). Lipidoid B nanoparticles with either
R1362 or R1263 induced greater antibody production than CpG 1826 ODN, with
approximately twice the total IgG levels. Mice vaccinated with D-R1263 nanoparticles
had greater total anti-Ova antibody titers than those mice vaccinated with D-R1362
nanoparticles. We also examined the relative amounts of IgG and IgG2c anti-Ova
antibody titers. While CpG 1826 ODN had an unbiased response, vaccination with Ova
alone or Ova with lipidoid nanoparticles induced a slight IgGI bias (Th2 bias) (Figure
9d), which was not specific for RNA sequence. However, in vitro stimulation of
spleenocytes cultured with ovalbumin antigen resulted in high amounts of IFN-gamma
and IL-2 secretion levels indicating a strong Thl response (Figure 9e) that was strongest
for mice immunized with CpG 1826 or B-R1362 nanoparticles.
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NG(1s) 9
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AT + H2N-R2
+ H2N-R 2
-Me
N,
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Figure 1 - Parent compounds of lipidoid library for isRNA delivery - (a) A subset of
components from the larger lipidoid library [24] used in this study. When combined with
amine-containing cores (red) to form lipid-like structures, alkyl-acrylate (L) tails form a
hydrolysable ester bond, and alkyl-acrylamides (N) form non-degradable amine linkages.
Tail groups (blue) are coded according to linkage and number of carbons in the alkyl
chain. (b) Schematic of solvent-free batch synthesis process resulting in crude mixtures
of lipidoid components. All reactions were performed in excess of tail groups to drive
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AT R1-N H
R-N ~• + H2 N 
, NH2 H _ N H
H H N-RI
00
(1b)
(1c)
(la)
towards full substitution of all core amine groups. Primary amines may accept up to two
tail substitutions and secondary amines can accept up to one. Crude products typically
contain a mixture of fully n-substituted and n-1 substituted lipidoids with rare n-2
substitutions. (c) A subset of degradable lipidoids was further reacted with methyl-iodide
to form quaternized amine structures with a permanent positive charge. These materials
were coded with the "Q" designation.
ND(12) NF( 14) NG( 15• NP(16) NH(18• L Q
ND20 NF20 NG20 NP62 NH20 LB100 QD94
ND24 NF25 NG28 NP63 NH28 LB109 QD99
ND25 NF28 NG32 NP86 NH32 LD31 QD109
ND28 NF32 NG61 NP87 NH61 LD87 QF80
ND32 NF60 NG64 NP95 NH95 LF31 QF86
ND36 NF61 NG77 NP96 NH96 LF93 QF87
ND61 NF63 NG86 NP98 NH98 LF94 QF91
ND66 NF64 NG87 NP99 NH99 LF95 QG87
ND94 NF70 NG95 NP103 NH100 LF96 QG100
ND95 NF86 NG96 NP109 NH103 LF99
ND96 NF87 NG98 NH109 LF100
ND98 NF91 NG99 LF1 03
ND99 NF95 NG100 LF1 09
ND100 NF96 NG103 LG31
ND109 NF98 NG109 LG76
NF99 LG96
NF100 LG93
NF103
NF109
Table 1 - List of the 96 crude lipidoid products screened
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(2a)
IFN Activity Relative to L2K
1 2 3 4 5 6
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(2b)
IFN Activity Relative to L2K
NF100 02.5:1
NG100 10:1
NF100 05:1
ND100 10:1
ND100 15:1
NG100 02.5:1NIDF9 05 C4
NG100 15:1
NG87 15:1 R1263
ND96 02.5:1
N 96 10:1
N61 05:1N 9510:1
LF96 02.5:1
LF96 05:1
ND99 15:1
ND100 02.5:1
ND99 10:1
F80 15:1F80 05:1
F80 10:1
N 100 05:1D99 05:1
NF86 10:1LF96 10:1
LF96 15:1LG76 02.5:1
LF100 02.5:1QF80 02.5:1
ND109 02.5:1
ND95 15:1LF99 05:1
NF86 15:1
L2K R1362
NF103 02.5:1
LF99 10:1
LFIOO 05:1QF86 05:1
NF86 02.5:1
ND99 02.5:1
LF99 02.5:1
NF86 10:1 R1263
NG86 15:1
NG87 10:1 R1263
LG96 10:1LF99 15:1
NP87 15:1QF86 15:1
LG96 05:1LF00 15:1
ND98 15:1QF86 10:1
LG96 02.5:1L G76 15:1
76 10:187 05:16 02.5:1
F100 10:1
NG103 15:1
ND20 02.5:1hG76 05:162 10:1LG96 15:1
NG86 10:1 R1263NF95 10:1
NG86 15:1 R1263NG86 05:1 R1263
F94 10:1
N 103 10:1QF87 10:1
ND96 10:1
G87 15:1
NF86 05:1QF87 15:1QG100 02.5:1LF94 15:1
NF109 05:1QF87 02.5:1NG86 10:1
LF94 05:1QD94 02.5:1
ND98 1362ND96 05:1
NF86 15:1 R1263
LF109 05:1QG100 10:1
NF61 02.5:1
LF109 10:1
F91 02.5:1
NP62 02.5:1
NG64 05:1NP103 10:1
ND100 05:1ND96 15:1
NP103 15:1QG100 05:1QF91 15:1
NG86 05:1NF109 02.5:1
NF87 02.5:1
QG87 10:1
NG103 15:1 R1263QF91 10:1
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m 100 Core
I-I L2K
Figure 2 - Results of in vitro screen of 96 lipidoids - All 96 lipidoid compounds were
screened for isRNA delivery in vitro at 4 different mass ratios of lipidoid to RNA (15, 10,
5, 2.5 to 1), with an immunostimulatory RNA (R1362) and control RNA (R1263)
comprising over 900 unique transfection experiments. Complexes were added to 5x10
5
human PBMCs in 96 well plates at 200 ng RNA per well (1 tg/mL - 140 nM) for 16 -
20 hours. Type I interferon activity was determined by cell-based 293T-ISRE-RFP assay
and activity was normalized for each batch of PBMCs to activity of Lipofectamine 2000
complexed with R1362. (a) Highest activity per lipidoid of all 96 lipidoids. (b) Activity
of any formulation (lipidid, L:R ratio, or RNA) with relative activity above 0.5.
Lipidoids with the 100 core are colored in red; lipidoids with either the 86 or 87 core are
colored in blue. Dashed line indicates relative activity of 1. Each bar is the average of 4
repeats with standard deviation.
100 Core with R1362
Ce
N1
0
a,
,L
0
2.5 :1
1
LIUU QQG100
Figure 3 - Screening highlights immunostimulatory RNA delivery in vitro with 100-
core lipidoids - Type I interferon activity following human PBMC transfection with 100
core shown for all four weight ratios of lipidoid to RNA using immunostimulatory RNA
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R1362. Type I interferon activity was normalized to Lipofectamine 2000 delivery of
R1362. Activity in vitro of all 100-core materials complexed with control RNA R1263
was near or below detection limits (data not shown).
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ND(3)-100 ND(4)-100 A B C D ND(5)-98-1
R1263
-- -------
1 I I I I I
ND(3)-100 ND(4)-100 A B C D ND(5)-98-1
Figure 4 - Synthesis and in vitro isRNA delivery characterization of purified and
second generation lipidoids based on 100 core - (a) Second generation lipidoids were
designed based on the 100 core and 10 to 12 carbon alkyl-acrylamide tails with structures
as shown, synthesized, and purified into single isomer components. (b) Protection and
deprotection steps to generate ND(2)- 100 precursor in the synthesis of mixed-tail
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lipidoids of the 100 core. (c) Purified lipidoids and second generation 100-core materials
were screened in vitro for R1362 isRNA delivery with R1263 RNA as a control. Type I
interferon activity is normalized to Lipofectamine 2000 with R1362 (dotted line).
Effective RNALipidoid Half Width (nm) PolydispersityDiameter (nm) Encapsulation
ND(5)-98-1 71.4 28.8 0.163 88.3%
NC(5)-98-1 106.1 48.4 0.208 90.3%
NC(3)-116 83.1 33.8 0.165 91.6%
NC(3)-100 174.3 85.1 0.238 89.0%
A 112.4 53.6 0.227 91.9%
B 188.4 96.1 0.26 90.4%
C 142.8 54.5 0.145 90.9%
D 289.9 149.7 0.267 79.1%
Table 2 - Representative characteristics of lipidoid-RNA nanoparticles formulated
in liquid form at 11.5: 1 ratio after dialysis for in vivo injection. Particle sizes were
measured by dynamic light scattering. RNA encapsulation was determined by
competitive binding of Ribogreen with triton-X.
RNA Binding Affinity
-- ND(5)-98-1 -9- A
-- NC(5)-98-1 -.- B
- NC(3)-116 - C
S NC(3)-100 . D
163
1
1
CD
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1 2 3 4
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^^~
Figure 5 - Binding affinity of lipidoid-RNA nanoparticles formulated in liquid form
at 11.5: 1 ratio after dialysis for in vivo injection. Lipidoid-RNA nanoparticles were
incubated with increasing concentration of Triton-X to competitively dissociate R1362
RNA in the presence of the RNA-specific detection agent Ribogreen.
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Figure 6 -In vivo activation of innate immune responses following injection of
formulated lipidoid-RNA nanoparticles at 11.5:1 ratio of lipid to RNA. Lipidoid-
RNA nanoparticles were formulated with R1362 RNA and either dialyzed or lyophilized
to remove ethanol. 100 ug RNA was injected SC in BALB/c mice (n=3). R1362 with
DOTAP and mock injection with HBSS were included as controls. Blood was collected
at 6, 9, and 24 hours following injection. Serum (a) interferon-alpha, (b) IP-10, and (c)
IL-6 cytokine levels were measured. Spleens were also collected at 24 hours for staining
and FACS analysis of (d) CD3+ T-cell activation, CD 19+ B-cell (e) activation and (f)
maturation, and (g) DX5+ NK-cell activation. (h) Cytolytic activity of NK-cells was
measured by chromium release following incubation of spleenocytes with YAC-1 target
cells at a 100:1 ratio.
.ipidoid : RNA Peak 1 Peak 2Lipidoid Lipidoid RNA Formulation Polydispersityratio (nm) (nm)
ND(5)-98-1 15:1 lyophilized 2768 0.400
NC(5)-98-1 15: 1 lyophilized 165 1507 0.900
NC(3)-116 15: 1 lyophilized 167 0.292
NC(3)-100 15: 1 lyophilized 264 0.400
ND(3)-100 15: 1 lyophilized 146 707 0.756
ND(4)-100 15:1 lyophilized 87 659 1.000
B 15: 1 lyophilized 83 560 1.000
B 10:1 lyophilized 2946 1.000
B 15: 1 liquid 69 0.238
D 15:1 lyophilized 144 1160 0.798
D 10:1 lyophilized 73 1209 0.620
D 15:1 liquid 143 0.400
Table 3 - Representative characteristics of lipidoid-RNA nanoparticles formulated
in liquid form at 15 : 1 and 10 : 1 ratios after resuspension for in vivo injection.
Particle sizes were measured by dynamic ligh scattering after resuspension in HBSS for
injection.
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Figure 7 - In vivo activation of innate immune responses following injection of
formulated lipidoid-RNA nanoparticles at 15:1 and 10:1 ratio, lipid to RNA.
Lipidoid-RNA nanoparticles were formulated with R1362 RNA and either dialyzed or
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(7h)
1 •
I
I a I
lyophilized to remove ethanol. 100 ug RNA was injected subcutaneously in BALB/c
mice (n=4). R1362 with DOTAP and mock injection with HBSS were included as
controls. Blood was collected at 6, 9, 12, and 24 hours following injection. Serum (a)
interferon-alpha, (b) IP-10, and (c) IL-6 cytokine levels were measured. Spleens were
also collected at 24 hours for staining and FACS analysis of (d) CD3÷ T-cell activation,
CD19 ÷ B-cell (e) activation and (f) maturation, and (g) DX5÷ NK-cell activation. (h)
Cytolytic activity of NK-cells was measured by chromium release following incubation
of spleenocytes with YAC- 1 target cells at a 100:1 ratio.
Lipidoid RNA Average (nm) Peak (nm) TimeIntensity (%)
R1362 140.0 162.2
R1263 125.0 171 Immediately
............... a fte r
R1362 174.0 199.8 formulationD ......... ..  ......... ........ . -.................. ..... ...... ............ .......... ...  ...... , ....... .    u l  t io n
R1263 172.2 258
R1362 124.0 188 (100%)
R1263 133.0 188 (100%)
B .. .... ..... .......... . .... . . . . .. ... ...... ...................... ........ ...... .. .....................................
R1362 + Ova 122.0 168 (100%)
R1263 + Ova 136.0 183(100%)
R1362 130.0 41 (23%), 278 (75%) One month
after
35 (17%), 149 (28%), formulationR1263 179.0 5582 (54%)
D . .. . ...  . ... . . . .. .. .... .. ........  ........................ . . . . . .
R1362 + Ova 133.0 58 (34%), 314 (63%)
32 (14%), 142 (30%),R1263 + Ova 182.0 32 (14%),142 (30%),686 (53%)
Table 4 -Size and stability of lipidoid-RNA nanoparticles formulated in liquid form
at 15 : 1 ratio. Particles sizes were measured by dynamic light scattering immediately
after formulation or after 1 month of storage at room temperature. Average particle size
and size of peak intensity are reported. If multiple size peaks were detected, the relative
intensity is indicated by (%). Chicken ovalbumin protein antigen (Ova) was mixed with
nanoparticles at a 2 : 1 ratio (w/w) of RNA: Ova immediately prior to measurement.
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Figure 8 - Characterization of cytokine response from B and D lipidoid-RNA
nanoparticles in vivo. Lipidoids B [ND(2)NA(2)-100] and D [ND(2)LD(2)-100] were
formulated with the strong TLR7/8 agonist R1362 RNA as well as the weak TLR7/8
agonist R1263 RNA as control in liquid form. (a) Dose-response of IFN-alpha (top), IP-
10 (middle), and IL-6 (bottom) at 9 and 12 hours following SC injection into 129sv mice
(n=4) at 3, 10, 30, and 100 pg of R1362 RNA in lipidoid B (left) and D (right, note scale
change for IFN-alpha and IP-10) nanoparticles. (b) Serum cytokine responses of IFN-
alpha (left), IP-10 (middle), and IL-6 (right) following IV injection into 129sc mice (n=4)
of 75 ptg of active R1362 RNA or control R1263 RNA formulated in lipidoid
nanoparticles at 3, 6, and 9 hours after injection. (c) Serum cytokine response of IFN-
alpha (left), IP-10 (middle) and IL-6 (right) at 6 hours following IV injection of 50 ipg
RNA into lipidoid nanoparticles in TLR7-", MyD88-", or C57B1/6 (WT) mice (n=4). (d)
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Serum cytokine response of IFN-alpha (top left), IP-10 (top right) or IL-6 (bottom) at 6
hours following IV injection of 30 p~g RNA in lipidoid nanoparticles into TLR7-', TLR9/
, C57B1/6 (WT), TLR4 "", or C3H (WT) mice (n=3 or 4). Bacterial LPS was included as a
positive control but not investigated in TLR7'- mice. Lipidoid D nanoparticles with
R1263 were not investigated in TLR7 -/ or TLR9 -/ mice. Lipidoid B and D nanoparticles
marked with (*) are the same batch as in figure (c) for direct comparison. TLR7 - -, TLR9-
/, and MYD88-/ mice were bred on the C57B1/6 background; TLR4-/ mice were bred on
the C3H background. Error bars represent SEM of average of 2 repeated measurements
per sample.
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Figure 9 - Lipidoid-RNA nanoparticles adjuvant intramuscular protein vaccination
- Lipidoids B [ND(2)NA(2)-100] and D [ND(2)LD(2)-100] were formulated with the
strong TLR7/8 agonist R1362 RNA or control R1263 RNA in liquid form. Lipidoid-
RNA nanoparticles with 28 ýtg of RNA were mixed with 20 jig chicken ovalbumin
protein antigen (Ova) immediately prior to IM injection into C57B1/6 mice (n=10). For
comparison, Ova protein antigen alone and naked CpG 1826 ODN, a TLR9 agonist,
mixed with Ova antigen were also injected. Mice were dosed three times, at days 0, 14,
and 21. After 28 days, spleenocytes were harvested for staining and FACS analysis of
(a) SINFEKL-specific tetramer staining of CD8 + T-cells (left) and PD-1 expression on
SINFEKL-specific CD8+ T-cells (right) (n=5). (b) Spleenocytes (n=5) were stimulated in
vitro with SINFEKL peptide. Intracellular staining was performed for expression of IFN-
gamma (left) and TNF-alpha (right) on SINFEKL-specific CD8+ T-cells. At 28 days,
blood was collected to investigate (c) serum total anti-Ova IgG antibody levels, and (d)
serum anti-Ova IgG1 and anti-Ova IgG2c antibody levels (n=10). (e) Spleenocytes were
restimulated in vitro with Ova protein and secreted cytokines were measured by ELISA
after 72 hours (IFN-g) or 24 hours (IL-2, TNF-a, IL-10, IL-4); shown as increase in
cytokine secretion between stimulated (Ova protein) and unstimulated (media control)
(n=10).
Discussion
The controlled drug delivery of immunostimulatory single strand RNA agonists to
cell types expressing TLR7 and TLR8 has the potential for therapeutic activation of the
innate immune system. We synthesized a library of cationic lipid-like materials [24] and
screened this library in a high throughput manner for the ability to deliver
immunostimulatory RNA (isRNA) in vitro using R1362, a 20-bp ssRNA sequence that
engages both TLR7 and TLR8 in a variety of immune cells and across multiple species
including human and mouse [18]. To control for non-specific activation, a secondary
screening with the weak TRL7/8 agonists R1263 [18] was performed. The majority of
intrinsic activity seems to be encapsulated in the core amine-containing structures. The
population of lipidoids achieving efficient isRNA delivery was highly enriched for a
specific diamine core, 100 (Figure 1) present in the top 3 compounds tested in the screen
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(Figure 2a). While other lipidoid compounds also showed promise as isRNA delivery
agents (Figures 2a and 2b), we focused on the 100-core due to its R1362-specific
potency and activity across a variety of related lipidoid compounds with variable tail-
lengths and chemistries (Figure 3). Lipidoid ND98 also displayed levels of isRNA
delivery activity that were RNA specific. A version of this lipidoid with a 98-core has
shown activity for siRNA delivery in vitro and in vivo [24, 27]. Screening of ND98 and
other lipidoids for immunostimulatory activity due to siRNAs also revealed 116-core
materials as active for isRNA delivery (Chapter 3, Figure 7), and 16-core and 98-core
materials were also further pursued for in vivo isRNA delivery.
Tail chain length and chemistry also affected in vitro isRNA delivery properties,
likely related to modulation of hydrophobic interactions, and may account for differences
in optimal ratios of lipid to RNA for different tail lengths on the same core (Figure 2b).
During screening, isRNA delivery was enhanced as lipidoid alkyl tails increased in
carbon length to from 12 to 15 carbons, but at even larger tail lengths (18 carbons), in
vitro isRNA delivery activity was diminished (Figure 3). Screening was based on
unrefined mixtures of lipidoids that could contain and unknown amount of fully or
partially substituted compounds. Driven by an excess of tail components during
synthesis, the majority of crude lipidoids screened contained a mixture of fully n-
substituted (where n is maximal number of substitutions) and n-1-partially substituted
lipidoids. Because this screening environment is completely aqueous, selection is biased
against hydrophobic materials and most activity is likely due to incompletely substituted
lipidoid compounds.
New 100-core based second generation lipidoids incorporating mixed alkyl chains
were developed and purified into both 3-tailed and 4-tailed components (Figure 4a) for
further testing in vitro and in vivo. Purification of 100-core materials into 3-tailed and 4-
tailed components confirmed that in vitro delivery of isRNA to TLR7 and TLR8 in
human PBMCs is completely due to incompletely substituted lipidoids that are water
soluble (Figure 4c). However, formulation of lipidoid nanoparticles for in vivo delivery
is done in ethanol to allow for hydrophobic components and avoid these limitations.
Lipidoid-RNA nanoparticles encapsulating R1362 RNA were formulated in a
variety of conditions and tested in vivo for activation of innate immune responses
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following SC administration. The most active lipidoid materials in vivo were also based
on the 100-core, validating that in vitro screening for isRNA delivery is predictive of in
vivo function (Figures 6 and 7). While the various materials tested have subtle
differences in nanoparticle size (Table 2) and binding affinity for RNA (Figure 5), these
differences do not seem to be able to explain the major differences in effective in vivo
isRNA delivery. However, the hydrophobic 4-tailed forms were more active than the 3-
tailed versions, and mixed-tail second generation lipidoids based on the 100-core had the
greatest activity.
SC injections of lipidoid D in BALB/c mice potently activated IFN-alpha and IP-
10 responses (Figures 6a-c, 7a-c, 8a) compared to lipidoid B. IFN-alpha is almost
exclusively produced by pDCs in responses to ssRNA activation of TLR7 in humans and
mice [4, 28]. IP-10 (CXCL10) is also produced primarily by pDCs in a ssRNA-
dependent manner [9, 10, 29]. The Type I IFN and chemokine production pattern
associated with SC injections of lipidoid D is indicative of efficient delivery of R1362 to
pDCs, and resulted in cellular activation remotely as measured in the spleen (Figures 6d-
h, 7d-h) associated preferentially with lipidoid D nanoparticles. Lipidoid B-mediated
delivery of R1362 and activation of pDCs was less than that of lipidoid D, but above
baseline and dose-dependent (Figure 8a). Lyophilization of either lipidoid B or lipidoid
D nanoparticles when formulated at a lipid to RNA ratio of 11.5 increased the activation
of pDCs to stimulate IFN-alpha and IP-10 (Figures 6a-c). Lipidoid D nanoparticles have
a larger characteristic size than lipidoid B nanoparticles, and lyophilization further
increases particle size (Table 3), providing evidence that particle size may play a role in
nanoparticle targeting to the endosome of pDCs. However, size is not the only factor in
subcutaneous pDC-targeted delivery of R1362 as lyophilization decreased pDC
activation at a L/R ratio of 15 (Figures 7a-c) and other similarly sized lipidoids showed
little characteristic activation of pDCs.
The differentiation in cytokine profiles between the B and D lipidoid
nanoparticles was less clear after lyophilization (Figure 6a-c, 7a-c), IV injection (Figure
8b) in 129sc mice or C3H mice (Figure 8d), though it was observed in C57B1/6 mice
(Figure 8c). Mice of the C57B1/6 strain have a lower capacity to produce pDC-mediated
cytokines owing to both a decreased amount of pDC and lower pDC activity [28] and
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may explain less robust responses in this mouse strain. Upon IV injection, IFN-alpha
was robustly produced in response to both lipidoid nanoparticles in an RNA-specific
manner, though some activation of IFN-alpha was observed with D-R1263 nanoparticles
(Figure 8b). This may reflect activation of TLR-independent cytosolic RNA sensors
such as PRK and RIG-I in dendritic cells [30] following endosomal escape of lipidoid-
nanoparticles. Similar results were observed with IP-10. However, both IFN-alpha and
IP-10 production were clearly TLR7- and MyD88-dependent, and independent of
functional TLR4 or TLR9, indicating an ssRNA-specific TLR-mediated action rather
than endosomal escape, contamination with LPS, or a non-specific activation directed
against the lipid itself leading to IFN-alpha and IP-10 production.
Lipidoid B, in contrast to lipidoid D, potently activated IL-6 (Figures 6a-c, 7-ac,
8a) following SC administration. IL-6 is produced by murine pDCs in response to viral
ssRNA [9, 10] and together with IFN-alpha is important for plasma cell differentiation
and generation of antiviral immunity [31 ]. IL-6 is also produced by myeloid DCs
(mDCs) and monocyte-derived DCs (moDCs) [4]. Previously, large amounts of IL-6
were not found to be produced by human pDCs, which only express huTLR7, in response
to R1362 complexed with DOTAP, but significant IL-6 expression was observed in
human monocytes and mDCs, which express huTLR8 [18]. The differential activity of
lipidoid B in terms of high IL-6 production and lower IFN-alpha and IP-10 production
may be explained by delivery of R1362 preferentially to moDCs, mDCs, or monocytes
following SC injection.
Both lipidoid B and D nanoparticles induced high amounts of IL-6 when injected
IV with 75 gig RNA in 129sv mice, and R1362 isRNA delivery was only slightly more
active than R1263 control RNA delivery in stimulating IL-6 production (Figure 8b). In
the C57B1/6 strain, IL-6 appears to be induced in both a TLR7-dependent and TLR7-
independent manner at 50 jtg RNA dose IV, but is completely abolished without MyD88
signaling (Figure 8c). At lower doses, IL-6 production in response to R1362 delivery
was completely dependent upon TLR7 signaling (Figure 8d), and was actually increased
in mice deficient for TLR4 and TLR9. LPS readily activated IL-6 induction that was
completely TLR4-dependent, whereas activation of IL-6 by lipidoid nanoparticles was
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not affected by loss of TLR4 function, again indicating that LPS contamination or direct
activation of TLR4 by the lipidoid material itself was not responsible for IL-6 induction.
The MyD88-dependent TLRs in the mouse are TLR1, TLR2, TLR5, TLR6,
TLR7, TLR8, and TLR9; TLR4 has both MyD88-dependent and MyD88-independent
signalling and TLR3 signaling is completely MyD88 independent [21, 32]. Although
none of the lipidoid nanoparticle formulations tested positive for contamination of
bacterial endotoxin (LPS) by LAL assay, it is possible that TLR4 was activated in a
MyD88-independent manner. TLR5 recognizes flagella and induces TNF-alpha and IL-6
[33]. After forming homodimeric or heterodimeric complexes with each other, TLR1,
TLR2, and TLR6 are activated by bacterial diacyled or triacylated lipoproteins, in
particular the lipolyated amino-terminal residue [21], which may be mimicked by the
amino-alkyl linkages of lipidoid materials. These membrane-associated TLRs are
expressed on a most immune effector cell types including dendritic cells as at epithelial
surfaces and on platelets [5]. Interaction with TLR1/2/6 produces inflammatory
cytokines such as TNF-alpha and IL-12 [21], both of which were relatively low or just
above baseline levels following SC injection of lipidoids, but not IP-10 [34].
The IL-6 production induced by lipidoid-mediated isRNA delivery IV therefore
indicates a possible role for TLR8, or another MyD88-dependent receptor. Indeed, in
human PBMCs IL-6 production is strongly induced by small molecule TLR8 activation
but not by TLR7-specific ligands [35]. Additionally, the cytokine activation profile
observed with lipidoid B in particular is associated with TLR8-activity in humans. TLR7
and TLR8 are very closely related genetically [18, 35], in endosomal location and
signaling, and in mice are expressed in similar cell types [1]. It was previously believed
that TLR8 was non-functional in mice mostly based upon studies using small molecule
agonists of human TLR7 and TLR8 as well as DOTAP-delivered ssRNA [9-11, 36].
Recently it has been shown that mouse TLR8 can be activated under certain conditions
by co-delivery of TLR8 agonists, including R1362, with poly(dT) ODN [18, 37]. TLR8
has been hypothesized to be a low affinity sequence-dependent receptor for ssRNA while
TLR7 functions as a high affinity ssRNA receptor in human [36], and may require
adapter molecules to induce activation to ssRNA [18]. An alternative explanation is that
TLR8 is a low affinity a may not be sequence-specific, but a medium to high avidity
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receptor of ssRNA that requires ligand-induced homodimer formation, a theme common
in TLR activation [5, 21], that is only induced at sufficiently high concentrations of RNA.
It is likely that delivery of RNA to endosomal compartments is independent of
RNA sequence. Highly efficient delivery of RNA could lead to control RNA recognition
by TLR7 or due to TLR8 engagement of R1263 at high concentrations that are not
achieved using DOTAP. DOTAP-mediated CpG ODN delivery to TLR9 in has been
shown to cause normally non-stimulatory B-type CpG ODN to activate pDCs due to
alteration of endosomal trafficking by increasing endosomal residence time of DOTAP-
complexed B-type CpG ODNs [38]. Further, it was shown that complexing DOTAP with
A-type CpGs can cause conventional DCs (mDCs) to secrete IFN-alpha. It is therefore
reasonable to expect lipidoid-mediated delivery to somehow alter normal responses to
ssRNA that have not been observed with or without DOTAP or other delivery systems.
We observed innate immune responses to R1362 and R1263 in lipidoid nanoparticles that
are much stronger than those associated with DOTAP-mediated delivery in vivo (Figures
6 and 7). We hypothesize that this activation is due to previously unachieved high
endosomal concentrations of ssRNA that can activate TLR8 even in mice.
We investigated the adjuvant effects of lipidoid B and lipidoid D nanoparticles
complexes with both R1362 and R1263 RNA to adjuvant protein immunization
intramuscularly. All lipidoid injections induced adaptive immune responses that
approached or exceeded responses adjuvanted with CpG ODN. Antigen-specific T-cell
levels were greater for lipidoid B than lipidoid D nanoparticles, with some benefit of
R1362 RNA over R1263 RNA particularly for down-regulation of PD-1 on CD8+ T-cells,
which promotes lymphocyte survival (Figure 9a). Upon in vitro stimulation with
cognate antigen, effector T-cell responses as measured by intracellular IFN-gamma
expression were also higher for lipidoid B nanoparticles; again a modest benefit of R1362
RNA was observed (Figure 9b). Total IgG levels were increased by lipidoid-RNA
nanoparticle adjuvants by over 2-logs compared to protein immunization without
adjuvant and higher than CpG ODN adjuvant (Figure 9c), and indicating a slight Th2-
biased response due to lipidoid nanoparticle adjuvants that was not present with CpG
ODN adjuvant (Figure 9d). However, in vitro restimulation of spleenocytes with Ova
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protein revealed a strong Thl bias as IFN-g and IL-2 secretion was high while IL-4
secretion was low (Figure 9e).
These differences in antigen-specific responses could be reflections of different
activation of IL-6 or other cytokines due to preferential delivery to mDCs by lipidoid B,
TLR8 activation in mDCs, or a combination of both. Added benefit of R1362 RNA over
R1263 may reflect the effects of TLR7 engagement in pDCs and production of Type I
IFNs and other cytokines that bias Thl responses. Murine B cells also express TLR7 and
can be activated through it to produce a generally more Th2-type antibody profile
including mucosal IgM and IgA depending on specific B-cell subset [39]. Though TLR8
has been widely speculated to be non-functional in mice, it is widely expressed in many
immunocytes and may be more effective at inducing both humoral and cell-mediated
adaptive immune responses than TLR7 [1, 18, 35, 37], possibly due to more direct
activation of TLR8 within mDCs.
Recently, a stage 3 clinical trial of a CpG ODN adjuvant (TLR9 agonist) was put
on hold due to a serious adverse event. One patient in the treatment group was diagnosed
with Wegener's granulomatosis, an autoimmune immune complex disease. While it is
currently unknown if this was due to an underlying condition or new onset of the disease,
the safety of TLR agonists must always be careful considered. Efficient delivery of RNA
to TLR7 and TLR8 has practical applications for direct activation of the innate immune
system. However, strong TLR7 and TLR8 engagement have been shown to be involved
in generation of antibodies to RNA-associated autoantigens [40], and excessive TLR
7/8/9 engagement is associated with autoimmune conditions such as systemic lupus
erythematosus (SLE) [3, 7, 41]. Lipidoid-mediated delivery of chemically modified
RNAs to TLR7 and TLR8 [7, 15, 17] could also be utilized to block these receptors and
decrease the severity of autoimmune diseases.
Conclusions
Modulation of the innate immune system through Toll-like receptors has
therapeutic potential in a variety of fields including tumor therapies, anti-virals, vaccine
adjuvants, and autoimmunity. Immunostimulatory RNA (isRNA) therapy, which aims to
activate TLR7 and TLR8, has been limited by poor pharmacodynamic properties of RNA
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including stability and lack of cellular uptake mechanisms. Because the criteria for this
specific application are unknown, we took a high throughput screening approach to
discover novel materials for efficient delivery of RNA to TLR7/8. We applied an in vitro
high throughput screening method to a combinatorial library of lipidoids to investigate
isRNA delivery to human PBMCs. The top lipidoid isRNA delivery candidate materials
shared a common diamine core, termed 100. A second-generation of lipidoid materials
based on the 100-core chemistry was synthesized and purified; they showed high
efficiency for activation of type I interferon responses in vitro and were further pursued
for in vivo optimization.
Multiple rounds of nanoparticle formulation optimization were undertaken to
select two second-generation lipidoid derivatives, termed lipidoids B and D, for in-depth
characterization of innate immune responses to lipidoid-mediated isRNA delivery in vivo.
These active materials were both based on the 100-core, reflecting the predictive value of
in vitro screening. We discovered characteristic differences in the profile of innate
immune responses to lipidoid B and lipidoid D nanoparticles formulated with the TLR7/8
ssRNA agonist R1362 after subcutaneous injection that could be best explained by TLR-
mediated activation of distinct immune types. Lipidoid D nanoparticles preferentially
caused activation of innate immune responses typical of TLR7 engagement in pDCs,
such as potent secretion of IFN-alpha and IP-10. Lipidoid B nanoparticles produced
innate immune responses typical of TLR7/8 engagement in mDC and moDCs, in
particular activation of IL-6.
By comparing responses to intravenous injection of lipid-RNA nanoparticles in
genetically-modified mice deficient for a variety of TLRs and MyD88, we have
determined that immune responses to lipidoid particles exhibit a MyD88-depdendent
response that has both TLR7-dependent and TLR7-independent components. While we
cannot rule-out direct activation of lipidoids through engagement TLRs 1,2, or 6, the
activation of IL-6 in particular led us to hypothesize that RNA interactions with TLR8
may play a role in the observed responses. Neither small molecule agonists alone nor
ssRNA have been shown to activate murine TLR8. TLR8 activation in mice has only
been observed in the specific instance of co-delivery of TLR8 agonists with poly(dT)
ODNs. However, with the efficient delivery achieved by lipidoids we observed innate
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immune responses characteristic of both TLR7 and TLR8 activation. We believe that the
previously observed lack of activation of TLR8 is due to the inability to achieve high
sustained local concentrations of RNA in the endosomal compartment of TLR8-
expressing cells with DOTAP, and that activation associated with R1263, a low affinity
ligand for TLR7, may be due to TLR8 activation. We propose that TLR8 is functional in
mice as a low affinity ssRNA receptor that may require ligand-mediated dimerization to
achieve potent signaling.
Finally, we have investigated the ability of lipidoid-RNA nanoparticles to
adjuvant protein immunization. Vaccination with lipidoid-RNA nanoparticles increased
antigen-specific cell-mediated and humoral responses with CD8÷ T-cell levels
approaching or exceeding levels achieved with CpG ODN adjuvants. This lipidoid-
nanoparticle adjuvant response was not entirely RNA-specific possibly reflecting direct
adjuvant activity of the lipidoid material itself, or more likely engagement of another
receptor such as TLR8.
This is the first report to our knowledge of novel non-viral materials designed
specifically for delivery of immunostimulatory RNA. We also believe that this is the first
characterization of the potential for ssRNA agonists of TLR7/8 to adjuvant adaptive
immune responses. While we are unable to provide direct evidence of TLR8 activation,
we observed TLR7-dependent and TLR7-independent innate immune activation highly
suggestive that efficient delivery of ssRNA enabled by lipidoids can activate TLR8
activity previously not observed in mice. Efficient delivery of RNA to TLR7 and TLR8
opens a new door in innate immune stimulation for a wide variety of TLR7/8 applications
including vaccine adjuvants, anti-tumors, anti-virals, or autoimmune therapies.
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Chapter 6
Summary
The lipidpoids are a promising new class of materials for non-viral delivery of
small RNAs that may facilitate clinically relevant uses of the diverse functionalites of
RNA. These materials can condense RNA into small particles, facilitate uptake and
release in a variety of cell types, and be formulated with PEG and cholesterol for use in
vivo. We have previously demonstrated the versatility of this library for delivery of
siRNA molecules for in vitro and in vivo use [1, 2]. We hypothesized that the same RNA
can have multiple functions, and that these functions can be controlled by drug delivery
to the proper cell type and intracellular location. In the chapters of this thesis I have
demonstrated how the lipidoids can be used to control another function of small RNAs to
stimulate innate immune responses.
RNA delivered to the cytosol can activate RNA interference (RNAi) if it has the
correct siRNA structure, namely double-stranded complimentary sequences 20 to 23 nt's
in length with 3'-overhangs. RNAs with this structure are also able to activate Toll-like
receptors (TLRs) that control the innate immune response. We have shown that one
lipidoid material, ND98(5)-1, aka 98N12-5(1), which is the purified version of the crude
lipidoid product of the ND tail and 98 core, can be used to deliver siRNA molecules for
immune activation. By optimizing the formulation of ND98, we were able to achieve
highly efficient antiviral activity, inhibiting influenza A virus replication up to 300-fold
in the mouse lung. Through a sequence of chemical modifications to the siRNA that
block TLR7/8 interactions, we showed that the antiviral activities are indeed due to an
activation of the innate immune response to the siRNA and not attributed to the lipidoid
material. However, the lipidoid carrier is a necessary component of the delivery system,
and our ND98 formulation imparts the immunostimulatory function on the siRNA by
controlling delivery of the RNA. RNAs that activate TLRs are known as
immunostimulatory RNA (isRNA) [3], yet the definition of isRNA is more functional
than it is structural, as the same siRNA or other single stranded RNA appears to function
as an isRNA only when it is properly delivered to TLRs in the correct cell type [4]. Our
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work with immunostimulatory siRNA to inhibit influenza infection demonstrates the
powerful role that controlled delivery has upon isRNA function.
Spurred by this insight, we sought to investigate the rest of the lipidoid materials
for isRNA delivery activity by high-throughput screening (HTS) in the hopes of
identifying materials that could better deliver isRNA for therapeutic uses. To detect
innate immune activation in vitro, we made lipidoid-RNA complexes in 96-well plates
and transfected human peripheral blood mononuclear cells (PBMC). A small subset of
these cells, the plasmacytoid dendritic cells (pDC), are specialized to detect viral RNA,
express TLR7 in high copy number, and will react to isRNA transfection by producing
type I interferons [5-8]. Traditionally detection of type I interferons relies on
quantification of interferon alpha (IFN-a) by ELISA, which is time consuming and
expensive. We developed a novel assay based on a 293T cell line stably transfected with
mRFP under control of an interferon sensing response element (ISRE). Using FACS
analysis to quantify mRFP expression, we established a simple, inexpensive, high-
throughput capable method for quantifying IFN-a that achieves greater sensitivity and
dynamic range than ELISA.
The development of a HTS-compatible method for IFN quantification enabled
screening of the lipidoid library for isRNA delivery. Using a ssRNA that is a strong
TLR7/8 agonist [9], we screened 96 different lipidoids at 4 lipidoid to RNA ratios. We
found that a variety of lipidoid materials had isRNA delivery activity, and in particular
the 100-core lipidoids generated up to 3.5 times the IFN-a response of transfection with
Lipofectamine 2000 (L2K), a commercially available cationic lipid transfection agent.
Other cores such as the 98-core were also active, as was the 86/87-core, though these
cores also exhibited non-specific lipidoid-dose-response IFN-a activation when
transfected with a control non-active RNA. By comparing the results of isRNA delivery
screening to the results of siRNA delivery screening, we were able to identify additional
structure-function relationships that govern RNA delivery by lipidoids. Lipidoids were
identified that preferentially exhibited only one function or the other, such as the 31-core
lipidoids that deliver siRNAs very efficiently without inducing an innate immune
response. For lipidoids with active cores, such as the 100-core lipidoids, increasing the
tail length had a larger effect on siRNA delivery than isRNA delivery. We concluded
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that while the amine core was the key component of lipidoid-mediated isRNA delivery
activity, the alkyl tails can tailor the function of the core.
Building on the structure-function knowledge about the RNA delivery properties
of the lipidoid library obtained through screening, we sough to develop second-
generation lipidoids for in vivo delivery of isRNAs to stimulate the immune system in a
mouse model. Focusing on 100-core lipidoids, we generated a series of purified 3-tail
and 4-tail 100-core lipidoids. These materials, as well as some other promising lipidoids,
were screened for in vivo activity as measured by induction of a variety of cytokines and
cellular activation. Again, the 100-core materials were the most active, validating the
predictive power of our in vitro screening method. We optimized formulation of
lipidoid-based RNA nanoparticles for innate immune stimulation, and examined the
details of innate immune response to these formulations with highly active and control
(low activity) ssRNA agonists of TLR7/8. Lipidoid-RNA nanoparticles activated innate
immune cytokines indicative of delivery to both pDCs and dendritic cells of the myeloid
lineage (mDCs). We found a dose-response relationship of the cytokines IFN-a, IP-10,
and IL-6, all hallmarks of TLR activation, and in particular of TLR7/8 activation. We
also observed some non-RNA sequence specific activity raising the question of a
response to the lipidoid material itself. Using knockout mice, we discovered that IFN-a
and IP-10 production were completely TLR7 and MyD88-dependent, but that IL-6
production had a TLR7-independent component. Lipidoid-RNA nanoparticle innate
immune activation was also independent of TLR4 and TLR9 function. We hypothesized
that either the lipidoid was interacting with TLRs 1/2/6, or that highly efficient delivery
of ssRNA was activating TLR8 in mDCs in a manner not previously observed. The high
activity for lipidoid-mediated isRNA activity translated into a therapeutically relevant
demonstration of the adjuvant effects of lipidoid-RNA nanoparticles. Immunization with
a protein antigen together with lipidoid-RNA nanoparticles generated high levels of
antibodies and antigen-specific effector CD8 ÷ T-cells. This adaptive response was equal
or superior to that of immunization with protein and CpG-ODN, a TLR9 agonist. This is
the first demonstration of highly efficient ssRNA delivery in vivo to activation TLR7/8,
and the first demonstration of the adjuvant effects of TLR7/8 activation by ssRNAs.
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Future Work
The work outlined in this thesis has provided many insights into the role of drug
delivery in controlling RNA function including practical applications such as activating
or avoiding innate immune stimulation in delivery of siRNA therapeutics and using
ssRNA as vaccine adjuvants. Further work is required to validate observed structure-
function relationships within the lipidoid material library, to assign biological functions at
the intracellular or whole organism level, and to expand the possible applications of
isRNA delivery.
Purifying Crude Lipidoid Mixtures and Second Generation Lipidoids
I have hypothesized that RNA function can be controlled by drug delivery by
exerting control over intracellular destination. Certain materials such as the 98-core, 100-
core, or 31/32-core lipidoids may exert control over RNA function through intracellular
localization. The structure-function relationships observed so far have been based upon
crude mixtures of products. Further purification and re-testing of isRNA and siRNA
delivery activity are also required. New materials have also been generated based on the
98-core and 100-core structures that can provide further insight into the effects of tail
chemistry and length on lipidoid function for delivery of isRNA (See Figure 1).
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Figure 1 - PBMC activation of second generation lipidoids. Second generation
lipidoids were developed based upon the 98-core (Kl-16) and 100-core (K17-32).
Human PBMCs were transfected with lipidoids complexed with R1362 isRNA, and
cytokine production was assayed as described in Chapter 3.
Assigning Intracellular Location to RNA Function
To further test the hypothesis of delivery-dependent RNA function, validation of
intracellular location must be made to confirm that delivery to a specific compartment
has associated biological function. There are some simple methods that will help to
validate this hypothesis. First, materials that strongly activate TLRs are expected to
remain in endosomes instead of escaping into the cytoplasm, and materials with high
RNAi activity are expected to either avoid endosomal trafficking or escape endosomes
early with little residual endosomal retention. Second, blocking endosomal maturation
should prevent RNAi activity if endosomal escape is pH-mediated. Endosomal
maturation inhibitors such as chloroquine, which buffers endosomal acidification, or
bafilomycin Al, which blocks the ATPase proton pump responsible for acidification of
endosomes, could therefore influence RNA activity dependent on delivery mechanism.
Increasing endosomal retention should increase TLR activity; however, TLR activity also
requires acidification of endosomes. Third, distinguishing these effects directly may be
possible through direct visualization of endosomes and RNA via fluorescent labels and
confocal microscopy.
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Determining Receptor-specific and Cell-type-specific Activation ofInnate Immune
Responses
While intracellular delivery and location may lead to the observed RNA class
effects, in vitro and in vivo delivery specific to a certain cell type must also be important
in determining RNA function. Cells not expressing TLRs or other innate RNA receptors
are unlikely to respond to isRNA delivery. Cell types such as the plasmacytoid dendritic
cell, monocyte-derived dendritic cell, and B-cell all express various level of TLRs 7, 8,
and 9. Distinguishing the observed stimulation in PBMCs could be important for further
development of targeted strategies. While the pDCs are clearly activated following
lipidoid-isRNA injections, it is unclear which other cell types in vivo are involved in the
observed immune responses. Follow-up studies must be conducted utilizing knockout
mice to further prove TLR7/TLR8-mediated effects of ssRNA on innate immune activity.
Additionally, RNA-sequence independent vaccine adjuvant effects were observed.
Repeated investigations are necessary to tease out RNA sequence dependence and
material-specificity of the role lipidoid-RNA nanoparticles play as vaccine adjuvants.
Application of RNA Drug Delivery to Treating Autoimmune Diseases
Finally, I have shown that lipidoids can efficiently deliver RNA to activate TLRs
both in vitro and in vivo. The TLRs 7,8, and 9 also play a key role in the activation of
autoimmune responses in diseases like systemic lupus erythematosus (SLE) [10-12] (See
Figure 2). I have also shown that lipidoids can deliver chemically-modified RNA that
prevent TLR7/8/9 activity. Certain chemical modifications can prevent TLR-mediated
recognition of immunostimulatory sequences [13], and RNA with chemical modifications
may even act as TLR antagonists [14].
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Figure 2 - Schematic of TLR involvement in autoimmune complex diseases. Auto-
reactive antibodies specific for DNA or RNA form immune complexes with their targets
that are taken up by pDCs or B-cells, possibly through surface Fc receptors. Once
internalized, the complexed nucleic acids activate cytokines and interferons through
TLRs 7 (RNA) and 9 (DNA) in a MyD88-dependent fashion, resulting in increased
stimuli to B-cells producing the auto-reactive antibodies [10].
The delivery of RNA-based TLR antagonists to pDC, B-cells, or MDC presents
an opportunity to specifically block the cycle of TLR-mediated support of the production
of auto-reactive antibodies. Antagonizing TLR activity in the setting of autoimmune
antibody-nucleic acid complexes could suppress innate immune activation, such as
increased IFN-a levels [11] associated with SLE, that is associated with various
autoimmune diseases. The data presented in this thesis provide a background for
development of lipidoid-based platforms for delivery of RNA-based TLR antagonists.
Conclusions
This work has shown that the activity of small RNAs can be controlled by drug
delivery with therapeutically relevant implications. The knowledge gained from these
investigations and the continued development of lipidoid-based materials may some day
enable ssRNA therapies. Preventing siRNA-mediated activation of TLRs may be
accomplished by chemical modification, but if a material can deliver siRNAs effectively
to both TLRs and cytosolic RNAi machinery, then the dual activity of siRNAs could be
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harnessed for potent anti-viral and anti-tumor purposes. Efficient delivery of isRNA
could also be useful as an adjuvant to vaccines to improve the quality and quantity of
immune responses to vaccination. Finally, delivery of modified RNA to TLR7/8 as
antagonists might be useful for blocking innate immune activation as a therapeutic
measure in controlling auto-immune disease.
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